

# CITATION REPORT

List of articles citing

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

DOI: 10.2337/dc12-0413

Diabetes Care, 2012, 35, 1364-79.

**Source:** <https://exaly.com/paper-pdf/53763438/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2345	REVIEWS. <b>2001</b> , XLVI, 151-152		
2344	Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379.	14.6	9
2343	Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2012, 35, e72-3	14.6	5
2342	Comment on: Inzucchi et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2012, 35, e71; author reply e72-3	14.6	7
2341	Glucose control and cardiovascular outcomes: reorienting approach. <b>2012</b> , 3, 110		7
2340	Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. <b>2012</b> , 124, 95-108		6
2339	Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials. <i>Diabetes Care</i> , <b>2012</b> , 35, 2698-705	14.6	11
2338	Intensification of Type 2 Diabetes in Adolescents: Guess What? Exercise Wins!. <b>2012</b> , 30, 164-167		
2337	National standards for diabetes self-management education and support. <b>2012</b> , 38, 619-29		105
2336	New antidiabetic therapies: innovative strategies for an old problem. <b>2012</b> , 23, 569-75		16
2335	A Patient-Centered Approach: A Step in the Right Direction. <b>2012</b> , 25, 130-131		
2334	What have we learned about the treatment of type 2 diabetes? The evolving paradigms. <b>2012</b> , 19, 449-64		2
2333	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. <b>2012</b> , 124, 21-32		33
2332	Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. <b>2012</b> , 124, 33-40		9
2331	De nieuwe ADA/EASD-consensus type 2 diabetes en wat u daarvan moet weten. <b>2012</b> , 10, 206-216		
2330	Frühe Insulintherapie im Netzwerk individualisierter Therapie des Typ-2-Diabetes. <b>2012</b> , 7, 429-433		
2329	National standards for diabetes self-management education and support. <i>Diabetes Care</i> , <b>2012</b> , 35, 2393-406	14.6	137

2328	Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. <b>2012</b> , 124, 74-83		16
2327	In search of improved glucose control: helping the patient decide between insulin injections and infusion pump therapy. <b>2012</b> , 2, 405-417		
2326	Therapie des Typ-2-Diabetes im klinischen Alltag – Ergebnisse aus einem standardisierten nicht interventionellen Register (SIRTA). <b>2012</b> , 7, 434-441		
2325	Diabetes: East meets West. The Joint American Association of Clinical Endocrinologists-Chinese Society of Endocrinology (AAACE-CSE) Symposium. <b>2012</b> , 4, 221-6		
2324	Effects of renal denervation on insulin resistance. <b>2012</b> , 10, 1381-6		9
2323	Predicting outcomes and assessing control with alternate glycemic markers. <b>2012</b> , 14, 749-52		4
2322	Type 2 diabetes: the evolution of a disease. <b>2012</b> , 12, 290-298		2
2321	Doctor, stop needling me: an update on alternative routes of insulin administration. <b>2012</b> , 2, 395-404		2
2320	Diabetes in older adults. <i>Diabetes Care</i> , <b>2012</b> , 35, 2650-64	14.6	745
2319	Humalog (lispro) for type 2 diabetes. <b>2012</b> , 12, 1541-50		10
2318	American diabetes association-European association for the study of diabetes position statement: due diligence was conducted. <i>Diabetes Care</i> , <b>2012</b> , 35, 1201-3	14.6	12
2317	Insulin therapy and cancer in type 2 diabetes. <b>2012</b> , 2012, 240634		14
2316	Will New Lipid Guidelines Abandon LDL Treatment Targets?. <b>2012</b> , 38, 4-6		
2315	Lebensumstände der Patienten zu selten Thema im Arztgespräch. <b>2012</b> , 6, 43-45		
2314	Patientenzentrierte Diabetesbehandlung: Back to the Roots!. <b>2012</b> , 6, 1-1		
2313	Module 18. Update on pharmacological options in the management of type 2 diabetes. <b>2012</b> , 10, 1-11		
2312	Aging, diabetes, and the public health system in the United States. <b>2012</b> , 102, 1482-97		101
2311	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. <b>2012</b> , 380, 475-83		278

2310	Type 2 diabetes: which drug as add-on to metformin?. <b>2012</b> , 379, 2222-3		2
2309	Choosing a blood-glucose-lowering agent after metformin. <b>2012</b> , 379, 2220-1		5
2308	Hypoglycaemia: a therapeutic concern in type 2 diabetes. <b>2012</b> , 379, 2215-6		14
2307	Year in diabetes 2012: The diabetes tsunami. <b>2012</b> , 97, 4293-301		62
2306	Response letter. Effects of linagliptin. <b>2012</b> , 14, 1056-7		
2305	Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. <b>2012</b> , 14, 721-31		18
2304	Pharmacokinetics of a fixed-dose combination of mitiglinide and metformin versus concurrent administration of individual formulations in healthy subjects: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover study. <b>2012</b> , 32, 799-804		7
2303	Actualizaci3n en el tratamiento de la diabetes mellitus tipo 2. <b>2012</b> , 11, 1397-1405		
2302	Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. <i>Diabetes Care</i> , <b>2012</b> , 35, 2100-7	14.6	42
2301	El nuevo «Position statement of the ADA/EASD on the management of hyperglycemia in type 2 diabetes». Perspectiva desde el Grupo de Trabajo de Consensos y Guas Clnicas de la Sociedad Espaola de Diabetes. <b>2012</b> , 28, 79-80		3
2300	Alas, a Patient-Centred Guidelines on the Glycemic Management in People with Type 2 Diabetes Mellitus. <b>2012</b> , 36, 87-89		0
2299	Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. <b>2012</b> , 13, 2663-71		8
2298	Efficacy and safety of exenatide once weekly: an overview of the DURATION trials. <b>2012</b> , 7, 611-623		2
2297	Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. <b>2012</b> , 13, 2545-54		5
2296	2. Pharmacological Treatment of Type 2 Diabetes: Advantages and Dilemmas. <b>2012</b> , 27-48		2
2295	[Current treatment of type 2 diabetes]. <b>2012</b> , 53, 1399-410		8
2294	Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. <b>2012</b> , 28, 1465-74		38
2293	Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE. <b>2012</b> , 11, 148		1

2292	Are diabetes management guidelines applicable in 'real life'?. <b>2012</b> , 4, 47	4
2291	Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. <b>2012</b> , 14, 1145-54	44
2290	Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. <b>2012</b> , 66, 1147-57	12
2289	A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. <b>2012</b> , 13, 1451-67	21
2288	How do we gauge the success of treatment of diabetes?. <b>2012</b> , 4, 193-4	1
2287	Glucagon-like peptide-1 receptor agonists and their effects on weight reduction. <b>2012</b> , 3, 490-1	4
2286	Diabetes in older adults: a consensus report. <b>2012</b> , 60, 2342-56	329
2285	Exenatide extended-release: a review of its use in type 2 diabetes mellitus. <b>2012</b> , 72, 1679-707	22
2284	Dapagliflozin: a review of its use in type 2 diabetes mellitus. <b>2012</b> , 72, 2289-312	59
2283	Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data. <b>2012</b> , 110, 32B-42B	5
2282	Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement. <b>2012</b> , 110, 50B-57B	30
2281	Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival. <b>2012</b> , 110, 58B-68B	55
2280	Physicians' prescribing patterns for patients with diabetes are changing for the better. <b>2012</b> , 125, e11-2	2
2279	Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. <b>2012</b> , 34, 2082-90	15
2278	Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. <b>2012</b> , 38, 550-7	18
2277	Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study. <b>2012</b> , 38, 507-14	23
2276	Paciente de 65 años con diabetes no conocida. <b>2012</b> , 11, 1059.e1-1059.e4	
2275	El señor Serna está preocupado. <b>2012</b> , 11, 1123.e1-1123.e4	

2274	Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results. <b>2012</b> , 22, 1007-12	9
2273	Molecular action and pharmacogenetics of metformin: current understanding of an old drug. <b>2012</b> , 2, 439-452	13
2272	Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. <b>2012</b> , 29, 1005-15	10
2271	Patient centred care in diabetology: an Islamic perspective from South Asia. <b>2012</b> , 11, 30	17
2270	[Insulin therapy of diabetes]. <b>2012</b> , 124 Suppl 2, 17-22	3
2269	Drug Therapy for Type 2 Diabetes. <b>2012</b> ,	
2268	Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes. <b>2012</b> , 12, 891	20
2267	Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE. <b>2012</b> , 3, 9	12
2266	Individualising type 2 diabetes management: new treatment options and models of care. <b>2012</b> , 197, 196-7	1
2265	Increase in direct diabetes-related costs and resource use in the 6 months following initiation of insulin in patients with type 2 diabetes in five European countries: data from the INSTIGATE study. <b>2012</b> , 4, 383-93	12
2264	Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. <b>2012</b> , 5, 165-74	23
2263	Clinical practice. Diagnosis of diabetes. <b>2012</b> , 367, 542-50	134
2262	Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. <b>2013</b> , 15, 3-14	49
2261	Electroacupuncture to treat painful diabetic neuropathy: study protocol for a three-armed, randomized, controlled pilot trial. <b>2013</b> , 14, 225	12
2260	Linagliptin: pharmacology, efficacy and safety in type 2 diabetes treatment. <b>2013</b> , 5, 25	23
2259	Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. <b>2013</b> , 4, 269-83	7
2258	Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen. <b>2013</b> , 4, 309-19	2
2257	Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. <b>2013</b> , 4, 331-45	82

2256	Safety and effectiveness of insulin detemir in different age-groups in the a1chieve study. <b>2013</b> , 4, 77-90	8
2255	Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries. <b>2013</b> , 4, 91-102	26
2254	Safety and effectiveness of insulin aspart in Basal-bolus regimens regardless of age: a1chieve study results. <b>2013</b> , 4, 103-18	8
2253	Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. <b>2013</b> , 4, 119-45	98
2252	Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis. <b>2013</b> , 4, 153-66	4
2251	Evaluation of stepwise insulin treatment as an add-on to current oral antidiabetic drugs therapy in Japanese patients with type 2 diabetes: STEADY study. <b>2013</b> , 4, 233-242	
2250	Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. <b>2012</b> , 18 Suppl 3, 6-26; quiz 27-8	6
2249	Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. <b>2013</b> , 34, 7994-8001	42
2248	HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. <i>Diabetes Care</i> , <b>2013</b> , 36, 3535-42	14.6 167
2247	Hypoglycemia: minimizing its impact in type 2 diabetes. <b>2013</b> , 19, 526-35	27
2246	Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. <b>2013</b> , 13, 9	25
2245	Personalizing guidelines for diabetes management: twilight or dawn of the expert?. <b>2013</b> , 11, 161	18
2244	Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. <b>2013</b> , 35, 226-35	22
2243	Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. <b>2013</b> , 28, 876-85	15
2242	Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. <b>2013</b> , 28, 691-7	28
2241	Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?. <b>2013</b> , 44, 343-5	19
2240	Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?. <b>2013</b> , 44, 47-58	28
2239	Insulin therapy for type 2 diabetes. <b>2013</b> , 43, 529-34	8

2238	Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes. <b>2013</b> , 13, 319-28	2
2237	Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. <b>2013</b> , 13, 342-9	17
2236	Diabetes and HIV: current understanding and future perspectives. <b>2013</b> , 13, 419-27	44
2235	Personalized decision support in type 2 diabetes mellitus: current evidence and future directions. <b>2013</b> , 13, 205-12	23
2234	Complementing insulin therapy to achieve glycemic control. <b>2013</b> , 30, 557-76	28
2233	[Diabetes and osteoporosis: pathophysiological interactions and clinical importance for geriatric patients]. <b>2013</b> , 46, 390-7	4
2232	[Obesity in the elderly: clinical relevance and therapy options]. <b>2013</b> , 46, 398-402	6
2231	Canagliflozin: first global approval. <b>2013</b> , 73, 979-88	57
2230	Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. <b>2013</b> , 382, 941-50	526
2229	The early treatment of type 2 diabetes. <b>2013</b> , 126, S2-9	39
2228	Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus. <b>2013</b> , 29, 673-9	8
2227	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <b>2013</b> , 159, 262-74	596
2226	Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. <b>2013</b> , 33, 707-17	46
2225	Stepwise intensification of insulin therapy in type 2 diabetes management--exploring the concept of the basal-plus approach in clinical practice. <b>2013</b> , 30, 276-88	37
2224	Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. <b>2013</b> , 1, 208-19	309
2223	The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the Aâdhieve observational study. <b>2013</b> , 101, 326-32	1
2222	Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. <b>2013</b> , 166, 823-30.e5	162
2221	Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy. <b>2013</b> , 7, 223-5	0



2220	[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?]. <b>2013</b> , 141 Suppl 2, 14-9		1
2219	Estado actual del tratamiento farmacológico de la diabetes mellitus. Una aproximación práctica. <b>2013</b> , 11, 2730-2740		
2218	The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. <b>2013</b> , 19, 1050-61		23
2217	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , <b>2013</b> , 36, 1779-88	14.6	114
2216	Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. <b>2013</b> , 1, 28-34		129
2215	Position statement: hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. <b>2013</b> , 60, 517.e1-517.e18		20
2214	Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. <b>2013</b> , 305, E987-98		41
2213	Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. <b>2013</b> , 29, 921-9		23
2212	Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 µg. <b>2013</b> , 35, 795-807		34
2211	Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. <b>2013</b> , 39, 34-41		49
2210	Clinical decisions. Glycemic management in a patient with type 2 diabetes. <b>2013</b> , 369, 1370-2		7
2209	Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function. <b>2013</b> , 15, 1101-10		20
2208	Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. <b>2013</b> , 440, 76-81		77
2207	Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. <b>2013</b> , 39, 485-96		59
2206	Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a 12-week randomized, double-blind study. <i>Diabetes Care</i> , <b>2013</b> , 36, 3875-81	14.6	111
2205	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <b>2013</b> , 34, 2444-52		213
2204	Fasiglifam as a new potential treatment option for patients with type 2 diabetes. <b>2013</b> , 14, 2591-600		15
2203	Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. <b>2013</b> , 126, S21-7		25

2202	Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. <b>2013</b> , 126, S10-20	57
2201	American Association of Clinical Endocrinologistsâ€™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <b>2013</b> , 19, 1-48	102
2200	The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. <b>2013</b> , 30, 1067-85	8
2199	Patient preferences for the treatment of type 2 diabetes: a scoping review. <b>2013</b> , 31, 877-92	66
2198	Lixisenatide: a review of its use in patients with type 2 diabetes mellitus. <b>2013</b> , 27, 509-23	14
2197	Incorporating lag time to benefit into prevention decisions for older adults. <b>2013</b> , 310, 2609-10	109
2196	Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. <b>2013</b> , 382, 1413-23	140
2195	Diabetes prevention: perspectives and actions of one company. <b>2013</b> , 44, S333-8	5
2194	Impact of behavioral interventions in the management of adults with type 2 diabetes mellitus. <b>2013</b> , 13, 860-8	4
2193	Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. <b>2013</b> , 5, 57	138
2192	Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?. <b>2013</b> , 73, 1649-51	6
2191	Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glyceemic control. <b>2013</b> , 12, 129	31
2190	Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. <b>2013</b> , 12, 131	8
2189	Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non-interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice. <b>2013</b> , 5, 43	2
2188	Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. <b>2013</b> , 13, 602	92
2187	Heterogeneity in the costs of type 1 diabetes in a developing country: what are the determining factors?. <b>2013</b> , 5, 83	2
2186	Initial management of severe hyperglycemia in patients with type 2 diabetes: an observational study. <b>2013</b> , 4, 375-84	3
2185	Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. <b>2013</b> , 4, 195-220	59

2184	Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. <b>2013</b> , 4, 417-30	20
2183	Incretin-based therapies: focus on effects beyond glycemic control alone. <b>2013</b> , 4, 221-38	12
2182	The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. <b>2013</b> , 30, 1128-40	21
2181	Age-specific effectiveness and safety of newly initiated insulin therapy in Japanese patients with uncontrolled diabetes. <b>2013</b> , 4, 473-86	1
2180	Poor glycemic control in younger women attending Malaysian public primary care clinics: findings from adults diabetes control and management registry. <b>2013</b> , 14, 188	6
2179	Triologue Plus: Management of cardiovascular risk in hyperglycaemic/diabetic patients at hospital discharge. <b>2013</b> , 50, 989-98	2
2178	Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials. <b>2013</b> , 5, 70	9
2177	Prevalence, sociodemographic distribution, treatment and control of diabetes mellitus in Panama. <b>2013</b> , 5, 69	11
2176	Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. <b>2013</b> , 30, 1009-18	36
2175	The Metabolic Syndrome. <b>2013</b> ,	6
2174	Once weekly exenatide: efficacy, tolerability and place in therapy. <b>2013</b> , 15, 871-81	20
2173	Choice of early treatment regimen and impact on $\beta$ cell preservation in type 2 diabetes. <b>2013</b> , 67, 876-87	15
2172	Temas de actualidad en cardiología: riesgo vascular y rehabilitaci3n cardiaca. <b>2013</b> , 66, 124-130	9
2171	Diabetes mellitus. <b>2013</b> , 7-15	
2170	Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. <b>2013</b> , 30, 1160-71	103
2169	Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. <b>2013</b> , 35, 1211-1222.e2	23
2168	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. <b>2013</b> , 27, 274-9	13
2167	Dapagliflozin: a guide to its use in type 2 diabetes mellitus. <b>2013</b> , 29, 194-199	

2166	Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes. <b>2013</b> , 29, 1599-608	15
2165	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. <b>2013</b> , 10, 289-301	119
2164	Cardiovascular disease and the use of insulin. <b>2013</b> , 15, 789-91	1
2163	Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. <b>2013</b> , 1281, 64-91	452
2162	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. <b>2013</b> , 67, 1267-82	245
2161	Comprehensive approach to the management of diabetes: offering improved outcomes for diabetics and the healthcare system. <b>2013</b> , 3, 505-528	2
2160	Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 update. <b>2013</b> , 61, 2020-6	208
2159	Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. <b>2013</b> , 29, 911-20	26
2158	The tolerability and safety of DPP-4 inhibitors for the treatment of older people with type 2 diabetes mellitus: an observational study. <b>2013</b> , 13, 187-191	2
2157	A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2013</b> , 29, 793-9	5
2156	Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. <b>2013</b> , 29, 1083-91	30
2155	Rapid oxalate determination in blood and synthetic urine using a newly developed oxometer. <b>2013</b> , 27, 145-8	1
2154	Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus. <b>2013</b> , 29, 1587-97	1
2153	Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. <b>2013</b> , 10, 302-14	63
2152	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. <b>2013</b> , 15, 523-30	38
2151	GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. <b>2013</b> , 154, 127-39	234
2150	Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus. <b>2013</b> , 8, 21-35	1
2149	GLP-1 receptor activated insulin secretion from pancreatic $\beta$ cells: mechanism and glucose dependence. <b>2013</b> , 15, 15-27	193

2148	Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. <b>2013</b> , 15, 42-54	74
2147	Will PPAR- $\delta$ agonist therapy still have a role in diabetes management in 2013?. <b>2013</b> , 3, 41-51	1
2146	[Comments to the study DIABES]. <b>2013</b> , 140, 142-3	
2145	Diabetes management in the kidney patient. <b>2013</b> , 97, 135-56	17
2144	It's time to change the way we manage nursing home residents with diabetes. <b>2013</b> , 34, 412-5	
2143	SGLT2 inhibitors for diabetes: turning symptoms into therapy. <b>2013</b> , 382, 917-8	10
2142	Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. <b>2013</b> , 185, 1-8	111
2141	Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. <b>2013</b> , 60, 517.e1-517.e18	2
2140	Prática de exercício físico e níveis de atividade física habitual em doentes com diabetes tipo 2 â€” estudo piloto em Portugal. <b>2013</b> , 8, 9-15	8
2139	Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: A population study. <b>2013</b> , 60, 557-569	4
2138	Pioglitazona en el control glucémico, perfil lipídico y riesgo cardiovascular: revisión actualizada sobre sus beneficios y datos emergentes sobre su seguridad. <b>2013</b> , 29, 1-12	
2137	Differences regionales chez les 987 diabétiques de type 2 de la cohorte française GRODIAB ^ lâ€™inclusion. <b>2013</b> , 7, 563-571	
2136	[Management of type 2 diabetes: patient education]. <b>2013</b> , 42, 880-5	1
2135	Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. <b>2013</b> , 62, 121-127	54
2134	Pragmatic diabetes management in nursing homes: individual care plan. <b>2013</b> , 14, 791-800	17
2133	What was new about vascular risk in the year 2012?. <b>2013</b> , 213, 442-452	
2132	Management of hyperglycemia in the intensive care unit: when glucose reaches critical levels. <b>2013</b> , 25, 7-13	1
2131	Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes. <b>2013</b> , 5, 51-57	

2130	Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies. <b>2013</b> , 5, 43-50		
2129	Diabetes and osteoporosis: Action of gastrointestinal hormones on the bone. <b>2013</b> , 213, 293-7		5
2128	Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the Aâdhieve study. <b>2013</b> , 101 Suppl 1, S45-9		3
2127	DAWN, lâūube dâūne nouvelle mēdecine. <b>2013</b> , 7, S1-S4		1
2126	Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbAâā 2013, 67, 317-21		20
2125	Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus. <b>2013</b> , 8, 345-349		
2124	American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. <b>2013</b> , 19, 536-57		196
2123	Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S212-8	14.6	33
2122	Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. <b>2013</b> , 382, 409-416		109
2121	Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. <b>2013</b> , 62, 1772-8		48
2120	Critical care diabetes education: who, what, when, where, and why. <b>2013</b> , 25, 123-30		
2119	Update in cardiology: Vascular risk and cardiac rehabilitation. <b>2013</b> , 66, 124-30		1
2118	Diabetes and osteoporosis: Action of gastrointestinal hormones on the bone. <b>2013</b> , 213, 293-297		
2117	Collaboration designed to increase translation of diabetes research outcomes into clinical practice. <b>2013</b> , 35, 712-3		
2116	Clinical decision making in diabetes: Use of glucagon-like peptide-1 (GLP-1) receptor agonists in clinical practice (where, when, and which?)âāIntroduction. <b>2013</b> , 5, 31-32		
2115	The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes. <b>2013</b> , 39, 290-8		26
2114	[Insulin therapy in type 2 diabetes]. <b>2013</b> , 32 Suppl 1, 25-31		1
2113	Aportaciones de los nuevos fīmacos para la diabetes. <b>2013</b> , 20, 155-165		

2112	Frailty and diabetes. <b>2013</b> , 382, 1386-7	20
2111	Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. <b>2013</b> , 213, 377-84	13
2110	Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. <b>2013</b> , 39, 306-13	41
2109	Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?. <b>2013</b> , 74, 207-10	
2108	Diabetes clinical decision-making in patients at risk: Taking patient complexity into account. <b>2013</b> , 5, 33-42	
2107	[Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: a population study]. <b>2013</b> , 60, 557-69	5
2106	Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients. <b>2013</b> , 213, 377-384	
2105	Improvements in our understanding of diabetes mellitus. <b>2013</b> , 88, 907-9	2
2104	Comparing diabetes drugs--helping clinical decisions?. <b>2013</b> , 381, 93-4	2
2103	Evidence-informed guidelines for treating frail older adults with type 2 diabetes: from the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) program. <b>2013</b> , 14, 801-8	54
2102	One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus. <b>2013</b> , 7, 143-7	1
2101	Thiazolidinediones/insulin use and cancer risk: insights from the recent meta-analyses. <b>2013</b> , 39, 3-5	1
2100	Estudio observacional de eficacia y seguridad del cambio de insulina NPH a glargina en atención primaria. Estudio LAURA. <b>2013</b> , 29, 137-144	4
2099	Management of post-transplant diabetes. <b>2013</b> , 13, 121-9	21
2098	Proton pump inhibitors: impact on glucose metabolism. <b>2013</b> , 43, 22-32	10
2097	Progression through diabetes therapies among new elderly users of metformin: a population-based study. <b>2013</b> , 30, e51-5	5
2096	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. <b>2013</b> , 26, 67-74	48
2095	Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. <b>2013</b> , 9, 67-8	30

2094	Age ≥60 years was an independent risk factor for diabetes-related complications despite good control of cardiovascular risk factors in patients with type 2 diabetes mellitus. <b>2013</b> , 48, 485-91		30
2093	New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity. <b>2013</b> , 35, A3-17		19
2092	Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. <b>2013</b> , 15, 372-82		460
2091	Incretins: what is known, new and controversial in 2013?. <b>2013</b> , 39, 89-93		5
2090	Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?. <b>2013</b> , 15, 967-77		50
2089	A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. <b>2013</b> , 35, 634-645.e1		19
2088	Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. <b>2013</b> , 9, 763-75		38
2087	Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. <b>2013</b> , 139, 51-9		105
2086	The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. <b>2013</b> , 13, 307-18		20
2085	Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. <i>Diabetes Care</i> , <b>2013</b> , 36, 2628-38	14.6	155
2084	Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. <b>2013</b> , 47, 490-505		28
2083	Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes. <b>2013</b> , 8, 229-238		4
2082	Treatment with Metformin. <b>2013</b> , 99-116		1
2081	Standards of medical care in diabetes--2013. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 1, S11-66	14.6	2668
2080	Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. <b>2013</b> , 1, 329-38		140
2079	The Metabolic Syndrome and Cancer. <b>2013</b> , 55-61		1
2078	Emerging gliptins for type 2 diabetes. <b>2013</b> , 18, 245-58		24
2077	Pharmacist-physician collaboration for diabetes care: the diabetes initiative program. <b>2013</b> , 47, 781-9		38



2076	Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus. <b>2013</b> , 33, 627-38		7
2075	Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. <b>2013</b> , 30, 81-101		46
2074	Diabetes mellitus in the next decade: novel pipeline medications to treat hyperglycemia. <b>2013</b> , 35, 714-23		4
2073	Relationships between gastric emptying, postprandial glycemia, and incretin hormones. <i>Diabetes Care</i> , <b>2013</b> , 36, 1396-405	14.6	201
2072	Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin. <b>2013</b> , 30, 337-53		9
2071	Diabetes and its comorbidities--where East meets West. <b>2013</b> , 9, 537-47		102
2070	The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). <b>2013</b> , 27, 280-6		36
2069	Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. <b>2013</b> , 70, 1123-31		10
2068	Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabetes. <b>2013</b> , 23, 4011-8		104
2067	Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. <i>Diabetes Care</i> , <b>2013</b> , 36, 1807-14	14.6	111
2066	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and $\beta$ cell function: the triple oral therapy. <b>2013</b> , 30, 846-54		10
2065	Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus. <b>2013</b> , 15, 335-41		6
2064	Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. <b>2013</b> , 98, 1845-59		158
2063	Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. <b>2013</b> , 56, 5094-114		62
2062	The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. <b>2013</b> , 33, 984-99		66
2061	Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. <b>2013</b> , 15, 291-300		54
2060	Unleash metformin: reconsideration of the contraindication in patients with renal impairment. <b>2013</b> , 47, 1488-97		28
2059	Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus. <b>2013</b> , 6, 603-12		3

2058	Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE). <b>2013</b> , 30, 167-75	12
2057	[Treatment of type 2 diabetes in the elderly]. <b>2013</b> , 140, 134.e1-134.e12	27
2056	Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. <b>2013</b> , 39, 397-403	30
2055	Inhibition of dipeptidyl peptidase (DPP)-IV and $\alpha$ -glucosidase activities by pepsin-treated whey proteins. <b>2013</b> , 61, 7500-6	140
2054	Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. <b>2013</b> , 19, 718-28	7
2053	Diabetes. <b>2013</b> , 9, 475-486	1
2052	Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus. <b>2013</b> , 29, 253-259	
2051	Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. <b>2013</b> , 47, 1532-9	23
2050	Prevention of exercise-related injuries and adverse events in patients with type 2 diabetes. <b>2013</b> , 89, 715-21	23
2049	Thyroid safety in patients treated with liraglutide. <b>2013</b> , 36, 140-5	15
2048	Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. <b>2013</b> , 15, 776-85	55
2047	Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. <b>2013</b> , 47, 1301-11	22
2046	The evolving role of the diabetes educator. <b>2013</b> , 345, 307-313	3
2045	Evaluation of type 2 diabetes mellitus medication management and control in older adults. <b>2013</b> , 28, 296-306	3
2044	Romanian Journal of Diabetes Nutrition and Metabolic Diseases - 20 Years After. <b>2013</b> , 20, 5-9	
2043	Comparison of physician practice patterns for older adults compared to NHANES diabetes cohort on oral/other therapy. <b>2013</b> , 13, 153-60	
2042	A practice-based research network focused on comparative effectiveness research in type 2 diabetes management. <b>2013</b> , 125, 172-80	1
2041	Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. <b>2013</b> , 125, 101-8	4

2040	Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin. <b>2013</b> , 125, 79-90		4
2039	The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. <b>2013</b> , 7, 511-6		7
2038	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. <b>2013</b> , 125, 7-20		62
2037	Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. <b>2013</b> , 125, 214-26		20
2036	SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. <b>2013</b> , 62, 1800-7		73
2035	Exenatide once weekly: opportunities in the primary care setting. <b>2013</b> , 125, 68-78		1
2034	Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?. <b>2013</b> , 41, 93-107		16
2033	Mechanisms of acute coronary syndromes. <b>2013</b> , 369, 883-4		50
2032	How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S180-9	14.6	12
2031	Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials. <b>2013</b> , 125, 145-54		8
2030	Interpreting adverse signals in diabetes drug development programs. <i>Diabetes Care</i> , <b>2013</b> , 36, 2098-106	14.6	20
2029	Alogliptin. <b>2013</b> , 48, 580-92		3
2028	Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. <b>2013</b> , 2013, 925874		19
2027	Comparison of two creatinine-based equations for predicting decline in renal function in type 2 diabetic patients with nephropathy in a korean population. <b>2013</b> , 2013, 848963		8
2026	Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 3860-2	14.6	59
2025	Is there evidence to support use of premixed or prandial insulin regimens in insulin-naive or previously insulin-treated type 2 diabetic patients?. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S205-11	14.6	8
2024	Saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adults. <b>2013</b> , 6, 15-24		
2023	Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. <b>2013</b> , 19, 751-7		6

2022	Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. <b>2013</b> , 41, 72-84		178
2021	Current Practice Patterns and Identified Educational Needs of Health Care Providers in Managing Patients With Type 2 Diabetes. <b>2013</b> , 31, 3-9		2
2020	Aging and endocrinology. <b>2013</b> , 453-465		
2019	Diabetes education: "Personal" family member or "impersonal" diabetes educator?. <b>2013</b> , 17, 945-6		
2018	Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria. <b>2013</b> , 2013, 895102		32
2017	Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S253-8	14.6	38
2016	Comment on: Raz et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes care</i> 2013;36:1779-1788. <i>Diabetes Care</i> , <b>2013</b> , 36, e192	14.6	1
2015	Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S292-300	14.6	4
2014	Lessons from the look action for health in diabetes study. <b>2013</b> , 17, S650-3		3
2013	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. <i>Diabetes Care</i> , <b>2013</b> , 36, 565-8	14.6	48
2012	Lessons from mouse models of high-fat diet-induced NAFLD. <b>2013</b> , 14, 21240-57		115
2011	Treat to goal: impact of clinical pharmacist referral service primarily in diabetes management. <b>2013</b> , 48, 656-61		4
2010	Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 2508-15	14.6	375
2009	Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride. <b>2013</b> , 18, e42		1
2008	Food insecurity and metabolic control among U.S. adults with diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 3093-9	14.6	124
2007	Effecten van liraglutide in de behandeling van type 2 diabetes in Nederland. <b>2013</b> , 11, 22-27		
2006	Insulin therapy attitudes and beliefs of physicians in Middle Eastern Arab countries. <b>2013</b> , 30, 560-7		15
2005	Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. <b>2013</b> , 169, 117-26		26

2004	Evaluation of a minimally invasive system for measuring glucose area under the curve during oral glucose tolerance tests: usefulness of sweat monitoring for precise measurement. <b>2013</b> , 7, 678-88		34
2003	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. <b>2013</b> , 7, 989-1001		28
2002	Effects of Consumer-Facing Technologies on Patient Engagement, Behavior Change, and Type 2 Diabetes-Related Health Outcomes. <b>2013</b> , 26, 98-101		4
2001	Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. <b>2013</b> , 125, 58-67		5
2000	Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. <b>2013</b> , 125, 47-57		62
1999	Persistent barriers and strategic practices: why (asking about) the everyday matters in diabetes care. <b>2013</b> , 39, 560-7		12
1998	Divide and Conquer: The Multidisciplinary Approach to Achieving Significant Long-Term Weight Loss and Improved Glycemic Control in Obese Patients With Type 2 Diabetes. <b>2013</b> , 31, 14-20		8
1997	Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. <i>Diabetes Care</i> , <b>2013</b> , 36, 1384-95	14.6	920
1996	Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S127-38	14.6	179
1995	Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. <b>2013</b> , 9, 681-94		11
1994	Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. <b>2013</b> , 125, 92-100		30
1993	Hypoglycemia in non-critically ill, hospitalized patients with diabetes: evaluation, prevention, and management. <b>2013</b> , 41, 109-16		14
1992	Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). <i>Diabetes Care</i> , <b>2013</b> , 36, 2254-61	14.6	173
1991	Common standards of basal insulin titration in type 2 diabetes. <b>2013</b> , 7, 771-88		35
1990	Effects of dapagliflozin on cardiovascular risk factors. <b>2013</b> , 125, 181-9		89
1989	Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly. <b>2013</b> , 26, 46-52		1
1988	First National Congress on Nutritional Medicine of the Dutch Nutraceutical Association. <b>2013</b> , 62, 146-157		1
1987	Achievement of goals in U.S. diabetes care, 1999-2010. <b>2013</b> , 368, 1613-24		670

1986	Response letter to Gazzaruso and colleagues. <b>2013</b> , 61, 667-8	
1985	Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus. <b>2013</b> , 6, 25-37	6
1984	The need for better insulin therapy. <b>2013</b> , 15 Suppl 1, 1-5	14
1983	A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. <b>2013</b> , 15, 1120-7	19
1982	The beneficial effect of metformin on $\beta$ cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. <b>2013</b> , 29, 664-72	20
1981	Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). <b>2013</b> , 67, 947-56	47
1980	Journal of Diabetes NEWS. <b>2013</b> , 5, 228-232	1
1979	Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. <b>2013</b> , 67, 307-16	61
1978	A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. <b>2013</b> , 38, 181-9	3
1977	Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. <b>2013</b> , 15, 455-62	24
1976	Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. <b>2013</b> , 67, 759-67	13
1975	A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. <b>2013</b> , 15, 1093-100	11
1974	Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. <b>2013</b> , 15, 463-73	376
1973	Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. <b>2013</b> , 4, 174-81	20
1972	Barriers to the delivery of diabetes care in the Middle East and South Africa: a survey of 1,082 practising physicians in five countries. <b>2013</b> , 67, 1144-50	12
1971	Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study. <b>2013</b> , 67, 1283-93	26
1970	American Diabetes Association 73rd Scientific Sessions, Chicago, Illinois, USA, 2013. <b>2013</b> , 5, 373-5	
1969	Self-titration of insulin in the management of people with type 2 diabetes: a practical solution to improve management in primary care. <b>2013</b> , 15, 690-700	33

1968	Metabolic syndrome in normoglycaemic elderly men. <b>2013</b> , 67, 964-70		2
1967	An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. <b>2013</b> , 15, 609-18		23
1966	National standards for diabetes self-management education and support. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 1, S100-8	14.6	141
1965	Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model. <b>2013</b> , 110, 690-5		46
1964	Clinical utility of insulin and insulin analogs. <b>2013</b> , 5, 67-78		31
1963	American Geriatrics Society identifies five things that healthcare providers and patients should question. <b>2013</b> , 61, 622-31		76
1962	The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study. <b>2013</b> , 16, 1231-7		8
1961	Comments on Petrak et al.'s "psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin": considerations for language and communication. <b>2013</b> , 15, 1053-4		2
1960	Dual peroxisome proliferator-activated receptor $\alpha$ /agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. <i>Diabetes Care</i> , <b>2013</b> , 36, 2923-30	14.6	162
1959	Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. <b>2013</b> , 3,		32
1958	Nutrition therapy recommendations for the management of adults with diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 3821-42	14.6	395
1957	Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care. <b>2013</b> , 31, 148-157		32
1956	[Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®))]. <b>2013</b> , 142, 134-43		1
1955	Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. <b>2013</b> , 60, 1275-80		42
1954	Association between beta cell function and future glycemic control in patients with type 2 diabetes. <b>2013</b> , 60, 517-523		24
1953	Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. <b>2013</b> , 36, 245-51		13
1952	Navigating complex patients using an innovative tool: the MTM Spider Web. <b>2013</b> , 53, 530-8		10
1951	Insulin: an evolving paradigm in diabetes management. <b>2013</b> , 19, 8-15		3

1950	Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. <b>2013</b> , 19, 792-9	46
1949	Kein Kontrollverlust über den Wolken!. <b>2013</b> , 7, 28-33	
1948	Comparative effectiveness for oral anti-diabetic treatments among newly diagnosed type 2 diabetics: data-driven predictive analytics in healthcare. <b>2013</b> , 2, 73-92	13
1947	Kardiovaskuläre Hochrisikopatienten mit Diabetes mellitus. <b>2013</b> , 13, 36-44	
1946	Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. <b>2013</b> , 61, 1152-60	25
1945	Management of type 2 diabetes. <b>2013</b> , 38, 13-6	3
1944	Pen colors facilitate the differentiation of SoloSTAR <sup>®</sup> insulin pens by users with normal and impaired color vision. <b>2013</b> , 3, 25-30	1
1943	Lipoprotein abnormalities in patients with type 2 diabetes and metabolic syndrome. <b>2013</b> , 26, 13-8	8
1942	Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C. <b>2013</b> , 19, 64-72	14
1941	Intensive versus conventional glycaemic control for treating diabetic foot ulcers. <b>2013</b> ,	2
1940	Canagliflozin: a novel treatment option for type 2 diabetes. <b>2013</b> , 7, 1399-408	18
1939	Effects of glucagon-like peptide-1 receptor agonists on renal function. <b>2013</b> , 4, 190-201	47
1938	South Carolina guidelines for diabetes care 2013. <b>2013</b> , 345, 296-301	1
1937	[Programs for continuing medical education: a session; 6. New trends in diabetes treatment--actions and usages of anti-diabetic medicines]. <b>2013</b> , 102, 624-31	
1936	Clinical utility and tolerability of linagliptin in diabetic patients. <b>2013</b> , 5, 67-78	1
1935	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. <b>2013</b> , 6, 171-85	6
1934	Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. <b>2013</b> , 6, 123-9	22
1933	Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. <b>2013</b> , 6, 435-44	7



1932 Is the indicator magnifying window for insulin pens helpful for elderly diabetic patients?. **2013**, 37, 149-51

1931 Response: efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes suboptimally controlled on oral antidiabetic therapy in Korea: a multicenter, open-label, single-arm study (diabetes metab j 2013;37:117-24). **2013**, 37, 214-5

1930 Metformin based dual-combination therapies in drug naïve type 2 diabetic patients. **2013**, 37, 429-32

3

1929 Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitus. **2013**, 8, 419-30

32

1928 Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. **2013**, 9, 247-57

11

1927 Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. **2013**, 6, 877-95

43

1926 [A patient-centered approach for the treatment of diabetes]. **2013**, 29, 683-4

1925 Comparison of DPP-4 Inhibitors. **2013**, 14, 111

2

1924 Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. **2013**, 19, 374-84

18

1923 Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. **2013**, 19, 462-70

16

1922 Learning theories reveal loss of pancreatic electrical connectivity in diabetes as an adaptive response. **2013**, 8, e70366

24

1921 The longitudinal association between depressive symptoms and initiation of insulin therapy in people with type 2 diabetes in primary care. **2013**, 8, e78865

15

1920 Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. **2013**, 6, 327-38

189

1919 Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?. **2013**, 74, 192-7

1918 Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. **2013**, 28, 881-7

9

1917 Update on Pharmacotherapy for Type 2 Diabetes. **2013**, 3, 250-361

1916 The science of hypoglycemia in patients with diabetes. **2013**, 9, 195-208

47

1915 Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. **2013**, 6, 75-9

14

1914	Lorcaserin for weight management. <b>2013</b> , 6, 209-16	11
1913	Role of insulin in the type 2 diabetes therapy: past, present and future. <b>2013</b> , 11, 137-44	17
1912	A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. <b>2013</b> , 7, 893-903	12
1911	Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients. <b>2013</b> , 37, 465-74	16
1910	[Diabetes: time to redefine goals?]. <b>2013</b> , 57, 545-9	2
1909	Pharmacological Treatments for Type 2 Diabetes. <b>2013</b> ,	0
1908	Psychodiabetic Kit and Its Application in Clinical Practice and Research. <b>2013</b> ,	
1907	Viewpoint: Using the patient-centred medicine clinical framework to better appreciate and explore the many barriers to care in Type 2 diabetes. <b>2014</b> , 6, 340	1
1906	Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting. <b>2014</b> , 7, 159-68	12
1905	Is adherence a relevant issue in the self-management education of diabetes? A mixed narrative review. <b>2014</b> , 7, 357-67	14
1904	Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. <b>2014</b> , 7, 229-39	4
1903	Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. <b>2014</b> , 8, 683-92	59
1902	Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies. <b>2014</b> , 20, 120-9	8
1901	Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. <b>2014</b> , 20, 501-12	20
1900	The durability of sitagliptin in elderly patients with type 2 diabetes. <b>2014</b> , 9, 1905-11	11
1899	Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly. <b>2014</b> , 8, 811-8	9
1898	Patient safety and minimizing risk with insulin administration - role of insulin degludec. <b>2014</b> , 6, 55-67	16
1897	Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin. <b>2014</b> , 8, 493-502	5

1896	Current status of prescription in type 2 diabetic patients from general hospitals in busan. <b>2014</b> , 38, 230-9	8
1895	Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. <b>2014</b> , 9, 1815-22	4
1894	Partnering with diabetes educators to improve patient outcomes. <b>2014</b> , 7, 45-53	54
1893	Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. <b>2014</b> , 9, e82880	47
1892	Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. <b>2014</b> , 9, e87799	11
1891	A randomized pilot trial of a moderate carbohydrate diet compared to a very low carbohydrate diet in overweight or obese individuals with type 2 diabetes mellitus or prediabetes. <b>2014</b> , 9, e91027	103
1890	Treatment pattern of type 2 diabetes differs in two German regions and with patients' socioeconomic position. <b>2014</b> , 9, e99773	14
1889	Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists. <b>2014</b> , 9, e106072	19
1888	[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals]. <b>2014</b> , 101, 175-83	7
1887	Low socioeconomic status is associated with increased risk for hypoglycemia in diabetes patients: the Diabetes Study of Northern California (DISTANCE). <b>2014</b> , 25, 478-90	39
1886	American Ginseng Extract (Panax quinquefolius L.) Is Safe in Long-Term Use in Type 2 Diabetic Patients. <b>2014</b> , 2014, 969168	14
1885	How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. <b>2014</b> , 10, 341-52	21
1884	Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia. <b>2014</b> , 7, 85-94	7
1883	Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. <b>2014</b> , 7, 399-409	12
1882	Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. <b>2014</b> , 9, 1963-80	42
1881	Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. <b>2014</b> , 3, 923-43	31
1880	Treating the elderly diabetic patient: special considerations. <b>2014</b> , 7, 391-400	6
1879	Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. <b>2014</b> , 3, 595-613	7

1878	Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes. <b>2014</b> , 01,	
1877	Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. <b>2014</b> , 7, 15-24	28
1876	Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. <b>2014</b> , 29, 90-7	30
1875	Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. <b>2014</b> , 8, 2493-505	12
1874	Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination. <b>2014</b> , 8, 227-36	4
1873	Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient. <b>2014</b> , 5, 305-15	17
1872	[Management of elderly patients with type 2 diabetes mellitus]. <b>2014</b> , 51, 210-3	
1871	Fixed-dose combination therapy in type 2 diabetes mellitus. <b>2014</b> , 20, 1322-32	18
1870	Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes. <b>2014</b> , 9, 1479-87	15
1869	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. <b>2014</b> , 05,	1
1868	Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients. <b>2014</b> , 6, 463-72	8
1867	Blood Pressure Control in Diabetic Nephropathy. <b>2014</b> , 04,	
1866	Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. <b>2014</b> , 114, S6-13	1
1865	Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. <b>2014</b> , 3, 212262	35
1864	Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). <b>2014</b> , 20, 785-91	22
1863	Clinical trial risk in type-2 diabetes: importance of patient history. <b>2014</b> , 17, 393-400	2
1862	Glycated hemoglobin HbA1c - a new risk marker for the outcome of cardiac surgery?. <b>2014</b> , 11, 7-11	1
1861	The right tool for the job. <b>2014</b> , 20, 1095-6	

1860	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. <b>2014</b> , 03,		1
1859	Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. <b>2014</b> , 5, 399-406		9
1858	Identifying consumer's needs of health information technology through an innovative participatory design approach among English- and Spanish-speaking urban older adults. <b>2014</b> , 5, 943-57		14
1857	The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus. <b>2014</b> , 20, 968-84		5
1856	Insulin supersensitivity and normoinsulinaemic hypoglycaemia in uncontrolled type 2 diabetes mellitus: clinical usefulness of 3 h assessment in the 75 g oral glucose tolerance test. <b>2014</b> , 2014,		3
1855	Understanding insulin management: Role of the pharmacist. <b>2014</b> , 20, 85-95		2
1854	Advances in managing type 2 diabetes: challenging old paradigms and developing new ones. <b>2014</b> , 6, 42		4
1853	Valoraci3n de la funci3n renal en diab3ticos tipo 2 y su adecuaci3n al tratamiento antidiab3tico oral. <b>2014</b> , 7, 8-13		
1852	Developing the diabetes team: practical issues of skill-mix change. <b>2014</b> , 25, 187-189		
1851	A patient-centred clinical approach to diabetes care assists long-term reduction in HbA1c. <b>2014</b> , 6, 195		8
1850	Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic. <b>2014</b> , 25, 1139-52		51
1849	Nutrition therapy recommendations for the management of adults with diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37 Suppl 1, S120-43	14.6	441
1848	Characteristics and practicalities of a new basal insulin. <b>2014</b> , 23, 16-20		2
1847	[Guidelines for the management of diabetes mellitus type 2]. <b>2014</b> , 40 Suppl 4, 11-8		5
1846	Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials. <b>2014</b> , 36, 1595-605		11
1845	Complicaciones de la diabetes y su asociaci3n con el estr3s oxidativo: un viaje hacia el da±o endotelial. <b>2014</b> , 21, 392-398		2
1844	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. <b>2014</b> , 4, 729-743		1
1843	An exploration of attitudes toward the use of patient incentives to support diabetes self-management. <b>2014</b> , 29, 552-63		14

1842	Novel antidiabetic nutrients identified by in vivo screening for gastric secretion and emptying regulation in rats. <b>2014</b> , 307, R869-78	6
1841	Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. <b>2014</b> , 71, 103-9	10
1840	Adverse effects and safety of SGLT-2 inhibitors. <b>2014</b> , 40, S28-34	64
1839	Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes. <b>2014</b> , 15, 235-49	4
1838	HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. <b>2014</b> , 57, 2475-84	99
1837	Hospital readmission and emergency department use based on prescribing patterns in patients with severely uncontrolled type 2 diabetes mellitus. <b>2014</b> , 16, 150-5	12
1836	Diabetes numeracy and blood glucose control: association with type of diabetes and source of care. <b>2014</b> , 32, 152-7	25
1835	Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. <b>2014</b> , 5, 567-78	10
1834	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. <b>2014</b> , 70, 1277-89	5
1833	Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment. <b>2014</b> , 34, 731-42	24
1832	Vitamin B12 deficiency is associated with adverse lipid profile in Europeans and Indians with type 2 diabetes. <b>2014</b> , 13, 129	48
1831	Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors. <b>2014</b> , 64-76	2
1830	Understanding incretins. <b>2014</b> , 40, 1751-4	5
1829	A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes. <b>2014</b> , 5, 521-34	10
1828	Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. <b>2014</b> , 37, 1211-8	7
1827	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. <b>2014</b> , 14, 129	48
1826	Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data. <b>2014</b> , 5, 483-98	2
1825	The association between different A1C-based measures of glycemia and risk of cardiovascular disease hospitalization. <i>Diabetes Care</i> , <b>2014</b> , 37, 167-72	14.6 11

1824	Alogliptin for the treatment of Type 2 diabetes. <b>2014</b> , 9, 547-559		1
1823	It's not black and white: individualizing metformin treatment in type 2 diabetes. <b>2014</b> , 99, 3125-8		5
1822	Improving medication adherence among patients with type 2 diabetes. <b>2014</b> , 27, 187-94		12
1821	Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. <b>2014</b> , 14, 869-78		10
1820	GLP-1-based strategies: a physiological analysis of differential mode of action. <b>2014</b> , 29, 108-21		12
1819	[Primary care for diabetic patients: a quality improvement cycle]. <b>2014</b> , 29, 302-10		0
1818	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 696-705	14.6	114
1817	Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. <b>2014</b> , 10, 599-608		4
1816	The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <b>2014</b> , 15, 2565-85		22
1815	Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data. <b>2014</b> , 9, 183-191		4
1814	Comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. <i>Diabetes Care</i> 2014;37:2132-2140. <i>Diabetes Care</i> , <b>2014</b> , 37, e261-2	14.6	1
1813	Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide. <b>2014</b> , 126, 35-46		22
1812	The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. <b>2014</b> , 126, 7-15		26
1811	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes. <b>2014</b> , 42, 96-108		6
1810	Increased circulating betatrophin concentrations in patients with type 2 diabetes. <b>2014</b> , 2014, 323407		84
1809	A suite of inpatient and outpatient clinical measures for pharmacy accountability: recommendations from the Pharmacy Accountability Measures Work Group. <b>2014</b> , 71, 669-78		8
1808	Cardiac autonomic dysfunction in type 2 diabetes - effect of hyperglycemia and disease duration. <b>2014</b> , 5, 130		38
1807	An accidental liraglutide overdose: case report. <b>2014</b> , 9, 23055		8

1806	Self-mixed/split insulin regimen: a serious omission in the ADA/EASD position statement. <i>Diabetes Care</i> , <b>2014</b> , 37, 3-4	14.6	2
1805	Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. <i>Diabetes Care</i> , <b>2014</b> , 37, 1024-31	14.6	52
1804	The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes. <b>2014</b> , 46, 348-53		10
1803	The Role of SIRT1 in Diabetic Kidney Disease. <b>2014</b> , 5, 166		55
1802	IRS1 G972R missense polymorphism is associated with failure to oral antidiabetes drugs in white patients with type 2 diabetes from Italy. <b>2014</b> , 63, 3135-40		14
1801	Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. <b>2014</b> , 126, 16-34		75
1800	Effective interventions to improve medication adherence in Type 2 diabetes: a systematic review. <b>2014</b> , 4, 29-48		41
1799	Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents. <b>2014</b> , 126, 111-25		4
1798	Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices. <b>2014</b> , 126, 145-60		18
1797	Bioequivalence of Canagliflozin/Metformin Immediate Release Fixed- Dose Combination Tablets Compared with Concomitant Administration of Single Components of Canagliflozin and Metformin in Healthy Fed Participants. <b>2014</b> , 06,		2
1796	Not so critical appraisal of dapagliflozin. <b>2014</b> , 8, 1101-4		
1795	Prescription Practice for Diabetes Management among a Female Population in Primary Health Care. <b>2014</b> , 2014, 103853		3
1794	Treat-to-target trials in diabetes. <b>2014</b> , 18, 166-74		9
1793	Allele and genotype frequency of a genetic variant in ataxia telangiectasia mutated gene affecting glycemic response to metformin in South Indian population. <b>2014</b> , 18, 850-4		8
1792	Prevalence of diabetes and cardiovascular risk factors in middle-class urban participants in India. <b>2014</b> , 2, e000048		43
1791	Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. <b>2014</b> , 40, 64-74		89
1790	Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial. <b>2014</b> , 62, 676-86		13
1789	Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus. <b>2014</b> , 126, 205-15		8



1788	Efficacy and safety of the adjustable gastric band - pooled interim analysis of the APEX and HERO studies at 48 weeks. <b>2014</b> , 30, 841-8	1
1787	Hypoglycemia, its implications in clinical practice, and possible ways to prevent it. <b>2014</b> , 30, 771-3	4
1786	Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. <b>2014</b> , 30, 1231-44	42
1785	Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. <b>2014</b> , 30, 1245-55	92
1784	Ethnic differences in psychological outcomes among people with diabetes: USA results from the second Diabetes Attitudes, Wishes, and Needs (DAWN2) study. <b>2014</b> , 30, 2241-54	31
1783	Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. <b>2014</b> , 30, 1219-30	45
1782	Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy. <b>2014</b> , 126, 95-106	7
1781	[Familial combined hyperlipidemia: consensus document]. <b>2014</b> , 46, 440-6	8
1780	A cascade of care for diabetes in the United States: visualizing the gaps. <b>2014</b> , 161, 681-9	99
1779	Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult. <b>2014</b> , 29, 110-23	8
1778	Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial. <b>2014</b> , 64, 269-75	4
1777	Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes (Teil 1). <b>2014</b> , 9, 145-196	1
1776	[Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus]. <b>2014</b> , 139 Suppl 2, S59-64	2
1775	Therapieoptionen des Diabetes mellitus Typ 2 bei hospitalisierten Patienten. <b>2014</b> , 9, R9-R20	
1774	Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes (Teil 2). <b>2014</b> , 9, 241-299	1
1773	[SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes]. <b>2014</b> , 139 Suppl 2, S52-8	3
1772	Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. <b>2014</b> , 10, 1585-605	35
1771	Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats. <b>2014</b> , 46, e111	28

1770	Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. <b>2014</b> , 4, e005942		10
1769	A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?—Moving toward personalized management of type 2 diabetes mellitus. <b>2014</b> , 126, 135-44		10
1768	Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors. <b>2014</b> , 126, 172-89		4
1767	Glycemic control in a 79-year-old female with mild cognitive impairment using a medication reminder device: a case report. <b>2014</b> , 26, 1045-8		7
1766	Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3. <b>2015</b> , 28, 327-31		6
1765	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. <b>2014</b> , 24, 1346-53		34
1764	National standards for diabetes self-management education and support. <i>Diabetes Care</i> , <b>2014</b> , 37 Suppl 1, S144-53	14.6	198
1763	[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin]. <b>2014</b> , 139 Suppl 2, S70-4		
1762	Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. <b>2014</b> , 6, 243-50		6
1761	Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. <b>2014</b> , 28, 880-6		36
1760	New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). <i>Diabetes Care</i> , <b>2014</b> , 37, 2755-62	14.6	226
1759	Intensification of medication and glycaemic control among patients with type 2 diabetes—the ADVANCE trial. <b>2014</b> , 16, 426-32		13
1758	Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. <b>2014</b> , 16, 645-50		31
1757	Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. <b>2014</b> , 6, 260-6		108
1756	Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. <b>2014</b> , 5, 499-520		33
1755	Dietary intake in Japanese patients with type 2 diabetes: Analysis from Japan Diabetes Complications Study. <b>2014</b> , 5, 176-87		28
1754	Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. <b>2014</b> , 16, 403-9		47
1753	Luseogliflozin for the treatment of type 2 diabetes. <b>2014</b> , 15, 2741-9		17

1752	Impact of «Conversation Map» tools on understanding of diabetes by Spanish patients with type 2 diabetes mellitus: A randomized, comparative study. <b>2014</b> , 61, 505-515	9
1751	Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia. <b>2014</b> , 61, 541-547	
1750	Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients. <b>2014</b> , 27, 180-8	26
1749	Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. <i>Diabetes Care</i> , <b>2014</b> , 37, 3309-16	14.6 78
1748	Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. <b>2014</b> , 16, 628-35	69
1747	Glycemic control in patients with type 2 diabetes mellitus in Spain. <b>2014</b> , 214, 429-436	1
1746	Aiming for better glucose control: is HbA(1c) of 7% the 'holy grail'? The clinical approach or seven clinical questions about 7. <b>2014</b> , 30, 346-9	1
1745	Early therapy for type 2 diabetes in China. <b>2014</b> , 2, 992-1002	42
1744	Empagliflozin for the treatment of type 2 diabetes. <b>2014</b> , 15, 2429-41	10
1743	Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes. <b>2014</b> , 16, 76-83	19
1742	Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. <b>2014</b> , 23, 699-710	30
1741	Severe obesity and diabetes self-care attitudes, behaviours and burden: implications for weight management from a matched case-controlled study. Results from Diabetes MILES--Australia. <b>2014</b> , 31, 232-40	12
1740	Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. <b>2014</b> , 14, 1992-2000	273
1739	Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. <b>2014</b> , 16, 1087-95	165
1738	Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. <b>2014</b> , 74, 2141-52	11
1737	Impact of the «Conversation Map» tools on understanding of diabetes by Spanish patients with type 2 diabetes mellitus: a randomized, comparative study. <b>2014</b> , 61, 505-15	12
1736	Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. <b>2014</b> , 36, 1606-15	22
1735	Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. <b>2014</b> , 2, 935-43	143

1734	The optimal morning:evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24-week multi-centre prospective, randomized controlled, open-labelled clinical study. <b>2014</b> , 31, 68-75	4
1733	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. <b>2014</b> , 16, 1257-64	73
1732	Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. <b>2014</b> , 30, 556-69	44
1731	Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy--a combined analysis of 713 type 2 diabetic patients. <b>2014</b> , 16, 248-54	5
1730	Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial. <b>2014</b> , 16, 186-92	13
1729	Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI. <b>2014</b> , 24, 1354-9	3
1728	Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia. <b>2014</b> , 61, 541-7	2
1727	Glycaemic control and implementation of the ADA/EASD-2006 consensus algorithm in type 2 diabetes mellitus patients in primary care in Spain. <b>2014</b> , 68, 28-39	2
1726	Mediterranean diet and type 2 diabetes. <b>2014</b> , 30 Suppl 1, 34-40	50
1725	Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31). <b>2014</b> , 5, 539-47	8
1724	Systematic review of the psychometric properties and theoretical grounding of instruments evaluating self-care in people with type 2 diabetes mellitus. <b>2014</b> , 70, 1209-27	45
1723	Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). <b>2014</b> , 5, 581-7	73
1722	Retinopathy, nephropathy, peripheral neuropathy and geriatric scale scores in elderly people with Type 2 diabetes. <b>2014</b> , 31, 107-11	20
1721	Diabetespatienten mit chronischer Niereninsuffizienz. <b>2014</b> , 10, 589-602	
1720	Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. <b>2014</b> , 6, 176-83	9
1719	The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. <b>2014</b> , 54, 61-9	2
1718	Insulintherapie bei multimorbiden geriatrischen Patienten. <b>2014</b> , 10, 482-485	1
1717	Insulintherapie bei Typ-2-Diabetes mellitus. <b>2014</b> , 10, 460-465	

1716	Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. <b>2014</b> , 53, 975-88			23
1715	Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. <b>2014</b> , 16, 147-58			273
1714	Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. <b>2014</b> , 19, 1231-40			57
1713	GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?. <b>2014</b> , 68, 557-67			71
1712	How many people inject insulin? UK estimates from 1991 to 2010. <b>2014</b> , 16, 553-9			31
1711	Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. <b>2014</b> , 17, 21-31			20
1710	Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. <b>2014</b> , 16, 206-14			7
1709	HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. <i>Diabetes Care</i> , <b>2014</b> , 37, 2141-8	14.6		166
1708	Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. <i>Diabetes Care</i> , <b>2014</b> , 37, 2723-30	14.6		61
1707	Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. <b>2014</b> , 17, 854-62			15
1706	Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus. <b>2014</b> , 5, 72-9			7
1705	Lessons from glargine trials: what is the goal fasting glucose with basal insulin?. <b>2014</b> , 6, 271-3			2
1704	A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. <b>2014</b> , 30, 2223-31			15
1703	Diabetes guidelines may delay timely adjustments during treatment and might contribute to clinical inertia. <b>2014</b> , 16, 768-70			10
1702	Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes. <b>2014</b> , 32, 170-7			5
1701	Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome. <b>2014</b> , 16, 722-7			4
1700	Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis. <b>2014</b> , 16, 801-11			40
1699	Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. <b>2014</b> , 16, 819-26			28

1698	Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study. <b>2014</b> , 6, 48		5
1697	A Brief History of the Development of Diabetes Medications. <b>2014</b> , 27, 82-6		86
1696	Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. <b>2014</b> , 63, 785-90		83
1695	Practice tips and tools for the successful use of U-500 regular human insulin: the diabetes educator is key. <b>2014</b> , 40, 153-65		18
1694	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management. <b>2014</b> , 11, 395-409		11
1693	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. <i>Diabetes Care</i> , <b>2014</b> , 37, 1924-30	14.6	40
1692	Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. <b>2014</b> , 30, 761-70		3
1691	Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2763-73	14.6	182
1690	Association of glycemic control with mortality in patients with diabetes mellitus undergoing percutaneous coronary intervention. <b>2014</b> , 7, 503-9		19
1689	Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists. <b>2014</b> , 32, 32-43		5
1688	Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. <b>2014</b> , 31, 1287-305		51
1687	The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist. <b>2014</b> , 5, 367-83		19
1686	Initial experience and evaluation of reusable insulin pen devices among patients with diabetes in emerging countries. <b>2014</b> , 5, 545-55		12
1685	Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage. <b>2014</b> , 14, 153		16
1684	Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. <b>2014</b> , 14, 162		5
1683	Behavioral health coaching for rural veterans with diabetes and depression: a patient randomized effectiveness implementation trial. <b>2014</b> , 14, 191		17
1682	Further investigation of the psychometric properties of the Insulin Treatment Appraisal Scale among insulin-using and non-insulin-using adults with type 2 diabetes: results from Diabetes MILES-Australia. <b>2014</b> , 12, 87		14
1681	Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes. <b>2014</b> , 6, 110		13

1680	Is hypoglycemia fear independently associated with health-related quality of life?. <b>2014</b> , 12, 167	36
1679	Increased circulating RANTES in type 2 diabetes. <b>2014</b> , 25, 46-51	16
1678	Hemoglobin A1C, mean glucose, and persistence of glycation ratios in insulin-treated diabetes. <b>2014</b> , 20, 252-60	10
1677	Clinical Considerations for Insulin Pharmacotherapy in Ambulatory Care, Part One: Introduction and Review of Current Products and Guidelines. <b>2014</b> , 32, 66-75	4
1676	Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. <b>2014</b> , 126, 56-65	10
1675	Canagliflozin: a new option for managing diabetes. <b>2014</b> , 27, 47-50	1
1674	MALAdaptive: do we avoid metformin unnecessarily?. <b>2014</b> , 27, 136-41	2
1673	Canagliflozin: a new class of antidiabetic agent targeting the sodium-glucose cotransporter. <b>2014</b> , 22, 97-104	7
1672	Update on the American Diabetes Association Standards of Medical Care. <b>2014</b> , 39, 22-32; quiz 32-3	16
1671	Role of the acute care nurse in managing patients with heart failure using evidence-based care. <b>2014</b> , 37, 357-76	6
1670	Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus. <b>2014</b> , 347, 491-501	4
1669	A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. <b>2014</b> , 5, 385-402	11
1668	Revascularization versus medical treatments in stable coronary artery disease: predicting the future of novel drug therapies for stable angina. <b>2014</b> , 63, 213-7	1
1667	Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. <b>2014</b> , 126, 19-32	23
1666	Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. <b>2014</b> , 63, 1303-14	30
1665	Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. <b>2014</b> , 126, 49-59	1
1664	Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes. <b>2014</b> , 32, 81-6	5
1663	Evidence-based practice use of incretin-based therapy in the natural history of diabetes. <b>2014</b> , 126, 66-84	9



1662	SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem. <b>2014</b> , 126, 111-7	16
1661	Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. <b>2014</b> , 126, 33-48	23
1660	Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. <b>2014</b> , 11, 34-40	12
1659	Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. <b>2014</b> , 126, 190-204	10
1658	Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. <b>2014</b> , 5, 854-9	30
1657	Personalized Diabetes Management: Moving from Algorithmic to Individualized Therapy. <b>2014</b> , 27, 87-91	22
1656	Metformin in patients with type 2 diabetes and kidney disease: a systematic review. <b>2014</b> , 312, 2668-75	355
1655	Pharmacotherapy considerations in diabetes and obesity: setting patients up for success. <b>2014</b> , 126, 100-9	4
1654	Simplifying and interpreting the FACTS of noninferiority trials: A stepwise approach. <b>2014</b> , 71, 1926, 1928, 1930-1	1
1653	Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. <b>2014</b> , 126, 93-105	15
1652	Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. <b>2015</b> , 11, 9-23	9
1651	Does gestational diabetes result in cochlear damage?. <b>2014</b> , 128, 961-5	10
1650	Typ-2-Diabetes. <b>2014</b> , 107-202	
1649	Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. <b>2014</b> , 2014, 294017	14
1648	Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study. <b>2014</b> , 14, 61	7
1647	National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. <b>2014</b> , 174, 678-86	199
1646	Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. <b>2014</b> , 126, 60-72	20
1645	Response to comment on Khunti et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. <i>Diabetes Care</i> , <b>2014</b> , 37, e114	14.6 0



1644	Stepping up: a nurse-led model of care for insulin initiation for people with type 2 diabetes. <b>2014</b> , 31, 349-56		25
1643	Identifying and meeting the challenges of insulin therapy in type 2 diabetes. <b>2014</b> , 7, 267-82		39
1642	Combining clinical judgment with guidelines for the management of type 2 diabetes: overall standards of comprehensive care. <b>2014</b> , 126, 85-94		5
1641	Introduction to personalized medicine in diabetes mellitus. <b>2014</b> , 5, e0002		18
1640	An Ethnographic Study of Diabetes: Implications for the Application of Patient Centred Care in Cameroon. <b>2014</b> , 2014, 1-12		5
1639	Influence of gastric emptying on the control of postprandial glycemia: physiology and therapeutic implications. <b>2014</b> , 12, 251-3		8
1638	Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data. <b>2014</b> , 69, 171-6		3
1637	The use of clinical guidelines highlights ongoing educational gaps in physicians' knowledge and decision making related to diabetes. <b>2014</b> , 14, 186		17
1636	Cardiovascular events and geriatric scale scores in elderly (70 years old and above) type 2 diabetic patients at inclusion in the GERODIAB cohort. <i>Diabetes Care</i> , <b>2014</b> , 37, 304-11	14.6	14
1635	Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. <b>2014</b> , 16, 1239-46		57
1634	Modifying effect of obesity on the association between sitting and incident diabetes in post-menopausal women. <b>2014</b> , 22, 1133-41		18
1633	[INERTIA study: Clinical inertia in non-insulinized patients on oral hypoglycemic treatment. A study in Spanish primary and specialty care settings]. <b>2014</b> , 142, 478-84		14
1632	Platelet function and hyperglycemia in acute coronary syndrome. <b>2014</b> , 67, 3-5		2
1631	How to prevent and treat pharmacological hypoglycemias. <b>2014</b> , 214, 202-208		
1630	[Use of glucose-lowering drugs in a primary care setting in Malaga during the years 2008-2012]. <b>2014</b> , 40, 4-11		5
1629	How to prevent and treat pharmacological hypoglycemias. <b>2014</b> , 214, 202-8		2
1628	Clinical and economic characteristics associated with type 2 diabetes. <b>2014</b> , 214, 121-30		11
1627	Research on hormonal contraception and HIV - Authors' reply. <b>2014</b> , 383, 305-6		5

1626	The glyceic status of diabetes in an urban area of Cambodia. <b>2014</b> , 104, e34-7	2
1625	Type 2 diabetes mellitus in elderly institutionalized patients. <b>2014</b> , 214, 521-528	
1624	[Cardiovascular effects and safety of glucose-lowering drugs: current situation]. <b>2014</b> , 40, 80-8	1
1623	Evaluation of the relationship between weight change and glyceic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. <b>2014</b> , 103, 402-11	17
1622	Impairment of executive cognitive control in type 2 diabetes, and its effects on health-related behavior and use of health services. <b>2014</b> , 37, 414-22	16
1621	SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes). <b>2014</b> , 46, 3-5	19
1620	Characteristics of patients with type 2 diabetes mellitus grouped by 5 classes of oral hypoglycemic agents based on assessment of treatment satisfaction. <b>2014</b> , 5, 134-143	1
1619	Baseline glyceic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients. <b>2014</b> , 46, 43-51	40
1618	New developments in diabetes management: medications of the 21st century. <b>2014</b> , 36, 477-84	22
1617	Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. <b>2014</b> , 51, 269-75	5
1616	Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. <b>2014</b> , 36, 84-100.e9	116
1615	Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment. <b>2014</b> , 28, 37-46	42
1614	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. <b>2014</b> , 57, 891-901	79
1613	Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MODaliTY of Insulin treatment eValuation (MOTIV) registry results. <b>2014</b> , 51, 655-61	6
1612	Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. <b>2014</b> , 74, 325-51	37
1611	Can primary care team-based transition to insulin improve outcomes in adults with type 2 diabetes: the stepping up to insulin cluster randomized controlled trial protocol. <b>2014</b> , 9, 20	13
1610	Sulfonylureas: a new look at old therapy. <b>2014</b> , 14, 473	92
1609	Real-world cost-effectiveness: lower cost of treating patients to glyceic goal with liraglutide versus exenatide. <b>2014</b> , 31, 202-16	17

1608 Saxagliptin: a guide to its use in type 2 diabetes mellitus. **2014**, 30, 92-99

1607 Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. **2014**, 31, 289-317 7

1606 Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. **2014**, 31, 345-61 28

1605 ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. **2014**, 21, 137-47 22

1604 Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. **2014**, 13, 33 49

1603 Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. **2014**, 51, 295-303 36

1602 Capsule commentary on Patrick et al., trends in insulin initiation and treatment intensification among patients with type 2 diabetes. **2014**, 29, 356

1601 Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. **2014**, 29, 320-7 18

1600 Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. **2014**, 37, 99-108 20

1599 Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study. **2014**, 34, 201-209 8

1598 Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve study. **2014**, 5, 113-26 1

1597 Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve study. **2014**, 5, 127-40 3

1596 Results from the UK cohort of SOLVE: providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. **2014**, 8, 57-63 10

1595 Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). **2014**, 100 Suppl 2, ii1-ii67 340

1594 An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. **2014**, 8, 29-60 246

1593 The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. **2014**, 10, 88-103 127

1592 Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. **2014**, 16, 467-77 204

1591 Updates on the management of diabetes in dialysis patients. **2014**, 27, 135-45 86

1590 Prise en charge pragmatique du diabétique en EHPAD. **2014**, 8, 37-45

1589	The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. <b>2014</b> , 38, 45-52	49
1588	Étude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d'un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine. <b>2014</b> , 8, 47-55	
1587	An update on the pharmacogenomics of metformin: progress, problems and potential. <b>2014</b> , 15, 529-39	42
1586	Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. <b>2014</b> , 1, 54-60	22
1585	Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. <b>2014</b> , 80, 825-33	49
1584	Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. <b>2014</b> , 40, 973-80	119
1583	Metformin usage in type 2 diabetes mellitus: are safety guidelines adhered to?. <b>2014</b> , 44, 266-72	18
1582	Computerized Clinical Decision Support for Patients with Diabetes and Chronic Kidney Disease. <b>2014</b> , 215-228	1
1581	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. <b>2014</b> , 30, 1209-18	7
1580	Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. <b>2014</b> , 16, 396-402	76
1579	Mad about "U". <b>2014</b> , 99, 771-3	2
1578	Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines--a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems. <b>2014</b> , 31, 1078-85	36
1577	Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. <b>2014</b> , 16, 433-42	64
1576	Non-diabetic renal disease in Croatian patients with type 2 diabetes mellitus. <b>2014</b> , 104, 443-50	27
1575	Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. <b>2014</b> , 36, 698-710	41
1574	Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. <b>2014</b> , 24, 689-97	148
1573	Diabetes and Kidney Disease. <b>2014</b> ,	0

1572	Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience. <b>2014</b> , 16, 241-6	14
1571	Insulin resistance, diabetes, and cardiovascular risk. <b>2014</b> , 16, 419	99
1570	Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment. <b>2014</b> , 10, 276-81	9
1569	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <b>2014</b> , 383, 1068-83	915
1568	Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. <b>2014</b> , 30, 431-45	15
1567	Inappropriate prescribing among elderly home care patients in Japan: prevalence and risk factors. <b>2014</b> , 5, 90-6	25
1566	Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the Community of Madrid (Spain). <b>2014</b> , 61, 11-7	6
1565	Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. <b>2014</b> , 104, 92-6	36
1564	Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. <b>2014</b> , 74, 223-42	65
1563	Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. <b>2014</b> , 30, 163-75	125
1562	Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. <b>2014</b> , 34, 135-46	34
1561	[Clinical evidence for metabolic surgery]. <b>2014</b> , 85, 952-6	0
1560	Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. <b>2014</b> , 74, 2161-74	37
1559	Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. <b>2014</b> , 16, 679-87	53
1558	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. <b>2014</b> , 9, 1223-51	21
1557	The older patient with diabetes: a practical approach. <b>2014</b> , 30, 88-95	9
1556	Anorexia nervosa complicated by diabetes mellitus: the case for permissive hyperglycemia. <b>2014</b> , 47, 671-4	10
1555	One-minute mental status examination for category fluency is more useful than mini-mental state examination to evaluate the reliability of insulin self-injection in elderly diabetic patients. <b>2014</b> , 5, 340-4	6

1554	Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. <b>2014</b> , 16, 588-601		26
1553	Diabetes in the elderly living in care homes. <b>2014</b> , 214, 517-8		
1552	Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). <i>Diabetes Care</i> , <b>2014</b> , 37, 2926-33	14.6	189
1551	Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. <b>2014</b> , 16, 1247-56		54
1550	The importance of weight management in type 2 diabetes mellitus. <b>2014</b> , 68, 682-91		133
1549	Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. <b>2014</b> , 16, 457		23
1548	One size does not fit all glycemic targets for type 2 diabetes. <b>2014</b> , 5, 134-41		21
1547	Metformin nephrotoxicity insights: will they change clinical management?. <b>2014</b> , 6, 111-2		4
1546	A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. <b>2014</b> , 16, 443-50		40
1545	Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. <b>2014</b> , 16, 567-75		19
1544	Lantus solostar in real life medical practice. <b>2014</b> , 21, 9-15		
1543	Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany. <b>2014</b> , 30, 785-9		5
1542	Diabetes: safety and efficacy of albiglutide-results from two trials. <b>2014</b> , 10, 514-6		
1541	Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. <b>2014</b> , 31, 861-72		14
1540	Konsequenzen für die Praxis. <b>2014</b> , 156, 76-79		1
1539	[Is there a rationale for early insulin treatment in type 2 diabetes?]. <b>2014</b> , 156, 37-40		
1538	Dapagliflozin: a review of its use in patients with type 2 diabetes. <b>2014</b> , 74, 2191-209		60
1537	Old and new basal insulin formulations: understanding pharmacodynamics is still relevant in clinical practice. <b>2014</b> , 16, 695-706		13

1536	Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. <b>2014</b> , 16, 223-30		31
1535	Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. <b>2014</b> , 40, 391-9		24
1534	Cystic fibrosis related diabetes--a new perspective on the optimal management of postprandial glycemia. <b>2014</b> , 28, 904-11		17
1533	Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. <b>2014</b> , 28, 831-5		21
1532	Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). <i>Diabetes Care</i> , <b>2014</b> , 37, 2168-76	14.6	208
1531	Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. <b>2014</b> , 48, 1494-501		46
1530	Hypoglycemia. <b>2014</b> , 127, S17-24		57
1529	Insuline et v�tu du patient : barri�re ou levier ?. <b>2014</b> , 8, 423-429		2
1528	Programme « L&Vous » : laboration d�une charte de bonne utilisation de l�insuline basale chez le patient diab�tique de type 2. <b>2014</b> , 8, 408-414		4
1527	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , <b>2014</b> , 37, 2647-59	14.6	48
1526	Aanbevelingen voor voedingstherapie bij de behandeling van volwassenen met diabetes. <b>2014</b> , 12, 51-56		
1525	Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). <i>Diabetes Care</i> , <b>2014</b> , 37, 2149-58	14.6	199
1524	Pharmacological treatment and therapeutic perspectives of metabolic syndrome. <b>2014</b> , 15, 329-41		56
1523	Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. <b>2014</b> , 74, 1769-84		30
1522	Metformin and cancer: mounting evidence against an association. <i>Diabetes Care</i> , <b>2014</b> , 37, 1786-8	14.6	67
1521	Glycemic treatment of diabetes mellitus. <b>2014</b> , 69-95		
1520	Traitement du diab�te et cancer : enqu�te � propos de deux controverses. <b>2014</b> , 8, 372-379		1
1519	Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. <b>2014</b> , 2, 801-9		174

1518	Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus. <b>2014</b> , 7, 225-33		2
1517	SGLT-2 inhibitors as second-line therapy in type 2 diabetes. <b>2014</b> , 2, 678-9		5
1516	Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. <i>Diabetes Care</i> , <b>2014</b> , 37, 740-50	14.6	204
1515	Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. <b>2014</b> , 70, 1149-58		94
1514	Cost effectiveness of liraglutide in type II diabetes: a systematic review. <b>2014</b> , 32, 1079-91		14
1513	Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. <b>2014</b> , 2, 740-53		123
1512	Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis. <b>2014</b> , 36, 1443-53.e9		16
1511	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. <b>2014</b> , 16, 1016-27		180
1510	Glycemic control in patients with type 2 diabetes mellitus in Spain. <b>2014</b> , 214, 429-36		28
1509	[Effects of GLP-1 receptor agonists on carbohydrate metabolism control]. <b>2014</b> , 143 Suppl 2, 18-22		
1508	[Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy]. <b>2014</b> , 143 Suppl 2, 12-7		1
1507	New developments in insulin therapy for type 2 diabetes. <b>2014</b> , 127, S39-48		20
1506	We can change the natural history of type 2 diabetes. <i>Diabetes Care</i> , <b>2014</b> , 37, 2668-76	14.6	59
1505	A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. <b>2014</b> , 16, 833-40		47
1504	Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. <b>2014</b> , 31, 621-38		59
1503	Glucose turnover after replacement of usual therapy by insulin in insulin-naïve type 2 diabetes subjects. <b>2014</b> , 99, 2225-32		5
1502	[Familial combined hyperlipidemia: consensus document]. <b>2014</b> , 40, 374-80		5
1501	Optical control of insulin release using a photoswitchable sulfonylurea. <b>2014</b> , 5, 5116		90



1500	Hemoglobin A1c in patients on peritoneal dialysis: how should we interpret it?. <b>2014</b> , 18, 375-82		11
1499	[Cardiovascular preventive recommendations]. <b>2014</b> , 46 Suppl 4, 3-15		4
1498	The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. <b>2014</b> , 17, 827-36		5
1497	[Role of classical oral glucose-lowering medications in current treatment]. <b>2014</b> , 40 Suppl 2, 9-15		
1496	Challenges associated with insulin therapy in type 2 diabetes mellitus. <b>2014</b> , 127, S11-6		39
1495	The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?. <b>2014</b> , 14, 799-808		17
1494	Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). <i>Diabetes Care</i> , <b>2014</b> , 37, 2159-67	14.6	243
1493	Individualizing HbA1c targets for patients with diabetes: impact of an automated algorithm within a primary care network. <b>2014</b> , 31, 839-46		9
1492	Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. <b>2014</b> , 31, 1505-14		35
1491	Nuevos fármacos para la diabetes mellitus tipo 2: amigos o enemigos. Reflexiones sobre una nueva guía de «armonización» del tratamiento de la diabetes mellitus tipo 2. <b>2014</b> , 30, 91-94		
1490	A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. <b>2014</b> , 31, 1032-8		21
1489	Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 2084-90	14.6	76
1488	Use of antidiabetic drugs in the U.S., 2003-2012. <i>Diabetes Care</i> , <b>2014</b> , 37, 1367-74	14.6	152
1487	Padrão terapêutico numa população de diabéticos tipo 2: relação com o tempo de doença e nível de cuidados de saúde. <b>2014</b> , 9, 15-20		2
1486	Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. <b>2014</b> , 16, 1165-73		203
1485	Comment on Moore et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. <i>Diabetes care</i> 2013;36:2981-2987. <i>Diabetes Care</i> , <b>2014</b> , 37, e150	14.6	4
1484	Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. <b>2014</b> , 16, 48-56		73
1483	Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. <b>2014</b> , 384, 1349-57		318

1482	Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals. <b>2014</b> , 11, 1381-9	16
1481	Glucemic control in patients with type 2 diabetes mellitus in Spain: Quo vadis?. <b>2014</b> , 214, 453-4	
1480	[Unmet needs in the treatment of type 2 diabetes]. <b>2014</b> , 143 Suppl 2, 41-3	
1479	Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. <b>2014</b> , 14, 165-76	5
1478	Effect of telehealth on glycaemic control: analysis of patients with type 2 diabetes in the Whole Systems Demonstrator cluster randomised trial. <b>2014</b> , 14, 334	25
1477	A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy. <b>2014</b> , 6, 73	16
1476	Metformin pharmacogenomics: current status and future directions. <b>2014</b> , 63, 2590-9	90
1475	Association between different hemoglobin A1c levels and clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus. <b>2014</b> , 15, 757-62	11
1474	The importance of patient compliance with insulin pens: how can a new user-friendly pen help?. <b>2014</b> , 11, 629-32	2
1473	Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <b>2014</b> , 45, 2160-236	2808
1472	Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c. <b>2014</b> , 168, 457-465.e2	11
1471	Telehealth Insulin Program: Managing Insulin in Primary Care. <b>2014</b> , 10, 567-574	2
1470	Indirect bioequivalence assessment using network meta-analyses. <b>2014</b> , 70, 947-55	3
1469	Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. <b>2014</b> , 28, 361-77	29
1468	Post-meal $\beta$ -cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose. <b>2014</b> , 6, 68	6
1467	A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. <b>2014</b> , 16, 527-36	41
1466	Standards of medical care in diabetes--2014. <i>Diabetes Care</i> , <b>2014</b> , 37 Suppl 1, S14-80	14.6 3373
1465	Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination. <b>2014</b> , 114, S22-9	5

1464	Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. <b>2014</b> , 348, g2366	153
1463	Rational use of electronic health records for diabetes population management. <b>2014</b> , 14, 479	20
1462	Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. <b>2014</b> , 5, 183-91	4
1461	Efficacy of liraglutide in a real-life cohort. <b>2014</b> , 5, 193-206	15
1460	Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. <b>2014</b> , 5, 207-24	12
1459	Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. <b>2014</b> , 5, 225-42	42
1458	Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice. <b>2014</b> , 5, 243-54	15
1457	Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycaemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. <b>2014</b> , 5, 267-83	60
1456	Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. <b>2014</b> , 34, 383-93	17
1455	Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy. <b>2014</b> , 34, 513-9	7
1454	Vildagliptin: a review of its use in type 2 diabetes mellitus. <b>2014</b> , 74, 587-610	26
1453	Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. <b>2014</b> , 74, 807-24	50
1452	The evolution of insulin glargine and its continuing contribution to diabetes care. <b>2014</b> , 74, 911-27	62
1451	Safety and efficacy of colesevelam HCl in the treatment of elderly patients. <b>2014</b> , 31, 461-70	5
1450	Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. <b>2014</b> , 37, 477-95	37
1449	An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol. <b>2014</b> , 15, 82	8
1448	A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin monotherapy. <b>2014</b> , 14, 17	17
1447	Management of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: an observational study. <b>2014</b> , 14, 23	7

1446	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. <b>2014</b> , 13, 65		135
1445	Patient preferences for noninsulin diabetes medications: a systematic review. <i>Diabetes Care</i> , <b>2014</b> , 37, 2055-62	14.6	56
1444	Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. <b>2014</b> , 63, 2188-95		153
1443	Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. <b>2014</b> , 31, 1178-84		31
1442	Pharmacogenomics of Oral Antidiabetic Drugs. <b>2014</b> , 683-713		0
1441	Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. <b>2014</b> , 16, 410-7		96
1440	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with $\beta$ -glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. <b>2014</b> , 16, 761-5		14
1439	Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 1014-20	14.6	17
1438	Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study. <b>2014</b> , 16, 442-6		1
1437	Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 634-43	14.6	86
1436	Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. <b>2014</b> , 384, 2228-34		278
1435	Rationale, design, and implementation of a cluster randomized trial using certified diabetes educators to intensify treatment for glycemia, blood pressure and lipid control: REMEDIES 4D. <b>2014</b> , 39, 124-31		7
1434	Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study. <b>2014</b> , 30, 1769-76		6
1433	Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. <b>2014</b> , 16, 457-66		170
1432	Prise en charge des patients diabétiques de type 2 durant le Ramadan : quelle place pour les inhibiteurs de la DPP-4 ?. <b>2014</b> , 8, 299-305		
1431	Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. <b>2014</b> , 17, 499-507		6
1430	Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study. <b>2014</b> , 20, 412-20		17
1429	Glycemic control using individualized targets among diabetic patients in Spain: a population-based study. <b>2014</b> , 67, 151-3		1

1428	Treating the whole not the hole: necessary coupling of technologies for diabetic foot ulcer treatment. <b>2014</b> , 20, 137-42	37
1427	Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. <b>2014</b> , 62, 1252-62	114
1426	Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action. <b>2014</b> , 40, 4S-26S	
1425	Insulin therapy in people with type 2 diabetes: opportunities and challenges?. <i>Diabetes Care</i> , <b>2014</b> , 37, 1499-508	14.6 94
1424	Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. <b>2014</b> , 36, 494-506	39
1423	The importance of incretin therapies for managing type 2 diabetes. <b>2014</b> , 2, 95-7	5
1422	How do health care professionals assess patients when initiating insulin therapy? A qualitative study. <b>2014</b> , 8, 49-55	5
1421	Linagliptin for elderly patients with type 2 diabetes. <b>2014</b> , 383, 306	
1420	Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. <b>2014</b> , 8, 111-7	15
1419	Is treatment with liraglutide efficient?. <b>2014</b> , 61, 202-208	4
1418	Type 2 diabetes mellitus in elderly institutionalized patients. <b>2014</b> , 214, 521-8	1
1417	Role of subcutaneous insulin management protocols and order sets in inpatient diabetes management. <b>2014</b> , 38, 101-17	3
1416	Strategies for the management of adverse events associated with mTOR inhibitors. <b>2014</b> , 28, 126-33	180
1415	Botanicals and translational medicine: a paradigm shift in research approach. <b>2014</b> , 30, S1-3	0
1414	Residual dysglycemia when at target HbA(1c) of 7% (53mmol/mol) in persons with type 2 diabetes. <b>2014</b> , 104, 370-5	19
1413	Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. <b>2014</b> , 2, 30-7	60
1412	Control de la glucemia de pacientes diabéticos en España mediante objetivos individualizados: un estudio de base poblacional. <b>2014</b> , 67, 151-153	3
1411	Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens. <b>2014</b> , 128, 70-6	14

1410	Glycaemic and haemoglobin A1c thresholds for detecting diabetic retinopathy: the fifth Korea National Health and Nutrition Examination Survey (2011). <b>2014</b> , 104, 435-42	19
1409	Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study. <b>2014</b> , 103, 286-91	7
1408	Funci3n plaquetaria e hiperglucemia en el s3ndrome coronario. <b>2014</b> , 67, 3-5	3
1407	Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). <b>2014</b> , 28, 386-92	90
1406	Basal insulin or longacting GLP-1 receptor agonists-making the right choice. <b>2014</b> , 2, 439-41	1
1405	Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. <b>2014</b> , 1, e3-e8	17
1404	Prioritization of patient-related factors according to renal function in antidiabetic drug selection: the REDIM Project. <b>2014</b> , 105, 199-205	2
1403	Is treatment with liraglutide efficient?. <b>2014</b> , 61, 202-8	4
1402	Glycemic management in ESRD and earlier stages of CKD. <b>2014</b> , 63, S22-38	58
1401	Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the community of Madrid (Spain). <b>2014</b> , 61, 11-17	4
1400	SGLT2 inhibitors in the treatment of type 2 diabetes. <b>2014</b> , 104, 297-322	113
1399	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. <b>2014</b> , 25, 407-14	101
1398	Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. <b>2014</b> , 16, 1111-20	81
1397	Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts. <i>Diabetes Care</i> , <b>2014</b> , 37, 372-80	14.6 13
1396	The pharmacogenetics of type 2 diabetes: a systematic review. <i>Diabetes Care</i> , <b>2014</b> , 37, 876-86	14.6 83
1395	Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. <b>2014</b> , 30, 742-8	12
1394	Factors associated with weight gain in people with type 2 diabetes starting on insulin. <i>Diabetes Care</i> , <b>2014</b> , 37, 2108-13	14.6 50
1393	Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. <b>2014</b> , 16, 560-8	35

1392	Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. <b>2014</b> , 16, 215-22	77
1391	Effect of risk factor control on simulated coronary heart disease events. <b>2014</b> , 114, 654	
1390	[Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN]. <b>2014</b> , 40, 261-73	3
1389	Control of type 2 diabetes after 1 year of laparoscopic adjustable gastric banding in the helping evaluate reduction in obesity (HERO) study. <b>2014</b> , 16, 1009-15	11
1388	Alogliptin benzoate for the treatment of type 2 diabetes. <b>2014</b> , 15, 851-63	11
1387	Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. <b>2014</b> , 28, 109-117	8
1386	Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. <b>2014</b> , 311, 2288-96	115
1385	HbA1c can be a useful glycemic control marker for patients with neonatal diabetes mellitus older than 20 weeks of age. <b>2014</b> , 436, 93-6	4
1384	Coronary artery disease and diabetes mellitus. <b>2014</b> , 32, 439-55	92
1383	Clinical and economic characteristics associated with type 2 diabetes. <b>2014</b> , 214, 121-130	0
1382	[Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica]. <b>2014</b> , 142, 85.e1-10	15
1381	Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (. <b>2014</b> , 1, 31-37	16
1380	Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. <b>2014</b> , 2, 464-73	126
1379	[111th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: 8. Progress in treatment of diabetes]. <b>2014</b> , 103, 2275-81	
1378	Switching from insulin to liraglutide improved glycemic control and the quality of life scores in a case of type 2 diabetes and active Crohn's disease. <b>2014</b> , 53, 1637-40	1
1377	Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia. <b>2014</b> , 5, 110	59
1376	Linagliptin: from bench to bedside. <b>2014</b> , 8, 431-46	16
1375	Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems. <b>2014</b> , 45	9



- 1374 Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. **2014**, 124, 485-7 31
- 1373 Patient profiling in diabetes and role of canagliflozin. **2014**, 367
- 1372 Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. **2014**, 10, 465-75 8
- 1371 2014 Meet-The-Professor: Endocrine Case Management. **2014**,
- 1370 CVD and type 2 diabetes: The nurse prescriber's role. **2014**, 9, 325-329
- 1369 A novel probiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report. **2014**, 5, 29-32 26
- 1368 A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. **2014**, 7, 25-30 9
- 1367 [Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database]. **2014**, 134, 299-304 14
- 1366 Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. **2014**, 61, 447-56 6
- 1365 Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes. **2014**, 61, 513-21 3
- 1364 Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced. **2014**, 61, 911-9
- 1363 Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. **2014**, 62, 324-7 17
- 1362 The importance of understanding the impact of preference in clinical trials of diabetes interventions. **2014**, 6, 496-8 1
- 1361 The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(®) study. **2014**, 68, 1338-44 7
- 1360 Type II diabetes and its therapy in clinical practice - results from the standardised non-interventional registry SIRTA. **2014**, 68, 1442-53 2
- 1359 Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). **2014**, 68, 1309-17 16
- 1358 Lixisenatide: clinical profile and available evidence. **2014**, 4, 71-84 2
- 1357 Pioglitazone, a peroxisome proliferator-activated receptor  $\gamma$  activator, suppresses coronary spasm. **2014**, 25, 671-7 7



1356	Lixisenatide in the treatment of Type 2 diabetes. <b>2014</b> , 9, 197-199	
1355	Misled by the Morning "Fasting" Plasma Glucose. <b>2015</b> , 9, 1342-5	5
1354	Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. <b>2015</b> , 15, 496	29
1353	Empagliflozin âinsulinunabhangige Kontrolle der Glykmieparameter bei Diabetes mellitus Typ 2 durch Inhibition des Natrium-Glukose-Cotransporters SGLT2. <b>2015</b> , 10, 247-265	2
1352	Clinical Predictors of Progressive Beta-Cell Failure in Type 2 Diabetes. <b>2015</b> , 63, 802-5	5
1351	Benefits to health care professionals and patients with diabetes of a novel blood glucose meter that provides pattern recognition and real-time automatic messaging compared to conventional paper logbooks. <b>2015</b> , 12, 27-33	6
1350	Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. <b>2015</b> , 31, 537-44	11
1349	Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. <b>2015</b> , 55, 1369-77	21
1348	Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. <b>2015</b> , 17, 675-81	101
1347	Impact on glycated haemoglobin of a biological response-based measure of medication adherence. <b>2015</b> , 17, 843-8	9
1346	Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. <b>2015</b> , 17, 859-67	161
1345	Implications of incretin-based therapies on cardiovascular disease. <b>2015</b> , 69, 531-49	10
1344	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. <b>2015</b> , 6, 182-91	15
1343	Efficacy and safety of lixisenatide in elderly (â5 years old) and very elderly (â5 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. <b>2015</b> , 31, 204-11	30
1342	Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. <b>2015</b> , 17, 994-1002	61
1341	Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. <b>2015</b> , 69, 1427-37	13
1340	Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial. <b>2015</b> , 6, 692-8	19
1339	Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. <b>2015</b> , 62, 399-409	21

- 1338 Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. **2015**, 62, 593-603 19
- 1337 Advances in the Discovery and Development of Peptide Therapeutics. **2015**,
- 1336 Type 2 diabetes mellitus. **2015**, 1, 15019 651
- 1335 TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL. **2015**, 21, 782-93 46
- 1334 American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â2015. **2015**, 21, 1-87 390
- 1333 Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. **2015**, 44, 1203-12 35
- 1332 [Programs for Continuing Medical Education: A session; 3. Diagnosis and treatment for diabetes 2014]. **2015**, 104, 490-5
- 1331 Cross-sectional and Longitudinal Analyses of Factors Contributing to the Progressive Loss of the Î²-cell Function in Type 2 Diabetes. **2015**, 54, 1971-6 3
- 1330 Changes in diabetes care indicators: findings from German National Health Interview and Examination Surveys 1997-1999 and 2008-2011. **2015**, 3, e000135 37
- 1329 2015 Meet-The-Professor: Endocrine Case Management. **2015**,
- 1328 Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. **2015**, 5, e009088 53
- 1327 Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. **2015**, 8, 73-81 12
- 1326 Clinical management of diabetes in ethnic groups. **2015**, 240-248
- 1325 Impaired glucose metabolism treatment and carcinogenesis. **2015**, 10, 589-594 4
- 1324 Peptides in metabolic diseases. **2015**, 112-130
- 1323 THE SYNERGY TO ENABLE GLYCEMIC CONTROL FOLLOWING EMERGENCY DEPARTMENT DISCHARGE PROGRAM FOR ADULTS WITH TYPE 2 DIABETES: STEP-DIABETES. **2015**, 21, 1227-39 13
- 1322 Was kommt nach Metformin?. **2015**, 12, 14-15
- 1321 Insulin dosing and outcomes among commercially insured patients with type 2 diabetes in the United States. **2015**, 37, 2297-2308.e1 6

1320 Wie kriegt man das Gefüisiko in den Griff?. **2015**, 9, 34-45

1319 Observatoire << L&Vous >> du diabéte de type 2 insulinotraité: le patient. **2015**, 9, 3S14-3S17

1318 Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Using Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes. **2015**, 32, 1206-21 26

1317 Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIC). **2015**, 15, 46 33

1316 Association of inpatient and outpatient glucose management with inpatient mortality among patients with and without diabetes at a major academic medical center. **2015**, 10, 228-35 1

1315 Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?. **2015**, 33, 2185-97 43

1314 The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. **2015**, 32, 890-8 25

1313 Evaluation of the Effectiveness of the H.A.N.D.S.M Program: A School Nurse Diabetes Management Education Program. **2015**, 31, 402-10 9

1312 Administration of granulocyte-colony stimulating factor accompanied with a balanced diet improves cardiac function alterations induced by high fat diet in mice. **2015**, 15, 162 8

1311 Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. **2015**, 15, 67 17

1310 Similarities and differences between patients included and excluded from a randomized clinical trial of vitamin D supplementation for improving glucose tolerance in prediabetes: interpreting broader applicability. **2015**, 16, 306 3

1309 Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. **2015**, 7, 91 14

1308 Proportion of Brazilian diabetes patients that achieve treatment goals: implications for better quality of care. **2015**, 7, 113 9

1307 Oral hypoglycemic agents: do the ends justify the means?. **2015**, 1, 19 4

1306 The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes. **2015**, 28, 227-9 4

1305 Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy. **2015**, 24, 1615-26 8

1304 Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differences. **2015**, 31, 269-79 4

1303 Clinical Insights Into a New, Disposable Insulin Delivery Device. **2015**, 28, 209-13 7

1302	Empagliflozin as add-on to metformin in people with Type 2 diabetes. <b>2015</b> , 32, 1555-67	58
1301	Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. <b>2015</b> , 17, 665-74	39
1300	Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. <b>2015</b> , 17, 809-12	33
1299	Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. <b>2015</b> , 17, 896-903	22
1298	Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. <b>2015</b> , 17, 1075-84	43
1297	Clinical outcomes and resource use after 24 months of insulin therapy in Turkish patients with type 2 diabetes: subgroup analysis of the TREAT study. <b>2015</b> , 69, 588-96	
1296	Thymic emigration patterns in patients with type 2 diabetes treated with metformin. <b>2015</b> , 146, 456-69	14
1295	New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?. <b>2015</b> , 32, 291-296a	
1294	Effect of Habitual Khat Chewing on Glycemic Control, Body Mass Index, and Age at Diagnosis of Diabetes in Patients with Type 2 Diabetes Mellitus in Yemen. <b>2015</b> , 8, 47-53	15
1293	Factors that drive insulin-dosing decisions of diabetes care providers: a vignette-based study in the Netherlands. <b>2015</b> , 32, 69-77	4
1292	Safety of antidiabetes medications: An update. <b>2015</b> , 98, 185-95	23
1291	Postoperative morbidity and mortality in type-2 diabetics after fast-track primary total hip and knee arthroplasty. <b>2015</b> , 120, 230-238	49
1290	Using qualitative methods in developing an instrument to identify barriers to self-care among persons with type 2 diabetes mellitus. <b>2015</b> , 24, 1024-37	5
1289	Comparison of the effects of Korean mindfulness-based stress reduction, walking, and patient education in diabetes mellitus. <b>2015</b> , 17, 516-25	27
1288	Potentiation of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting Alpha2-Adrenoceptor Antagonist. <b>2015</b> , 117, 392-8	3
1287	Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. <b>2015</b> , 17, 868-77	17
1286	Diabetes quality of care at a university community in Beirut. <b>2015</b> , 21, 824-30	3
1285	Diabetes self-management programmes in older adults: a systematic review and meta-analysis. <b>2015</b> , 32, 1404-14	58

1284	Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. <b>2015</b> , 17, 1194-7	6
1283	Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time. <b>2015</b> , 69, 186-98	13
1282	Diabetes Mellitus Care Provided by Nurse Practitioners vs Primary Care Physicians. <b>2015</b> , 63, 1980-8	35
1281	Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. <b>2015</b> , 4, 121-9	19
1280	Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). <b>2015</b> , 17, 1133-41	31
1279	Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes. <b>2015</b> , 25, 475-84	5
1278	Unintended positive and negative effects of drugs on lipoproteins. <b>2015</b> , 26, 325-37	3
1277	Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. <b>2015</b> , 17, 659-64	18
1276	10.2 Diabetes mellitus. <b>2015</b> ,	
1275	Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies. <b>2015</b> , 7, 95-103	8
1274	Diabetic patients' perspectives on the challenges of glycaemic control. <b>2015</b> , 7,	14
1273	Whey protein: The "whey" forward for treatment of type 2 diabetes?. <b>2015</b> , 6, 1274-84	42
1272	Prevalence, Clinical Correlates, and Use of Glucose-Lowering Drugs among Older Patients with Type 2 Diabetes Living in Long-Term Care Facilities. <b>2015</b> , 2015, 174316	5
1271	Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes. <b>2015</b> , 10, 991-1001	2
1270	Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. <b>2015</b> , 8, 49-56	37
1269	Intensive individualized reinforcement education is important for the prevention of hypoglycemia in patients with type 2 diabetes. <b>2015</b> , 39, 154-63	19
1268	Insulin Initiation in Insulin-Naŕe Korean Type 2 Diabetic Patients Inadequately Controlled on Oral Antidiabetic Drugs in Real-World Practice: The Modality of Insulin Treatment Evaluation Study. <b>2015</b> , 39, 481-8	9
1267	The multinational second Diabetes, Attitudes, Wishes and Needs study: results of the French survey. <b>2015</b> , 9, 289-97	20

1266	Empowerment, motivation, and medical adherence (EMMA): the feasibility of a program for patient-centered consultations to support medication adherence and blood glucose control in adults with type 2 diabetes. <b>2015</b> , 9, 1243-53	27
1265	Pragmatic measurement of health satisfaction in people with type 2 diabetes mellitus using the Current Health Satisfaction Questionnaire. <b>2015</b> , 6, 103-15	11
1264	Effectiveness of a serious game for medical education on insulin therapy: a pilot study. <b>2015</b> , 59, 470-3	10
1263	Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. <b>2015</b> , 21, 1204-12	8
1262	Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes. <b>2015</b> , 11, 107-16	8
1261	The effects of glucose-lowering therapies on diabetic kidney disease. <b>2015</b> , 11, 191-200	9
1260	Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial. <b>2015</b> , 8, 137-45	7
1259	Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism. <b>2015</b> , 21, 3606-20	38
1258	The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?. <b>2015</b> , 21, 678-87	5
1257	Targeting composite treatment of type 2 diabetes in middle-income countries--walking a tightrope between hyperglycaemia and the dangers of hypoglycaemia. <b>2015</b> , 106, 57-61	2
1256	Clinical significance of barriers to blood glucose control in type 2 diabetes patients with insufficient glycemic control. <b>2015</b> , 9, 837-45	8
1255	Clinical use of pasireotide for Cushing's disease in adults. <b>2015</b> , 11, 425-34	15
1254	[Adherence to nutritional recommendations and sociodemographic variables in patients with diabetes mellitus]. <b>2015</b> , 49, 619-25	10
1253	Optimizing care and outcomes for people with type 2 diabetes - lessons from a translational research program on insulin initiation in general practice. <b>2014</b> , 1, 60	4
1252	Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK. <b>2015</b> , 9, 1611-22	37
1251	The role of empagliflozin in the management of type 2 diabetes by patient profile. <b>2015</b> , 11, 739-49	7
1250	Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study. <b>2015</b> , 11, 149-55	6
1249	Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. <b>2015</b> , 11, 17-31	39

1248	Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. <b>2016</b> , 12, 30-41	43
1247	Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options. <b>2015</b> , 11, 621-32	30
1246	Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. <b>2015</b> , 6, 136-44	19
1245	The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. <b>2015</b> , 10, e0123116	22
1244	Use of the analytic hierarchy process for medication decision-making in type 2 diabetes. <b>2015</b> , 10, e0126625	26
1243	Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study. <b>2015</b> , 10, e0129922	6
1242	Quality of Diabetes Care: The Challenges of an Increasing Epidemic in Mexico. Results from Two National Health Surveys (2006 and 2012). <b>2015</b> , 10, e0133958	29
1241	Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. <b>2015</b> , 10, e0126704	28
1240	The Personalized Approach for Detecting Prediabetes and Diabetes. <b>2016</b> , 12, 58-65	1
1239	Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. <b>2015</b> , 15, 196-205	250
1238	Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial database. <b>2015</b> , 21, 243-53	45
1237	The Genetic Profile from HLA and Non-HLA Loci Allows Identification of Atypical Type 2 Diabetes Patients. <b>2015</b> , 2015, 485132	6
1236	Euglycemia in Diabetic Rats Leads to Reduced Liver Weight via Increased Autophagy and Apoptosis through Increased AMPK and Caspase-3 and Decreased mTOR Activities. <b>2015</b> , 2015, 497431	5
1235	Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study. <b>2015</b> , 2015, 251485	6
1234	Towards patient-oriented diabetes care: results from two KORA surveys in southern Germany. <b>2015</b> , 2015, 368570	5
1233	Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. <b>2015</b> , 2015, 706416	26
1232	New pharmacological approaches to diabetes management. <b>2015</b> , 26, 140-146	1
1231	Psychosocial management of diabetes: Role of diabetes educator. <b>2015</b> , 03, 058-060	



1230	Prediabetes: The Variation between HbA1c and Fasting Plasma Glucose. <b>2015</b> , Suppl 2,	2
1229	Type 2 diabetes drugs: a review. <b>2015</b> , 33, 304-10; quiz 311-2	6
1228	Myths and Misconceptions about Insulin Therapy among Latinos/ Hispanics with Diabetes: A Fresh Look at an Old Problem. <b>2015</b> , 06,	2
1227	βcell dysfunction: Its critical role in prevention and management of type 2 diabetes. <b>2015</b> , 6, 109-24	112
1226	Design and development of a scale of perceived barriers to self-care in patients with type 2 diabetes mellitus: an exploratory factor analysis. <b>2015</b> , 7, 1486-93	1
1225	Food habits of hypertensive and diabetics cared for in a Primary Health Care service in the South of Brazil. <b>2015</b> , 28, 197-206	4
1224	Overview of Glucagon-like Peptide-1 Receptor Agonists. <b>2015</b> , 33, 538-44	0
1223	Pharmacological Treatments for Type 2 Diabetes. <b>2015</b> ,	1
1222	Success of a sustained pharmaceutical care service with electronic adherence monitoring in patient with diabetes over 12 months. <b>2015</b> , 2015,	4
1221	Clinical predictors and time course of the improvement in βcell function with short-term intensive insulin therapy in patients with Type 2 diabetes. <b>2015</b> , 32, 645-52	12
1220	Fluorescence lifetime imaging ophthalmoscopy in type 2 diabetic patients who have no signs of diabetic retinopathy. <b>2015</b> , 20, 61106	59
1219	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. <b>2015</b> , 5, e007791	9
1218	[Appropriate medication prescribing in older people]. <b>2015</b> , 36, 677-89	9
1217	What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. <b>2015</b> , 108, 405-13	7
1216	Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. <b>2015</b> , 58, 4665-77	23
1215	Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. <b>2015</b> , 17, 607	21
1214	Polymorphisms of rs174616 in the FADS1-FADS2 gene cluster is associated with a reduced risk of type 2 diabetes mellitus in northern Han Chinese people. <b>2015</b> , 109, 206-12	13
1213	Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. <b>2015</b> , 45, 520-9	14



1212	Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?. <b>2015</b> , 24, 223-7	18
1211	The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. <b>2015</b> , 109, 378-88	64
1210	Automatic summarization of risk factors preceding disease progression an insight-driven healthcare service case study on using medical records of diabetic patients. <b>2015</b> , 18, 1163-1175	3
1209	The pace of change in medical practice and health policy: collision or coexistence?. <b>2015</b> , 30, 848-52	14
1208	β-cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. <b>2015</b> , 15, 602	172
1207	Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study. <b>2015</b> , 108, 432-40	26
1206	[Guidelines in the management of the diabetes mellitus type 2]. <b>2015</b> , 41, 334-42	
1205	Clinical considerations for insulin pharmacotherapy in ambulatory care, part two: review of primary literature and an evidence-based approach for treatment. <b>2015</b> , 33, 20-7	1
1204	Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventonal PROVIL Study. <b>2015</b> , 33, 55-61	16
1203	Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. <b>2015</b> , 31, 643-65	11
1202	Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. <b>2015</b> , 15, 23	7
1201	Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. <b>2015</b> , 16, 8	5
1200	Pharmacological treatment and current management of peripheral artery disease. <b>2015</b> , 116, 1579-98	66
1199	Diabetes and Dyslipidemia in Treated Human Immunodeficiency Virus Infection and Approaches for Cardiometabolic Care. <b>2015</b> , 441-469	
1198	A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes--impact on adherence. <b>2015</b> , 10, e0118296	66
1197	Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin. <b>2015</b> , 127, 277-81	
1196	Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial. <b>2015</b> , 109, 141-8	14
1195	Getting to goal in newly diagnosed type 2 diabetes using combination drug "subtraction therapy". <b>2015</b> , 64, 1005-12	2

1194	Towards Personalization of Diabetes Therapy Using Computerized Decision Support and Machine Learning: Some Open Problems and Challenges. <b>2015</b> , 237-260	20
1193	Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. <b>2015</b> , 6, 92-102	17
1192	Perioperative Care of the Surgical Patient. <b>2015</b> , 155-180	
1191	Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database. <b>2015</b> , 6, 627-634	5
1190	Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study. <b>2015</b> , 6, 192-200	22
1189	Present status of clinical deployment of glucokinase activators. <b>2015</b> , 6, 124-32	60
1188	Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. <b>2015</b> , 17, 1056-64	74
1187	User Assessment of "InsuOnLine," a Game to Fight Clinical Inertia in Diabetes: A Pilot Study. <b>2015</b> , 4, 335-43	14
1186	Demographic Disparities Among Medicare Beneficiaries with Type 2 Diabetes Mellitus in 2011: Diabetes Prevalence, Comorbidities, and Hypoglycemia Events. <b>2015</b> , 18, 283-9	11
1185	Time dictates: emerging clinical analyses of the impact of circadian rhythms on diagnosis, prognosis and treatment of disease. <b>2015</b> , 15 Suppl 6, s50-3	1
1184	Hypoglycaemic episodes in patients with type 2 diabetes--risk factors and associations with patient-reported outcomes: The PANORAMA Study. <b>2015</b> , 41, 470-9	21
1183	Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England. <b>2015</b> , 3, e000057	24
1182	Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study. <b>2015</b> , 3, e000074	18
1181	Examining Dose of Diabetes Group Medical Visits and Characteristics of the Uninsured. <b>2015</b> , 37, 1033-61	7
1180	Borderline ankle-brachial index is associated with increased prevalence of micro- and macrovascular complications in type 2 diabetes: A cross-sectional analysis of 12,772 patients from the Joint Asia Diabetes Evaluation Program. <b>2015</b> , 12, 334-41	15
1179	Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes. <b>2015</b> , 9, 593-601	4
1178	Prevention Of Coronary Heart Disease And Stroke Complications In Type 2 Diabetes Mellitus: An Observational, Prospective Study. <b>2015</b> , 22, 175-185	
1177	Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort. <b>2015</b> , 52, 1093-101	4

1176	The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes. <b>2015</b> , 6, 611-625		9
1175	Insulinoterapia. <b>2015</b> , 11, 5510-5518		
1174	Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers. <b>2015</b> , 37, 1503-16		13
1173	Safety and effectiveness of long-acting versus intermediate-acting insulin for patients with type 1 diabetes: protocol for a systematic review and individual patient data network meta-analysis. <b>2015</b> , 5, e010160		3
1172	Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. <b>2015</b> , 6, 375-88		15
1171	GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. <b>2015</b> , 41, 6S16-6S20		11
1170	Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on!. <i>Diabetes Care</i> , <b>2015</b> , 38, 170-5	14.6	34
1169	Why are anti-obesity drugs stigmatized?. <b>2015</b> , 14, 185-9		13
1168	Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 403-11	14.6	171
1167	Control de factores de riesgo cardiovascular en pacientes diabéticos revascularizados: un subanálisis del estudio ICP-Bypass. <b>2015</b> , 68, 115-120		7
1166	Type 2 diabetes mellitus in France in 2012: results from the ObEpi survey. <b>2015</b> , 41, 55-61		36
1165	Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification. <b>2015</b> , 41, 223-30		13
1164	Control of cardiovascular risk factors in revascularized patients with diabetes: a subanalysis of the ICP-Bypass study. <b>2015</b> , 68, 115-20		2
1163	Metformin and its use in chronic kidney disease, cardiovascular disease and cancer. <b>2015</b> , 8, 69-74		
1162	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <b>2015</b> , 58, 429-42		496
1161	Quality of diabetes care in low- and middle-income Asian and Middle Eastern countries (1993-2012): 20-year systematic review. <b>2015</b> , 107, 203-23		35
1160	Health-related quality of life in women and men with type 2 diabetes: a comparison across treatment groups. <b>2015</b> , 29, 203-11		17
1159	Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. <b>2015</b> , 6, 3-18		33

1158 Vascular Complications of Diabetes Mellitus. **2015**, 1541-1593

1157	Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. <b>2015</b> , 169, 379-386.e1	18
1156	Depressive symptoms prior to and following insulin initiation in patients with type 2 diabetes mellitus: Prevalence, risk factors and effect on physician resource utilisation. <b>2015</b> , 9, 346-53	5
1155	Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 394-402	14.6 146
1154	Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 365-72	14.6 95
1153	Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. <b>2015</b> , 32, 531-41	82
1152	Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. <b>2015</b> , 37, 574-84	32
1151	Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration. <b>2015</b> , 35, 660-70	11
1150	Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. <b>2015</b> , 17, 136-44	21
1149	Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. <b>2015</b> , 17, 170-8	28
1148	(4) Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. <i>Diabetes Care</i> , <b>2015</b> , 38 Suppl, S20-30	14.6 173
1147	New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). <b>2015</b> , 17, 386-94	218
1146	Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. <i>Diabetes Care</i> , <b>2015</b> , 38, 384-93	14.6 210
1145	Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes. <b>2015</b> , 108, 170-8	8
1144	Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review. <b>2015</b> , 32, 853-64	19
1143	Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. <b>2015</b> , 6, 125-138	43
1142	Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. <b>2015</b> , 17, 42-51	37
1141	Antidiabetic treatment patterns in a medicare advantage population in the United States. <b>2015</b> , 32, 169-78	3

1140 Pharmacologic Approach to Type 2 Diabetes in Obese Patients. **2015**, 171-202

1139 The effect of glibenclamide on insulin secretion at normal glucose concentrations. **2015**, 58, 43-9

7

1138 Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. *Diabetes Care*, **2015**, 38, 376-83

14.6 202

1137 Expedited diagnosis and management of inpatient hyperosmolar hyperglycemic nonketotic syndrome. **2015**, 27, 426-32

2

1136 Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy. **2015**, 7, 182-91

3

1135 Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study. **2015**, 127, 250-5

1134 Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. **2015**, 49, 351-9

39

1133 Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus. **2015**, 16, 781-4

2

1132 Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. **2015**, 64, 673-86

139

1131 Escaping the Hemoglobin A1c-Centric World in Evaluating Diabetes Mellitus Interventions. **2015**, 9, 1148-51

19

1130 Effectiveness of continuous glucose monitoring in dialysis patients with diabetes: the DIALYDIAB pilot study. **2015**, 107, 348-54

33

1129 Vascular function, insulin action, and exercise: an intricate interplay. **2015**, 26, 297-304

34

1128 Comment on: levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients. **2015**, 35, 757-8

1

1127 Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). **2015**, 6, 104-116

40

1126 Smart Health. **2015**,

8

1125 Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. **2015**, 21, 143-57

31

1124 Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. **2015**, 90, 356-65

45

1123 Efficacy of switching from premix analog insulin twice daily injection to insulin glargine once daily injection with sitagliptin. **2015**, 6, 33-38

3

1122	A comparison of the periodontal status in patients with type 2 diabetes based on glycated haemoglobin levels and other risk factors. <b>2015</b> , 60, 156-61	9
1121	Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study. <b>2015</b> , 31, 623-32	7
1120	Relationship between self-monitoring of blood glucose and glycaemic control among patients attending a specialist diabetes clinic in Jamaica. <b>2015</b> , 35, 26-32	1
1119	Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics. <b>2015</b> , 35, 277-97	4
1118	Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials. <b>2015</b> , 7, 448-61	11
1117	Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. <b>2015</b> , 14, 11	79
1116	Diabetes risks and health literacy in southern African American and Latino women. <b>2015</b> , 32, 12-23	6
1115	Detection of neuropathy using a sudomotor test in type 2 diabetes. <b>2015</b> , 5, 1-7	5
1114	Effect of the early intensive multifactorial therapy on the cardiovascular risk in patients with newly diagnosed type 2 diabetes: an observational, prospective study. <b>2015</b> , 88, 168-74	0
1113	Insulinoth�apie basale: pourquoi des objectifs glychmiques ambitieux?. <b>2015</b> , 9, 3S4-3S8	
1112	L'initiation de l'insulinoth�apie: une �tape difficile � ngocier pour les diab�tiques de type 2. <b>2015</b> , 9, 3S9-3S13	2
1111	Perspectives pour amliorer la prise en charge des patients diab�tiques de type 2 sous insuline. <b>2015</b> , 9, 3S34-3S42	0
1110	Valuation des effets cardiovasculaires du liraglutide : Conception et donn�es de base de lâ�tude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER� ). <b>2015</b> , 9, 316-328	1
1109	Assessment of possible efficacy of aqueous leaves extract of Psoralea bituminosa L. for anti-hyperglycaemic activity. <b>2015</b> , 5, 575-578	2
1108	Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. <b>2015</b> , 8, 20-27	1
1107	Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis. <b>2015</b> , 6, 317-28	9
1106	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. <b>2015</b> , 170, 753-759.e2	5
1105	Clinical use of insulin degludec. <b>2015</b> , 109, 19-31	43

1104	ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. <b>2015</b> , 9, 139-42		17
1103	Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. <b>2015</b> , 37, 1773-88.e1		64
1102	Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. <i>Diabetes Care</i> , <b>2015</b> , 38, 1372-82	14.6	223
1101	Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. <b>2015</b> , 109, 199-205		44
1100	Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents. <b>2015</b> , 354, 279-89		47
1099	Hyperglycemia. <b>2015</b> , 85-100		
1098	Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population. <b>2015</b> , 29, 1248-52		1
1097	Association of obesity with glucose, blood pressure, and lipid goals attainment in patients with concomitant diabetes and hypertension. <b>2015</b> , 31, 1623-31		6
1096	Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes. <b>2015</b> , 6, 273-87		24
1095	Joint influence of Patient-Assessed Chronic Illness Care and patient activation on glycaemic control in type 2 diabetes. <b>2015</b> , 27, 117-24		16
1094	Comparison of Patients Receiving Long-Term Metformin Therapy and Vitamin B Monitoring. <b>2015</b> , 31, 184-189		1
1093	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <b>2015</b> , 36, 2454-62		74
1092	Prevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities Study. <i>Diabetes Care</i> , <b>2015</b> , 38, 1290-8	14.6	22
1091	Why screening for type 2 diabetes is necessary even in poor resource settings. <b>2015</b> , 29, 961-4		9
1090	Adverse event notifications implicating metformin with lactic acidosis in Australia. <b>2015</b> , 29, 1261-5		17
1089	Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: Moving towards precision health for diabetes prevention. <b>2015</b> , 64, 1051-9		40
1088	Type 2 diabetes mellitus treatment patterns in U.S. nursing home residents. <b>2015</b> , 127, 429-37		4
1087	Food protein-derived bioactive peptides in management of type 2 diabetes. <b>2015</b> , 54, 863-80		107



1086	The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. <b>2015</b> , 58, 1409-21		122
1085	Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. <b>2015</b> , 37, 1493-502		18
1084	Diabetes Self-Management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. <b>2015</b> , 115, 1323-34		137
1083	Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. <b>2015</b> , 25, 898-905		45
1082	Authorised EU health claim for fructose. <b>2015</b> , 189-215		
1081	Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys. <b>2015</b> , 156, 2409-16		10
1080	Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study. <i>Diabetes Care</i> , <b>2015</b> , 38, 1742-9	14.6	60
1079	Time to be cautious about prescribing sulfonylureas?. <b>2015</b> , 65, 93-4		
1078	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. <b>2015</b> , 314, 151-61		260
1077	Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. <b>2015</b> , 37, 1789-96		10
1076	Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. <b>2015</b> , 110, 82-90		57
1075	Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. <b>2015</b> , 8, 8-19		13
1074	An observational study of glycemic control in canagliflozin treated patients. <b>2015</b> , 31, 1479-86		12
1073	Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. <b>2015</b> , 50, 553-8		14
1072	Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. <b>2015</b> , 29, 438-44		38
1071	Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control. <b>2015</b> , 33, 73-5		5
1070	Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus. <b>2015</b> , 72, 1097-103		7
1069	Metformin utilisation in Australian community and aged care settings. <b>2015</b> , 108, 336-41		3



1068	Using metformin in the presence of renal disease. <b>2015</b> , 350, h1758	9
1067	Emerging treatments for post-transplantation diabetes mellitus. <b>2015</b> , 11, 465-77	47
1066	Influences of health literacy, judgment skills, and empowerment on asthma self-management practices. <b>2015</b> , 98, 908-17	24
1065	Impact of socioeconomic status and gender on glycaemic control, cardiovascular risk factors and diabetes complications in type 1 and 2 diabetes: a population based analysis from a Scottish region. <b>2015</b> , 41, 145-51	34
1064	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimperide in Type 2 Diabetes (CAROLINA <sup>®</sup> ). <b>2015</b> , 12, 164-74	182
1063	Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. <b>2015</b> , 350, h454	59
1062	Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. <b>2015</b> , 41, 216-22	11
1061	Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. <b>2015</b> , 29, 838-45	25
1060	V-Go Insulin Delivery Device: A New Tool for Primary Care Settings. <b>2015</b> , 11, 341-346	0
1059	Clinical management of comorbid diabetes and psychotic disorders. <b>2015</b> , 2, 465-476	17
1058	Glucose metabolism in critically ill patients: are incretins an important player?. <b>2015</b> , 30, 201-8	5
1057	Impact des inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2) sur la glycémie post-prandiale. <b>2015</b> , 9, S17-S25	1
1056	Impact cardiovasculaire des incrtino-mimétiques chez le diabétique de type 2 : le point en 2015. <b>2015</b> , 9, 158-163	
1055	In vitro evaluation of hypoglycemic agents to target human islet amyloid polypeptide: a key protein involved in amyloid deposition and beta-cell loss. <b>2015</b> , 39, 373-82	6
1054	Eficacia y seguridad de una estrategia basal plus en pacientes con diabetes mellitus tipo 2 en la práctica clínica especializada. El estudio Basal Plus en España. <b>2015</b> , 31, 64-71	
1053	Le diabète de type 2 au stade de l'insuline : Quelle place pour les inhibiteurs de la DPP-4 ?. <b>2015</b> , 9, 53-63	
1052	Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes. <b>2015</b> , 8, 1-6	10
1051	Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. <b>2015</b> , 18, 198-205	25

1050	[Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015)]. <b>2015</b> , 27, 181-92		3
1049	Hypoglycaemia requiring medical assistance in patients with diabetes: a prospective multicentre survey in tertiary hospitals. <b>2015</b> , 41, 126-31		10
1048	Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. <b>2015</b> , 58, 1183-7		89
1047	Distinct HbA1c trajectories in a type 2 diabetes cohort. <b>2015</b> , 52, 267-75		37
1046	The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. <b>2015</b> , 26, 821-30		17
1045	Diabetespapienten mit chronischer Niereninsuffizienz. <b>2015</b> , 10, 63-76		1
1044	Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. <b>2015</b> , 32, 306-18		35
1043	Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. <b>2015</b> , 32, 341-55		67
1042	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. <b>2015</b> , 6, 127-42		32
1041	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. <b>2015</b> , 17, 689-98		3
1040	Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. <i>Diabetes Care</i> , <b>2015</b> , 38, 1218-27	14.6	97
1039	Shared decision making in type 2 diabetes with a support decision tool that takes into account clinical factors, the intensity of treatment and patient preferences: design of a cluster randomised (OPTIMAL) trial. <b>2015</b> , 16, 27		15
1038	Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. <b>2015</b> , 14, 12		49
1037	A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy. <b>2015</b> , 14, 13		6
1036	Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. <b>2015</b> , 19, 20		17
1035	Insulin initiation: bringing objectivity to choice. <b>2015</b> , 14, 17		10
1034	Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 1263-73	14.6	175
1033	Non-ICU hospital care of diabetes mellitus in the elderly population. <b>2015</b> , 15, 26		4

1032	Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. <b>2015</b> , 29, 595-8	30
1031	Evaluation of a Remote Monitoring System for Diabetes Control. <b>2015</b> , 37, 1216-25	23
1030	Treatment management and glycaemic control in a sample of 60 frail elderly diabetics with comorbidities. A retrospective chart review. <b>2015</b> , 26, 456-7	3
1029	Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males. <b>2015</b> , 32, 404-17	8
1028	Glycemic Variability: Assessing Glycemia Differently and the Implications for Dietary Management of Diabetes. <b>2015</b> , 35, 389-424	32
1027	Diabetes, myocardial infarction and stroke are distinct and duration-dependent predictors of subsequent cardiovascular events and all-cause mortality in older men. <b>2015</b> , 100, 1038-47	21
1026	Incretin-based medications for type 2 diabetes: an overview of reviews. <b>2015</b> , 17, 649-58	15
1025	Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. <b>2015</b> , 6, 29-40	9
1024	Injectable Coformulations in Diabetology. <b>2015</b> , 6, 101-11	12
1023	Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial. <b>2015</b> , 32, 201-15	12
1022	The Benefit of a Glucose-Sparing PD Therapy on Glycemic Control Measured by Serum Fructosamine in Diabetic Patients in a Randomized, Controlled Trial (IMPENDIA). <b>2015</b> , 129, 233-40	11
1021	Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. <b>2015</b> , 108, 350-9	18
1020	Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients. <b>2015</b> , 79, 1000-9	23
1019	Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. <i>Diabetes Care</i> , <b>2015</b> , 38, 1145-53	14.6 61
1018	The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. <b>2015</b> , 39, 383-9	25
1017	The Clinician's Guide to the Treatment of Obesity. <b>2015</b> ,	2
1016	Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR . <b>2015</b> , 30 Suppl 2, ii1-142	86
1015	Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. <b>2015</b> , 10, e0125879	98

1014	Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. <b>2015</b> , 17, 523-532	53
1013	Revisiting Disparities in Quality of Care Among US Adults With Diabetes in the Era of Individualized Care, NHANES 2007-2010. <b>2015</b> , 53, 25-31	19
1012	Multicenter cohort study of diabetes mellitus and impaired fasting glucose in HIV-infected patients in China. <b>2015</b> , 68, 298-303	11
1011	Metformin. <b>2015</b> , 4, 17-21	0
1010	Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. <b>2015</b> , 17, 581-590	153
1009	Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). <b>2015</b> , 17, 630-8	44
1008	New drugs for the treatment of diabetes mellitus. <b>2015</b> , 709-725	
1007	Combination therapy in type 2 diabetes mellitus. <b>2015</b> , 686-708	1
1006	Incretin-based therapies. <b>2015</b> , 726-744	
1005	An Overview of Glycemic Goals and Medications Used to Manage Type 2 Diabetes. <b>2015</b> , 50, 40-48	3
1004	DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. <b>2015</b> , 460, 1047-52	23
1003	Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?. <b>2015</b> , 8, 179-88	3
1002	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <b>2015</b> , 6, 61-7	24
1001	Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. <b>2015</b> , 261, 421-9	99
1000	Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. <b>2015</b> , 17, 699-702	37
999	New mechanisms of metformin action: Focusing on mitochondria and the gut. <b>2015</b> , 6, 600-9	103
998	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. <b>2015</b> , 12, 90-100	283
997	Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. <b>2015</b> , 3, 251-62	29

996	Alogliptin: a review of its use in patients with type 2 diabetes mellitus. <b>2015</b> , 75, 777-96	16
995	Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. <b>2015</b> , 108, 187-92	36
994	Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. <b>2015</b> , 4, 226-36	14
993	One Programme, Four Stakeholders: An Overview of the Utilisation of Patient-Reported Outcomes in Intervention Development to Meet the Needs of Regulators, Payers, Healthcare Professionals and Patients. <b>2015</b> , 29, 69-78	2
992	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. <b>2015</b> , 8, 273-82	1
991	Inkretin-basierte Therapie: ein ergänzender Therapieansatz bei Patienten mit Typ-1-Diabetes?. <b>2015</b> , 10, 85-90	
990	[S2k Guideline non-alcoholic fatty liver disease]. <b>2015</b> , 53, 668-723	85
989	The dynamic relationship between current and previous severe hypoglycemic events: a lagged dependent variable analysis among patients with type 2 diabetes who have initiated basal insulin. <b>2015</b> , 31, 1809-15	2
988	Interactive Exposure With a Blood Glucose Monitor With a Novel Glucose Color Range Indicator Is Associated With Improved Glucose Range Interpretation and Awareness in Patients With Type 2 Diabetes. <b>2015</b> , 9, 841-8	12
987	AFREZZA <sup>®</sup> (insulin human) Inhalation Powder: A Review in Diabetes Mellitus. <b>2015</b> , 75, 1679-86	21
986	Periaortitis induced by metformin. <b>2015</b> , 41, 344-345	1
985	An Overview of Metformin and Implications in the Workplace. <b>2015</b> , 63, 424-6	
984	Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. <b>2015</b> , 77, 83-9	4
983	Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. <b>2015</b> , 38, 1357-63	7
982	Attributing discrimination to weight: associations with well-being, self-care, and disease status in patients with type 2 diabetes mellitus. <b>2015</b> , 38, 863-75	36
981	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. <i>Diabetes Care</i> , <b>2015</b> , 38, 2293-300	14.6 35
980	New Therapeutic Approaches to Prevent or Delay Beta-Cell Failure in Diabetes. <b>2015</b> , 22, 311-319	
979	Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. <b>2015</b> , 31, 137-43	22

978	Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy. <b>2015</b> , 31, 1703-16		10
977	A Case-Based Guide to Clinical Endocrinology. <b>2015</b> ,		
976	Agonistes du r�cepteur au GLP-1 ou analogues rapides de lâ�nsuline chez les patients diab�tiques de type 2 en �chec d��nsulinoth�rapie basale : les r�sultats de lâ��tude 4B. <b>2015</b> , 9, 48-49		
975	Genetics, genomics and personalized medicine in Type 2 diabetes: a perspective on the Arab region. <b>2015</b> , 12, 417-431		5
974	Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes. <b>2015</b> , 75, 1523-34		16
973	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , <b>2015</b> , 38, e128-9	14.6	21
972	New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. <b>2015</b> , 49, 1153-61		28
971	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <b>2015</b> , 132, 691-718		239
970	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. <b>2015</b> , 127, 480-93		5
969	Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency. <b>2015</b> , 73, 362-71		41
968	A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus. <b>2015</b> , 63, 893-901		24
967	Comparison of the effects on glycaemic control and �cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). <b>2015</b> , 277, 137-50		37
966	Quantitative combination of natural anti-oxidants prevents metabolic syndrome by reducing oxidative stress. <b>2015</b> , 6, 206-217		32
965	Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada. <b>2015</b> , 37, 1677-88		9
964	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. <b>2015</b> , 6, 151-187		57
963	Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time. <b>2015</b> , 9, 482-9		17
962	The use of genetic information in the prediction of Type 2 diabetes. <b>2015</b> , 12, 483-496		4
961	Identification of matrine as a promising novel drug for hepatic steatosis and glucose intolerance with HSP72 as an upstream target. <b>2015</b> , 172, 4303-18		48

960	Teneligliptin: a review in type 2 diabetes. <b>2015</b> , 35, 765-72		16
959	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , <b>2015</b> , 38, 1567-82	14.6	133
958	Impact of Blood Glucose Reporting on Glycemic Variability in Veterans With Diabetes. <b>2015</b> , 9, 1348-9		
957	Current management of diabetes mellitus and future directions in care. <b>2015</b> , 91, 612-21		36
956	[Prevention of cardiovascular disease in patients with type 2 diabetes]. <b>2015</b> , 140, 645-9		1
955	Keys to long-term care of the liver transplant recipient. <b>2015</b> , 12, 639-48		35
954	Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR). <b>2015</b> , 3, e000059		14
953	Sleep apnea syndrome in endocrine clinics. <b>2015</b> , 38, 827-34		17
952	Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. <b>2015</b> , 201, 79-84		26
951	Differential regulation of angiotensin converting enzyme 2 and nuclear factor- $\kappa$ B by angiotensin II receptor subtypes in type 2 diabetic kidney. <b>2015</b> , 118, 71-81		21
950	Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. <b>2015</b> , 41, 417-30		105
949	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , <b>2016</b> , 39, 198-205	14.6	182
948	Translating What Works: A New Approach to Improve Diabetes Management. <b>2015</b> , 9, 857-64		18
947	Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. <b>2015</b> , 15, 227-32		25
946	Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011. <b>2015</b> , 16, 898.e9-14		6
945	Therapeutic potential of $\alpha$ -glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. <b>2015</b> , 16, 1959-81		142
944	Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. <b>2015</b> , 12, 249-57		11
943	Benchmarking by HbA1c in a national diabetes quality register--does measurement bias matter?. <b>2015</b> , 53, 1433-9		3



942	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , <b>2015</b> , 38, 1777-803	14.6	271
941	Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke. <b>2015</b> , 12, 463-6		13
940	Quadruple Response Factorial Design Optimization of Capillary Zone Electrophoresis Assay Procedure for Metformin and Sitagliptin Combination. <b>2015</b> , 38, 1379-1383		5
939	Poor stroke risk perception despite moderate public stroke awareness: insight from a cross-sectional national survey in Greece. <b>2015</b> , 24, 721-4		8
938	Clinical Outcomes of Continuation of Metformin Titration Instructions with Electronic Prescribing. <b>2015</b> , 2, 187-192		
937	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , <b>2015</b> , 38, e127	14.6	5
936	Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> 2015;38:140-149. <i>Diabetes Care</i> , <b>2015</b> , 38, e127	14.6	3
935	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials. <b>2015</b> , 127, 419-28		3
934	Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin+Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study. <b>2015</b> , 47, 895-900		10
933	Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. <b>2015</b> , 17, 294-303		156
932	Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. <b>2015</b> , 17, 179-87		68
931	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. <b>2015</b> , 64, 1786-93		141
930	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 140-9	14.6	1906
929	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. <b>2015</b> , 356, 443-53		41
928	Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?. <b>2015</b> , 38, 17-32		17
927	Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus. <b>2015</b> , 17, 231-44		9
926	Outcome analysis of hemoglobin A1c, weight, and blood pressure in a VA diabetes education program. <b>2015</b> , 47, 28-35		11
925	Clinical Inertia. <b>2015</b> ,		5



924	Neuromuscular electrostimulation and insulin sensitivity in patients with type 2 diabetes: the ELECTRODIAB pilot study. <b>2015</b> , 52, 285-91		9
923	Canagliflozin provides durable glyceic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. <i>Diabetes Care</i> , <b>2015</b> , 38, 355-64	14.6	170
922	Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. <b>2015</b> , 17, 268-75		115
921	Efficacy and tolerance of a diabetes specific formula in patients with type 2 diabetes mellitus: An open label, randomized, crossover study. <b>2015</b> , 9, 252-7		8
920	Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. <b>2015</b> , 6, 443-53		39
919	Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. <b>2015</b> , 14, 149-59		7
918	Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. <b>2015</b> , 17, 32-41		41
917	Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial. <b>2015</b> , 17, 276-84		8
916	The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice?. <b>2015</b> , 41, 132-7		14
915	Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. <b>2015</b> ,		1
914	Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?. <b>2015</b> , 277, 235-247		22
913	Glycemic targets: what is the evidence?. <b>2015</b> , 99, 47-67		10
912	Lifestyle intervention: nutrition therapy and physical activity. <b>2015</b> , 99, 69-85		8
911	Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. <b>2015</b> , 52, 21-9		20
910	Metformin and other antidiabetic agents in renal failure patients. <b>2015</b> , 87, 308-22		86
909	In vitro anti-diabetic effect and chemical component analysis of 29 essential oils products. <b>2015</b> , 23, 124-129		39
908	Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. <b>2015</b> , 9, 30-3		7
907	Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. <b>2015</b> , 52, 383-93		22

906	Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting. <b>2015</b> , 21, 68-76	14
905	Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation. <b>2015</b> , 18, 96-105	21
904	Mortality risk among sulfonylureas: a systematic review and network meta-analysis. <b>2015</b> , 3, 43-51	139
903	Reducing cardiovascular risk in type 2 diabetes mellitus. <b>2015</b> , 43, 7-12	1
902	Pharmacological Basis of Acute Care. <b>2015</b> ,	2
901	Diabetes and aging. <b>2015</b> , 31, xiii-xvi	1
900	Antidiabetic medications and polypharmacy. <b>2015</b> , 31, 17-27, vii	52
899	Incretin-based therapies. <b>2015</b> , 99, 107-29	22
898	Concomitant diabetes mellitus and heart failure. <b>2015</b> , 40, 7-43	54
897	Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. <b>2015</b> , 32, 27-34	15
896	Gender differences and patterns of cardiovascular risk factors in Type 1 and Type 2 diabetes: a population-based analysis from a Scottish region. <b>2015</b> , 32, 42-6	19
895	Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. <b>2015</b> , 6, 8-18	59
894	Plasma glucose monitoring and the subsequent HbA1c control in patients with type 2 diabetes on a basal supported oral therapy regimen in real life: subanalysis of the ALOHA study: a 24-week, prospective, open-label, multicenter, observational study. <b>2015</b> , 6, 66-76	2
893	Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. <b>2015</b> , 17, 15-22	17
892	Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. <b>2015</b> , 52, 47-53	38
891	Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. <b>2015</b> , 18, 359-65	22
890	Assessment of Silent Neuronal Injury Following Coronary Angiography and Intervention in Patients With Acute Coronary Syndrome. <b>2016</b> , 22, 52-9	3
889	Positive Regulation of Rhizophora mucronata Poir Extracts on Blood Glucose and Lipid Profile in Diabetic Rats. <b>2016</b> , 2,	1

888	EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES. <b>2016</b> , 22, 653-65	19
887	TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS. <b>2016</b> , 22, 546-54	6
886	Mode of administration of dulaglutide: implications for treatment adherence. <b>2016</b> , 10, 975-82	11
885	Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. <b>2016</b> , 40, 339-353	29
884	Metformin increases PDH and suppresses HIF-1 $\beta$ under hypoxic conditions and induces cell death in oral squamous cell carcinoma. <b>2016</b> , 7, 55057-55068	58
883	Vejle Diabetes Biobank - a resource for studies of the etiologies of diabetes and its comorbidities. <b>2016</b> , 8, 393-413	17
882	Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study. <b>2016</b> , 9, 217-23	11
881	Response: Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes (Diabetes Metab J 2015;39:498-506). <b>2016</b> , 40, 85-6	
880	Hypoglycemia: Culprit or Bystander?. <b>2016</b> , 40, 190-1	
879	Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus. <b>2016</b> , 40, 423-432	37
878	Maintenance of Clinical Endpoints After Discharge from a Pharmacist-Managed Risk Reduction Clinic at a Veterans Affairs Medical Center. <b>2016</b> , 22, 14-20	1
877	Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes. <b>2016</b> , 22, 449-66	8
876	Simplistic and complex thought in medicine: the rationale for a person-centered care model as a medical revolution. <b>2016</b> , 10, 449-57	19
875	Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients. <b>2016</b> , 10, 36	1
874	Factors associated with diet barriers in patients with poorly controlled type 2 diabetes. <b>2016</b> , 10, 37-44	20
873	Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy. <b>2016</b> , 12, 403-413	27
872	Phimosi with Preputial Fissures as a Predictor of Undiagnosed Type 2 Diabetes in Adults. <b>2016</b> , 96, 377-80	1
871	Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study. <b>2016</b> , 22, 272-80	14

870	Effects of Growth Hormone on Diurnal Insulin Sensitivity in Normal and Type 2 Diabetic Patients and Animal Models. <b>2016</b> , 7,	
869	The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication. <b>2016</b> , 17, 225	
868	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes. <b>2016</b> , 8, 19-34	3
867	"Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control. <b>2016</b> , 22, 1028-38	4
866	Oxygen-generating nanobiomaterials for the treatment of diabetes. <b>2016</b> , 331-353	1
865	Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics of Eastern and Western European Participants with Established Cardiovascular Disease in the LEADER Trial. <b>2016</b> , 07,	
864	Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin. <b>2016</b> , 10, 1539-46	0
863	Diabetes Drugs and Cardiovascular Safety. <b>2016</b> , 31, 239-44	10
862	Thromboprophylaxis in patients with atrial fibrillation: a real practice analysis. <b>2016</b> , 3, 16-22	0
861	Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors. <b>2016</b> , 22, 3252-60	16
860	THE EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES MELLITUS. <b>2016</b> , 9, 254	1
859	Impact of telephonic interviews on persistence and daily adherence to insulin treatment in insulin-naïve type 2 diabetes patients: dropout study. <b>2016</b> , 10, 851-61	5
858	Enhancing the Activity of Peroxisome Proliferator- Activated Receptor (PPAR) Activity through Natural Ligand Binding in Diabetes: Substantial Computational Approach. <b>2016</b> , 04,	1
857	EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM. <b>2016</b> , 22, 1406-1414	10
856	Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy. <b>2016</b> , 12, 12-17	19
855	Yoga for Adults with Type 2 Diabetes: A Systematic Review of Controlled Trials. <b>2016</b> , 2016, 6979370	114
854	Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones. <b>2016</b> , 2016, 7614270	35
853	Adaptation of the Godin Leisure-Time Exercise Questionnaire into Turkish: The Validity and Reliability Study. <b>2016</b> , 2016, 1-7	6

852	Evaluation of Hypoglycemia with Oral Hypoglycemic Agents by Using Spontaneous Adverse Event Reports Database. <b>2016</b> , 42, 416-428	3
851	The Change in HbA1c Associated with Initial Adherence and Subsequent Change in Adherence among Diabetes Patients Newly Initiating Metformin Therapy. <b>2016</b> , 2016, 9687815	7
850	Nepalese patients' perceptions of treatment modalities for type 2 diabetes. <b>2016</b> , 10, 1777-1786	14
849	Advances in the treatment of type 2 diabetes: impact of dulaglutide. <b>2016</b> , 9, 125-36	8
848	Metformin and Vitamin B12 Deficiency: Where Do We Stand?. <b>2016</b> , 19, 382-398	23
847	Reported Benefits of Insulin Therapy for Better Glycemic Control in Type 2 Diabetic Patients-Is This Applicable in Saudi Patients?. <b>2016</b> , 9, 13-7	1
846	The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents. <b>2016</b> , 10, 213-22	10
845	Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors. <b>2018</b> , 126, 268-276	3
844	The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece. <b>2018</b> , 126, 53-60	8
843	Dietary program and physical activity impact on biochemical markers in patients with type 2 diabetes: A systematic review. <b>2018</b> , 50, 590-610	14
842	The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation. <b>2018</b> , 26, 551-562	33
841	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <b>2018</b> , 6, 17-26	75
840	Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece. <b>2018</b> , 38, 67-77	8
839	Pharmacotherapy with Thymoquinone Improved Pancreatic $\beta$ Cell Integrity and Functional Activity, Enhanced Islets Revascularization, and Alleviated Metabolic and Hepato-Renal Disturbances in Streptozotocin-Induced Diabetes in Rats. <b>2018</b> , 101, 9-21	13
838	Effects of insulin analogs as an add-on to metformin on cutaneous microcirculation in type 2 diabetic patients. <b>2018</b> , 116, 6-14	4
837	Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. <b>2018</b> , 250, 188-194	12
836	Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. <b>2018</b> , 236, R29-R42	16
835	Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. <b>2018</b> , 30, 113-121	2

834	Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. <b>2018</b> , 20, 497-507	22
833	Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. <b>2018</b> , 34, 1-10	9
832	Diabetes primary prevention program: New insights from data analysis of recruitment period. <b>2018</b> , 34, e2943	7
831	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. <b>2017</b> , 9, 579	8
830	A risk score including body mass index, glycated haemoglobin and triglycerides predicts future glycaemic control in people with type 2 diabetes. <b>2018</b> , 20, 681-688	17
829	The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. <b>2018</b> , 26, 70-80	70
828	Effectiveness of a patient-centred, empowerment-based intervention programme among patients with poorly controlled type 2 diabetes: A randomised controlled trial. <b>2018</b> , 79, 43-51	26
827	Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis. <b>2018</b> , 9, 925-936	16
826	Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study. <b>2018</b> , 20, 1075-1079	6
825	Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes. <b>2018</b> , 62, 68-76	3
824	Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. <b>2018</b> , 10, 589-599	29
823	Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. <b>2018</b> , 20, 921-929	4
822	Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction. <b>2018</b> , 20, 153-159	9
821	Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. <b>2018</b> , 12, 155-162	7
820	INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES. <b>2018</b> , 24, 143-149	10
819	Safety of Metformin Therapy in Patients with Type 2 Diabetes Living on an Oxygen-Deficient Plateau, Tibet, China. <b>2018</b> , 126, 460-464	0
818	Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. <b>2018</b> , 20, 821-830	5
817	Family behaviours that have an impact on the self-management activities of adults living with Type 2 diabetes: a systematic review and meta-synthesis. <b>2018</b> , 35, 184-194	22

816	Individualizing Prevention for Older Adults. <b>2018</b> , 66, 229-234	32
815	SELF BLOOD GLUCOSE MONITORING UNDERESTIMATES HYPERGLYCEMIA AND HYPOGLYCEMIA AS COMPARED TO CONTINUOUS GLUCOSE MONITORING IN TYPE 1 AND TYPE 2 DIABETES. <b>2018</b> , 24, 47-52	9
814	Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study. <b>2018</b> , 135, 134-142	
813	Community Health Workers Supporting Clinical Pharmacists in Diabetes Management: A Randomized Controlled Trial. <b>2018</b> , 38, 58-68	10
812	Mitochondrial Targeted Therapies: Where Do We Stand in Mental Disorders?. <b>2018</b> , 83, 770-779	10
811	Building the patient-clinician relationship through conversation based on narrative approaches. <b>2018</b> , 35, 178-180	
810	L'Internista ospedaliero nella gestione del paziente diabetico complesso. <b>2018</b> , 6, 1	0
809	Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin. <b>2018</b> , 31, 261-266	1
808	Accuracy of a Self-monitoring Test for Identification and Monitoring of Age-related Macular Degeneration: A Diagnostic Case-control Study. <b>2018</b> , 12, 19-28	8
807	The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis. <b>2018</b> , 97, e11946	7
806	Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review. <b>2018</b> , 97, e11349	28
805	Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). <b>2018</b> , 2, 43	6
804	NSD2 is downregulated in T2DM and promotes $\beta$ cell proliferation and insulin secretion through the transcriptionally regulation of PDX1. <b>2018</b> , 18, 3513-3520	5
803	Treatment approach to type 2 diabetes: Past, present and future. <b>2018</b> , 9, 209-219	32
802	48 Diabetes mellitus Typ 1 und 2 und metabolisches Syndrom. <b>2018</b> ,	
801	PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. <b>2018</b> , 97, e13710	1
800	THE CIRCLE OF CARE IN DIABETES: FROM HOME TO HOSPITAL TO HOME. <b>2018</b> , 24, 1012-1014	2
799	Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study. <b>2018</b> , 65, 141-150	6



798	Diabetes Treatment, Control, and Hospitalization Among Adults Aged 18 to 44 in Minnesota, 2013-2015. <b>2018</b> , 15, E142	6
797	Monitoring glycaemic control in patients with diabetes mellitus. <b>2018</b> , 363, k4723	5
796	Type-2 diabetes mellitus and cardiovascular disease. <b>2018</b> , 14, 491-509	87
795	A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value. <b>2018</b> , 14, 34-38	1
794	Backpropagation Approach Supported by Image Compression Algorithm for the Classification of Chronic Condition Diseases. <b>2018</b> ,	2
793	Predictors of Glycemic Control in Patients with Type 2 Diabetes: A Subgroup Analysis of the Observational Registry of Basal Insulin Treatment Study in China. <b>2018</b> , 20, 825-832	1
792	Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. <b>2018</b> , 70, 915-921	3
791	Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials. <b>2018</b> , 8, 349-356	3
790	[Recommendations of the main clinical practice guidelines]. <b>2018</b> , 44 Suppl 1, 3-9	
789	The past decade in type 2 diabetes and future challenges. <b>2018</b> , 17, 451-459	7
788	Association of diabetes-related self-care activities with glycemic control of patients with type 2 diabetes in Pakistan. <b>2018</b> , 12, 2377-2385	16
787	Tailored Healthcare: Two Perspectives on the Development and Use of Patient Profiles. <b>2018</b> , 35, 1453-1459	8
786	Translation and validation of the PACIC+ questionnaire: the Thai version. <b>2018</b> , 19, 123	4
785	Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. <b>2018</b> , 8, e022448	3
784	Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers. <b>2018</b> , 40, 1729-1740	1
783	Changes in health services usage associated with insulin initiation in primary care. <b>2018</b> , 24, 155-161	
782	Managing Chronic Coronary Artery Disease in Patients with Diabetes. <b>2018</b> , 355-373	
781	Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland. <b>2018</b> , 9, 2325-2334	8



780	Improving Type 2 Diabetes Phenotypic Classification by Combining Genetics and Conventional Risk Factors. <b>2018,</b>	0
779	ISOLATION OF CUCURBITACIN-B FROM CUCUMIS CALLOSUS AND ITS HYPOGLYCEMIC EFFECT IN ISOLATED RAT ENTEROCYTES. <b>2018, 10, 123</b>	0
778	Illness Perception and Quality of Life in Type 2 Diabetes Mellitus Patients in Lampung, Indonesia. <b>2018, 10, 136</b>	
777	Blood Pressure Control and Other Quality of Care Metrics for Patients with Obesity and Diabetes: A Population-Based Cohort Study. <b>2018, 25, 391-399</b>	2
776	Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?. <b>2018, 14, 1149-1159</b>	8
775	Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study. <b>2018, 6, e000548</b>	6
774	Insulin Injection Technique is Associated with Glycemic Variability in Patients with Type 2 Diabetes. <b>2018, 9, 2347-2356</b>	6
773	Pancreatic Cancer and Diabetes Mellitus. <b>2018, 16, 466-478</b>	15
772	Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes. <b>2018, 9, 269-270</b>	2
771	Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. <b>2018, 19, 1841-1847</b>	6
770	2-Bromo-4'-methoxychalcone and 2-Iodo-4'-methoxychalcone Prevent Progression of Hyperglycemia and Obesity via 5'-Adenosine-Monophosphate-Activated Protein Kinase in Diet-Induced Obese Mice. <b>2018, 19,</b>	8
769	Development of the Dementia Assessment Sheet for Community-based Integrated Care System 8-items, a short version of the Dementia Assessment Sheet for Community-based Integrated Care System 21-items, for the assessment of cognitive and daily functions. <b>2018, 18, 1458-1462</b>	15
768	Patient and Provider Dilemmas of Type 2 Diabetes Self-Management: A Qualitative Study in Socioeconomically Disadvantaged Communities in Stockholm. <b>2018, 15,</b>	11
767	Self-management levels of diet and metabolic risk factors according to disease duration in patients with type 2 diabetes. <b>2018, 12, 69-77</b>	3
766	Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. <b>2018, 9, 1995-2014</b>	20
765	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set. <b>2018, 19, 427</b>	6
764	Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor. <b>2018, 33, 402</b>	
763	Strategies to assist uptake of pelvic floor muscle training for people with urinary incontinence: A clinician viewpoint. <b>2018, 37, 2658-2668</b>	8

762	Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). <b>2018</b> , 35, 928-936	5
761	National Rates of Initiation and Intensification of Antidiabetic Therapy Among Patients With Commercial Insurance. <i>Diabetes Care</i> , <b>2018</b> , 41, 1776-1782	14.6 3
760	Physicians' real-world experience with IDegLira: results of a European survey. <b>2018</b> , 6, e000531	10
759	Renal Sodium-Glucose Transporter-2 Inhibitors as Antidiabetic Agents. <b>2018</b> , 207-214	0
758	The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus. <b>2018</b> , 2018, 1890978	12
757	Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs. <b>2018</b> , 18, 83-85	
756	Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement. <b>2018</b> , 55, 1059-1066	11
755	Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol. <b>2018</b> , 7, 105	6
754	Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents. <b>2018</b> , 26, 4560-4566	6
753	Efficacy of Pharmacist Based Diabetes Educational Interventions on Clinical Outcomes of Adults With Type 2 Diabetes Mellitus: A Network Meta-Analysis. <b>2018</b> , 9, 339	30
752	Efficacy and Safety of Tenzinogliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2018</b> , 9, 449	11
751	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2018</b> , 9, 576	18
750	Glycemic Targets and Prevention of Chronic Complications. <b>2018</b> , 1-31	
749	Lack of coordination between partners: investigation of Physician-Preferred and Patient-Preferred (4P) basal insulin titration algorithms in the real world. <b>2018</b> , 12, 1253-1259	3
748	Streptozotocin-induced $\beta$ cell damage, high fat diet, and metformin administration regulate Hes3 expression in the adult mouse brain. <b>2018</b> , 8, 11335	3
747	Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. <b>2018</b> , 10, 413-421	7
746	Cystic Fibrosis-Related Diabetes. <b>2018</b> , 9, 20	40
745	Distinct Housing Conditions Reveal a Major Impact of Adaptive Immunity on the Course of Obesity-Induced Type 2 Diabetes. <b>2018</b> , 9, 1069	7

744	Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting. <b>2018</b> , 24, 805-814	5
743	Effect of Frey's procedure on islet cell function in patients with chronic calcific pancreatitis. <b>2018</b> , 17, 358-362	3
742	Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients. <b>2018</b> , 6,	11
741	Real-world prevalence of mild to moderate hypoglycemic episodes in type 2 diabetes in Portugal: Results from the HIPOS-PHARMA study. <b>2018</b> , 12, 537-546	4
740	A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. <b>2018</b> , 20, 2876-2884 <sup>19</sup>	
739	A preclinical overview of metformin for the treatment of type 2 diabetes. <b>2018</b> , 106, 1227-1235	36
738	Ertugliflozin for treatment of patients with Type 2 diabetes mellitus. <b>2018</b> , 11, 747-753	1
737	Wearable Contact Lens Biosensors for Continuous Glucose Monitoring Using Smartphones. <b>2018</b> , 12, 5452-5462	173
736	Individualised treatment targets in patients with type-2 diabetes and hypertension. <b>2018</b> , 17, 18	13
735	"I've made this my lifestyle now": a prospective qualitative study of motivation for lifestyle change among people with newly diagnosed type two diabetes mellitus. <b>2018</b> , 18, 204	23
734	PEGylated prodrugs of antidiabetic peptides amylin and GLP-1. <b>2018</b> , 292, 58-66	6
733	Levels of health awareness in diabetic patients during Ramadan 2015: Focus group discussion in Riyadh, Saudi Arabia. <b>2018</b> , 7 Suppl 1, S49-S54	3
732	SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic $\beta$ cell death in genetically obese mice. <b>2018</b> , 10, 181-189	8
731	High-Intensity Interval Training Is Equivalent to Moderate-Intensity Continuous Training for Short- and Medium-Term Outcomes of Glucose Control, Cardiometabolic Risk, and Microvascular Complication Markers in Men With Type 2 Diabetes. <b>2018</b> , 9, 475	11
730	The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. <b>2018</b> , 14, 955-963	7
729	Disparities in the Efficacy of Metformin in Combination with Dipeptidyl Peptidase-4 Inhibitor as Initial Treatment Stratified by Dosage and Ethnicity: A Meta-Analysis. <b>2018</b> , 20, 704-714	2
728	Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective. <b>2018</b> , 2018, 3718958	1
727	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <b>2018</b> , 32, 1035-1039	2

726	Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. <b>2018</b> , 12, 971-979	11
725	Type 2 diabetes and treatment intensification in primary care in Finland. <b>2018</b> , 55, 1171-1179	4
724	Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. <b>2018</b> , 12, 707-719	37
723	Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 2096-2104	14.6 34
722	The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective. <b>2018</b> , 9, 187-197	4
721	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. <b>2018</b> , 103, 2291-2301	125
720	Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. <b>2018</b> , 26, 3947-3952	5
719	Current Antidiabetic Drugs: Review of Their Efficacy and Safety. <b>2018</b> , 455-473	7
718	Adrenaline activation of the carotid body: Key to CO and pH homeostasis in hypoglycaemia and potential pathological implications in cardiovascular disease. <b>2019</b> , 265, 92-99	7
717	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <b>2019</b> , 21, 3-14	29
716	Short-term efficacy of high intensity group and individual education in patients with type 2 diabetes: a randomized single-center trial. <b>2019</b> , 42, 403-409	5
715	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. <b>2019</b> , 10, 418-428	13
714	Identification of novel analgesics through a drug repurposing strategy. <b>2019</b> , 9, 399-415	3
713	Effect of Telephone-Delivered Collaborative Goal Setting and Behavioral Activation vs Enhanced Usual Care for Depression Among Adults With Uncontrolled Diabetes: A Randomized Clinical Trial. <b>2019</b> , 2, e198634	16
712	Distinct trajectories of HbA in newly diagnosed Type 2 diabetes from the DPV registry using a longitudinal group-based modelling approach. <b>2019</b> , 36, 1468-1477	4
711	Can the Routine Use of Patient-Reported Outcome Measures Improve the Delivery of Person-Centered Diabetes Care? A Review of Recent Developments and a Case Study. <b>2019</b> , 19, 84	20
710	Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats. <b>2019</b> , 143, 153-163	11
709	Factors associated with clinical inertia in type 2 diabetes mellitus patients treated with metformin monotherapy. <b>2019</b> , 35, 2063-2070	3

708	Relevant patient characteristics for estimating healthcare needs according to healthcare providers and people with type 2 diabetes: a Delphi survey. <b>2019</b> , 19, 575		2
707	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , <b>2019</b> , 42, 2098-2107	14.6	15
706	Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. <b>2019</b> , 859, 172541		32
705	Development of a Healthy Lifestyle Assessment Toolkit for the General Public. <b>2019</b> , 6, 134		5
704	A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy. <b>2019</b> , 155, 107796		5
703	Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS. <b>2019</b> , 175, 112790		7
702	Association between Disturbances in Polyunsaturated Fatty Acid Metabolism and Development of Oxidative Stress during Experimental Diabetes Mellitus. <b>2019</b> , 167, 343-346		1
701	Improving empowerment, motivation, and medical adherence in patients with poorly controlled type 2 diabetes: A randomized controlled trial of a patient-centered intervention. <b>2019</b> , 102, 2238-2245		5
700	A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. <b>2019</b> , 2019, 228424031987657		1
699	Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. <b>2019</b> , 4, CD012368		13
698	Influence of Diabetes Complications on HbA Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. <i>Diabetes Care</i> , <b>2019</b> , 42, 2136-2142	14.6	3
697	A systematic review of diabetes self-management education interventions for people with type 2 diabetes mellitus in the Asian Western Pacific (AWP) region. <b>2019</b> , 6, 1424-1437		9
696	Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study. <b>2019</b> , 91, 776-785		12
695	Resources to Guide Exercise Specialists Managing Adults with Diabetes. <b>2019</b> , 5, 20		6
694	Verbesserung der Adhärenz zur Lebensstiländerung von Menschen mit Diabetes. <b>2019</b> , 15, 542-548		
693	Distinction of cardiometabolic profiles among people ≥5 years with type 2 diabetes: a latent profile analysis. <b>2019</b> , 19, 85		2
692	Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China. <b>2019</b> , 10, 1969-1984		3
691	Reduction of Severe Hypoglycaemia in People with Type 2 Diabetes after a Structured Inpatient Intervention. <b>2021</b> , 129, 587-592		4

690	Patients' perspective on self-management: type 2 diabetes in daily life. <b>2019</b> , 19, 605		17
689	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2272-2281	14.6	128
688	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. <b>2019</b> , 33, 107423		0
687	A systematic review exploring characteristics of lifestyle modification interventions in newly diagnosed type 2 diabetes for delivery in community pharmacy. <b>2019</b> , 27, 3-16		1
686	Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. <b>2019</b> , 131, 185-198		59
685	Differential vulnerability to neighbourhood disorder: a gene-environment interaction study. <b>2019</b> , 73, 388-392		10
684	Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes. <b>2019</b> , 13, 561-576		18
683	Impact of Lifestyle and Clinical Interventions on Mitochondrial Function in Obesity and Type 2 Diabetes. <b>2019</b> , 367-397		
682	Self and Family Management in Type 2 Diabetes: Influencing Factors and Outcomes. <b>2019</b> , 32, 189-197		2
681	Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. <b>2019</b> , 43, 276-286		11
680	The perceived barriers to insulin therapy among type 2 diabetic patients. <b>2019</b> , 19, 1638-1646		2
679	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. <b>2019</b> , 11, 42		6
678	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <b>2019</b> , 394, 39-50		186
677	Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground. <i>Diabetes Care</i> , <b>2019</b> , 42, 1615-1623	14.6	5
676	Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 1464-1472	14.6	4
675	Implications of resistin in type 2 diabetes mellitus and coronary artery disease: Impairing insulin function and inducing pro-inflammatory cytokines. <b>2019</b> , 234, 21758-21769		21
674	Guidelines for Medical Nutrition Therapy in Gestational Diabetes Mellitus: Systematic Review and Critical Appraisal. <b>2019</b> , 119, 1320-1339		19
673	Are patients with mild to moderate renal impairment on metformin or other oral anti-hyperglycaemic agents at increased risk of contrast-induced nephropathy and metabolic acidosis after radiocontrast exposure?. <b>2019</b> , 74, 651.e1-651.e6		3

672	Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and $\beta$ cell function in subjects with morbid obesity: a protocol for the Obesity urgency in T2Ds (seberg) study. <b>2019</b> , 9, e024573	8
671	Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. <b>2019</b> , 19, 213-225	4
670	Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. <b>2019</b> , 74, 328-337	18
669	Maltase Decorated by Chiral Carbon Dots with Inhibited Enzyme Activity for Glucose Level Control. <b>2019</b> , 15, e1901512	27
668	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <b>2019</b> , 10, 1297-1317	14
667	Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis. <b>2019</b> , 10, 835-852	9
666	Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. <b>2019</b> , 21, 2048-2057	12
665	Detection of Human Plasma Glucose Using a Self-Powered Glucose Biosensor. <b>2019</b> , 12, 825	12
664	Nutritional, antioxidant, glycaemic index and Antihyperglycaemic properties of improved traditional plantain-based () dough meal enriched with tigernut () and defatted soybean () flour for diabetic patients. <b>2019</b> , 5, e01504	22
663	Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm. <b>2019</b> , 13, 1935-1942	4
662	Quantification of Insulin Action in Human Subjects. <b>2019</b> , 3-35	
661	Insulin Initiation and Titration in Patients With Type 2 Diabetes. <b>2019</b> , 32, 104-111	12
660	Beyond model interpretability using LDA and decision trees for $\beta$ -amylase and $\beta$ -glucosidase inhibitor classification studies. <b>2019</b> , 94, 1414-1421	4
659	Study Protocol for the Effects of Artificial Intelligence (AI)-Supported Automated Nutritional Intervention on Glycemic Control in Patients with Type 2 Diabetes Mellitus. <b>2019</b> , 10, 1151-1161	8
658	Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. <b>2019</b> , 9, e025806	45
657	MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin. <b>2019</b> , 15, 309-320	2
656	Are we getting any better? A study on repair integrity in 1600 consecutive arthroscopic rotator cuff repairs. <b>2019</b> , 3, 12-20	6
655	Circulating Cell-Free mtDNA Contributes to AIM2 Inflammasome-Mediated Chronic Inflammation in Patients with Type 2 Diabetes. <b>2019</b> , 8,	53



654	Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. <b>2019</b> , 62, 1251-1256	24
653	Consensus pour la prise en charge de lấhyperglycémie dans le diabète de type 2 en Afrique subsaharienne. Rédigé par un groupe d'experts africains du diabète. <b>2019</b> , 13, 210-216	2
652	Dealing with complexity in type 2 diabetes. <b>2019</b> , 12, 315-322	
651	Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes. <b>2019</b> , 21, 1668-1679	26
650	Management of hypoglycemia in older adults with type 2 diabetes. <b>2019</b> , 131, 241-250	34
649	Improving patient self-care using diabetes technologies. <b>2019</b> , 10, 2042018818824215	23
648	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. <b>2019</b> , 21, 1429-1436	21
647	Perceptions of insulin therapy in people with type 2 diabetes and physicians: a cross-sectional survey conducted in France. <b>2019</b> , 13, 251-260	3
646	Progression of glucose-lowering diabetes therapy in TECOS. <b>2019</b> , 2, e00053	6
645	Effectiveness of Insulin Analogs Compared with Human Insulins in Pregnant Women with Diabetes Mellitus: Systematic Review and Meta-analysis. <b>2019</b> , 41, 104-115	0
644	Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting. <b>2019</b> , 21, 1373-1380	9
643	Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training. <b>2019</b> , 104, 1953-1966	14
642	Individualised targets for insulin initiation in type 2 diabetes mellitus-the influence of physician and practice: a cross-sectional study in eight European countries. <b>2019</b> , 9, e032040	2
641	AGR2 silencing contributes to metformin-dependent sensitization of colorectal cancer cells to chemotherapy. <b>2019</b> , 18, 4964-4973	3
640	Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes. <b>2019</b> , 7, e000700	18
639	Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. <b>2019</b> , 9, e024954	45
638	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. <b>2019</b> , 38, 721-735	1
637	Frequency and Clinical Associating Factors of Valvular Heart Disease in Asymptomatic Korean Adults. <b>2019</b> , 9, 16741	3



636	Meal-time + basal insulin therapy: Is all not well?. <b>2019</b> , 157, 107923	
635	Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers. <b>2019</b> , 37, 368-376	3
634	Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending. <b>2019</b> , 19, 703	0
633	Electrically assisted cycling for individuals with type 2 diabetes mellitus: protocol for a pilot randomized controlled trial. <b>2019</b> , 5, 136	1
632	Diet, Diabetes Status, and Personal Experiences of Individuals with Type 2 diabetes Who Self-Selected and Followed a Low Carbohydrate High Fat diet. <b>2019</b> , 12, 2567-2582	12
631	Using Electronic Clinical Decision Support in Patient-Centered Medical Homes to Improve Management of Diabetes in Primary Care: The DECIDE Study. <b>2019</b> , 42, 105-115	6
630	Prevalence and epidemiological characteristics of patients with diabetic retinopathy in Slovakia: 12-month results from the DIARET SK study. <b>2019</b> , 14, e0223788	3
629	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. <b>2019</b> , 38, 721-735	0
628	A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. <b>2019</b> , 21, 402-407	6
627	Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study. <b>2019</b> , 10, 714-722	8
626	Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. <b>2019</b> , 21, 439-443	8
625	Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. <b>2019</b> , 40, 268-332	132
624	2017 National Standards for Diabetes Self-Management Education and Support. <b>2019</b> , 45, 34-49	19
623	Metabolic Complications of Home Parenteral Nutrition and Short Bowel Syndrome. <b>2019</b> , 109-127	
622	Metformin hydrochloride and wound healing: from nanoformulation to pharmacological evaluation. <b>2019</b> , 29, 343-356	12
621	A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial. <b>2019</b> , 21, 930-938	16
620	Impact of haemoglobin A1c trajectories on chronic kidney disease progression in type 2 diabetes. <b>2019</b> , 24, 1026-1032	6
619	Evaluating the impact of an international short-term medical mission through diabetic glycemic control. <b>2019</b> , 41, 815-820	0

618	Glycemic and lipids control in patients with diabetes and cardiovascular or renal diseases across all the government health sectors in the Emirate of Dubai, United Arab Emirates. <b>2019</b> , 13, 590-594	0
617	Effects of light-emitting diode therapy (LEDT) on cardiopulmonary and hemodynamic adjustments during aerobic exercise and glucose levels in patients with diabetes mellitus: A randomized, crossover, double-blind and placebo-controlled clinical trial. <b>2019</b> , 42, 178-183	8
616	Physician Empathy Is Not Associated with Laboratory Outcomes in Diabetes: a Cross-sectional Study. <b>2019</b> , 34, 75-81	11
615	Effect of family-oriented diabetes programs on glycemic control: A meta-analysis. <b>2019</b> , 36, 387-394	3
614	Boarfish ( <i>Capros aper</i> ) protein hydrolysate has potent insulinotropic and GLP-1 secretory activity in vitro and acute glucose lowering effects in mice. <b>2019</b> , 54, 271-281	15
613	Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas. <b>2019</b> , 132, 408-412	6
612	Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes. <b>2019</b> , 59, 65-87	38
611	Effects of the combination of metformin and exercise on glycated hemoglobin, functional capacity, lipid profile, quality of life, and body weight. <b>2019</b> , 47, 1131-1145	4
610	The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. <b>2019</b> , 43, 477-482	3
609	Toward Better Understanding of Insulin Therapy by Translation of a PK-PD Model to Visualize Insulin and Glucose Action Profiles. <b>2019</b> , 59, 258-270	1
608	Stem-cell based organ-on-a-chip models for diabetes research. <b>2019</b> , 140, 101-128	36
607	EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. <b>2019</b> , 25, 144-155	5
606	Determinants of glycemic control among diabetes mellitus patients in a tertiary clinic in Gaborone, Botswana: findings and implications. <b>2019</b> , 47, 34-41	4
605	Evolving Role of PET/CT-MRI in Assessing Muscle Disorders. <b>2019</b> , 14, 71-79	7
604	Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan. <b>2019</b> , 10, 857-865	2
603	Production and evaluation of vildagliptin-loaded poly(dl-lactide) and poly(dl-lactide-glycolide) micro-/nanoparticles: Response surface methodology approach. <b>2019</b> , 37, 1265-1276	11
602	Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea. <b>2019</b> , 42, 851-857	2
601	Therapeutic medications against diabetes: What we have and what we expect. <b>2019</b> , 139, 3-15	25

600	Glycaemic management of type 2 diabetes. <b>2019</b> , 47, 32-39	5
599	Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. <b>2019</b> , 21, 883-892	11
598	Simultaneous quantitation of metformin and dapagliflozin in human plasma by LC-MS/MS: Application to a pharmacokinetic study. <b>2019</b> , 33, e4453	12
597	Concentrated insulins: History and critical reappraisal. <b>2019</b> , 11, 292-300	14
596	A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. <b>2019</b> , 45, 122-131	63
595	Meat intake and incidence of cardiovascular disease in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDACS). <b>2019</b> , 58, 281-290	9
594	Association between BMI and risk of severe hypoglycaemia in type 2 diabetes. <b>2019</b> , 45, 19-25	11
593	Racial/ethnic differences in healthcare use among patients with uncontrolled and controlled diabetes. <b>2019</b> , 24, 245-256	5
592	Hypoglycemia and Glucagon Utilization in Insulin-Treated Diabetic Patients. <b>2020</b> , 128, 493-498	2
591	Effect of different dietary patterns on glycemic control in individuals with type 2 diabetes mellitus: A systematic review. <b>2020</b> , 60, 1999-2010	12
590	Association of transcription factor 7-like 2 gene (TCF7L2) polymorphisms with stress-related hyperglycaemia (SRH) in intensive care and resulting outcomes: The READIAB study. <b>2020</b> , 46, 243-247	3
589	Evaluation of effectiveness of treatment paradigm for newly diagnosed type 2 diabetes patients in Chin: A nationwide prospective cohort study. <b>2020</b> , 11, 151-161	8
588	Preferences of people with Type 2 diabetes for diabetes care: a discrete choice experiment. <b>2020</b> , 37, 1807-1815	9
587	Development of simultaneous determination of empagliflozin and metformin in human plasma using liquid chromatography-mass spectrometry and application to pharmacokinetics. <b>2020</b> , 26, 117-130	11
586	Effectiveness of a primary care nurse delivered educational intervention for patients with type 2 diabetes mellitus in promoting metabolic control and compliance with long-term therapeutic targets: Randomised controlled trial. <b>2020</b> , 101, 103417	9
585	The Association between Glycemic Control in People with Diabetes and Symptoms at the End of Life: A Prospective Observational Consecutive Cohort Study. <b>2020</b> , 23, 406-410	0
584	Metformin-related lactic acidosis with acute kidney injury: results of a French observational multicenter study. <b>2020</b> , 58, 375-382	10
583	Hypertension in Polycystic Ovary Syndrome: Novel Insights. <b>2020</b> , 16, 55-60	10

582	L-lactic acidosis: pathophysiology, classification, and causes; emphasis on biochemical and metabolic basis. <b>2020</b> , 97, 75-88	21
581	Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management. <b>2020</b> , 19, 135-143	9
580	Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study. <b>2020</b> , 34, 107467	2
579	A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. <b>2020</b> , 29 Suppl 1, 86-92	3
578	Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice. <b>2020</b> , 11, 467-478	1
577	A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study. <b>2020</b> , 95, 90-100	15
576	A review of phenformin, metformin, and imeglimin. <b>2020</b> , 81, 390-401	24
575	Studies on characteristics and anti-diabetic and -nephritic effects of polysaccharides isolated from <i>Paecilomyces hepiali</i> fermentation mycelium in db/db mice. <b>2020</b> , 232, 115766	6
574	Family physician perceptions of the role and value of the clinical pharmacist in the management of patients with type 2 diabetes. <b>2020</b> , 3, 15-20	
573	Non-invasive detection of glucose via a solution-gated graphene transistor. <b>2020</b> , 145, 887-896	16
572	The effect of nettle ( <i>Urtica dioica</i> ) supplementation on the glycemic control of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <b>2020</b> , 34, 282-294	11
571	Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. <b>2020</b> , 22, 574-582	7
570	Time to Treatment Intensification in Newly Treated Adult Type 2 Diabetes Patients: Comparison of Canada and the United States. <b>2020</b> , 44, 312-316	1
569	Achieving the composite end-point of glycated hemoglobin . <b>2020</b> , 11, 647-652	1
568	2017 National Standards for Diabetes Self-Management Education and Support. <b>2020</b> , 46, 46-61	20
567	Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study. <b>2020</b> , 8,	0
566	Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. <b>2020</b> , 42, 1762-1777.e4	5
565	Validity of the Good Practice Guidelines: The example of type 2 diabetes. <b>2020</b> , 169, 108459	0

564	Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method. <b>2020</b> , 22, 821-825	2
563	Patient decisional needs when considering treatment intensification for type 2 diabetes: A qualitative study in China. <b>2020</b> , 170, 108471	2
562	Interactions Between Gut Microbiota, Host, and Herbal Medicines: A Review of New Insights Into the Pathogenesis and Treatment of Type 2 Diabetes. <b>2020</b> , 10, 360	12
561	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. <b>2020</b> , 30, 1926-1936	4
560	Cytogenetic effects of antidiabetic drug metformin. <b>2020</b> , 1-8	1
559	Assessment of vitamin B12 deficiency and associated risk factors among type 2 diabetic patients in Palestine. <b>2020</b> , 20, 200113	1
558	Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. <b>2020</b> , 18, 378	5
557	Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model. <b>2020</b> , 25,	7
556	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <b>2021</b> , 396, 2019-2082	90
555	Metformin Associated Lactic Acidosis in Clinical Practice - A Case Series. <b>2021</b> , 129, 842-847	2
554	Inhibitory potential on key enzymes relevant to type II diabetes mellitus and antioxidant properties of the various extracts and phytochemical constituents from Rumex acetosella L. <b>2020</b> , 44, e13415	1
553	Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach. <b>2020</b> , 11, 2237-2255	2
552	Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. <b>2020</b> , 13, 1178632920929982	0
551	Biomarkers in diabetic kidney disease. <b>2020</b> , 185-208	
550	IRWIS (IDegLira Real world Indian Study): A Real-World Observational Study For Use of IDegLira In Indian Patients. <b>2020</b> , 1, 100057	1
549	Impact of Metformin Use on Survival in Patients with Gastric Cancer and Diabetes Mellitus Following Gastrectomy. <b>2020</b> , 12,	3
548	Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study. <b>2020</b> , 33, 264-272	1
547	Determinants of glycaemic control among patients with type 2 diabetes: testing a process model based on self-determination theory. <b>2020</b> , 6, e04993	1

546	The Smart Life Stay (SLS) program: effects of a lifestyle intervention program in combination with health tourism and health guidance for type 2 diabetes. <b>2020</b> , 10, 33		2
545	Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin. <i>Diabetes Care</i> , <b>2020</b> , 43, 2333-2335	14.6	3
544	Therapy Escalation Following an Elevated HbA in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. <i>Diabetes Care</i> , <b>2020</b> , 43, e185-e187	14.6	1
543	Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes. <b>2020</b> , 11, 2521-2538		12
542	Adapting a home telemonitoring intervention for underserved Hispanic/Latino patients with type 2 diabetes: an acceptability and feasibility study. <b>2020</b> , 20, 324		2
541	Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy. <b>2020</b> , 17,		2
540	Trends in the process and outcome indicators of type 2 diabetes care: a cohort study from Eastern Finland, 2012-2017. <b>2020</b> , 21, 253		3
539	The Remission Rate of Type 2 Diabetes Outpatients with Premixed Insulin: The Result of a 5-Year Prospective Study. <b>2020</b> , 52, 316-321		
538	Therapeutic Potential of Ursonic Acid: Comparison with Ursolic Acid. <b>2020</b> , 10,		11
537	Overview of Therapeutic Inertia in Diabetes: Prevalence, Causes, and Consequences. <b>2020</b> , 33, 8-15		11
536	Diabetes specialist nurse point-of-care review service: improving clinical outcomes for people with diabetes on emergency wards. <b>2020</b> , 37, 50-54		0
535	Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. <b>2020</b> , 43, 1613-1622		8
534	Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners. <b>2020</b> , 20, 100224		1
533	Advances in the management of diabetes: therapies for type 2 diabetes. <b>2020</b> , 96, 610-618		1
532	Arctium lappa L. polysaccharide can regulate lipid metabolism in type 2 diabetic rats through the SREBP-1/SCD-1 axis. <b>2020</b> , 494, 108055		6
531	WITHDRAWN: Determinants of glycaemic control among patients with type 2 diabetes: Testing a process model based on self-determination theory. <b>2020</b> , 100063		
530	Prevalence and incidence of type 1 diabetes in Ireland: a retrospective cross-sectional study using a national pharmacy claims data from 2016. <b>2020</b> , 10, e032916		3
529	Cut-off points for Polish-language versions of depression screening tools among patients with Type 2 diabetes. <b>2020</b> , 14, 663-671		1

528	Semantic text mining in early drug discovery for type 2 diabetes. <b>2020</b> , 15, e0233956	8
527	Metformin protects against mouse oocyte apoptosis defects induced by arecoline. <b>2020</b> , 53, e12809	7
526	Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies. <b>2020</b> , 8,	13
525	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. <b>2020</b> , 21, 1565-1578	7
524	Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial. <b>2020</b> , 80, 587-600	12
523	Impact of patient-centred diabetes self-management education targeting people with type 2 diabetes: an integrative review. <b>2020</b> , 37, 909-923	10
522	Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c. <b>2020</b> , 34, 107575	0
521	Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey. <i>Diabetes Care</i> , <b>2020</b> , 43, 1227-1233	14.6 29
520	Metformin is distributed to tumor tissue in breast cancer patients in vivo: A C-metformin PET/CT study. <b>2020</b> , 181, 107-113	2
519	A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. <b>2020</b> , 20, 12	6
518	Prevalence, risk factors, and management of uncontrolled hypertension among patients with diabetes: A hospital-based cross-sectional study. <b>2020</b> , 14, 610-615	3
517	The importance of the AMPK gamma 1 subunit in metformin suppression of liver glucose production. <b>2020</b> , 10, 10482	9
516	Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. <b>2020</b> , 110, 154304	14
515	Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital. <b>2020</b> , 13, 34	1
514	Feeding behavior pattern and glycosylated hemoglobin in people with type 2 diabetes at the beginning and end of an educational intervention. <b>2020</b> , 67, 155-163	3
513	What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline. <b>2020</b> , 15, 1253-1265	4
512	Sociodemographic factors associated with HbA1c variability in type 2 diabetes: a prospective exploratory cohort study. <b>2020</b> , 20, 102	3
511	Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study. <b>2020</b> , 30, 1937-1944	1



510	Quality criteria/key components for high quality of diabetes management to avoid diabetes-related complications. <b>2020</b> , 29, 1235	1
509	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. <b>2020</b> , 21, 871-882	6
508	Therapeutic potential of metformin in normal glucose tolerant persons with metabolic syndrome. <b>2020</b> , 34, 30-37	2
507	Diabetes Technology and Therapy in the Pediatric Age Group. <b>2020</b> , 22, S89-S108	
506	Effect of simulated microgravity on the antidiabetic properties of wheatgrass () in streptozotocin-induced diabetic rats. <b>2020</b> , 6, 6	7
505	Clinical update: The important role of dual kidney function testing (ACR and eGFR) in primary care: Identification of risk and management in type 2 diabetes. <b>2020</b> , 14, 370-375	6
504	Structural and gamma-ray attenuation coefficients of different OAD films for nuclear medicine applications. <b>2020</b> , 172, 108785	3
503	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA <sup>®</sup> trial. <b>2020</b> , 22, 1062-1073	12
502	Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States. <b>2020</b> , 36, 741-748	1
501	Association between On-Treatment Haemoglobin A and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. <b>2020</b> , 9,	1
500	An Effective Model of Diabetes Care and Education: Revising the AADE7 Self-Care Behaviors. <b>2020</b> , 46, 139-160	43
499	Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study. <b>2020</b> , 11, 523-533	3
498	Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. <b>2020</b> , 162, 108042	2
497	Behavior change in diabetes practitioners: An intervention using motivation, action planning and prompts. <b>2020</b> , 103, 2312-2319	3
496	A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience. <b>2020</b> , 22, 1436-1442	3
495	Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. <b>2020</b> , 12, 177-189	4
494	Prevalence of Diabetes Medication Intensifications in Older Adults Discharged From US Veterans Health Administration Hospitals. <b>2020</b> , 3, e201511	4
493	Metabolic endoscopy by duodenal mucosal resurfacing: expert review with critical appraisal of the current technique and results. <b>2020</b> , 14, 375-381	3

492	Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States. <b>2020</b> , 13, 1023-1033	2
491	Persons with type 2 diabetes and high insulin persistence were associated with a lower risk of mortality: A nationwide retrospective cohort study. <b>2021</b> , 12, 146-154	0
490	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. <b>2021</b> , 15, 31-51	13
489	Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. <b>2021</b> , 44, 481-492	11
488	Efficacy and safety of DPP-IV inhibitors combined with basal insulin in the treatment of type 2 diabetes. <b>2020</b> , 13, 375	1
487	Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. <b>2021</b> , 40, 2169-2179	2
486	The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study. <b>2021</b> , 64, 349-360	8
485	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. <b>2021</b> , 23, 569-580	7
484	Cardiovascular events and mortality among type 2 diabetes mellitus patients newly prescribed first-line blood glucose-lowering drugs monotherapies: A population-based cohort study in the Catalan electronic medical record database, SIDIAP, 2010-2015. <b>2021</b> , 15, 323-331	2
483	Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study. <b>2021</b> , 28, e12670	
482	Task-sharing interventions for improving control of diabetes in low-income and middle-income countries: a systematic review and meta-analysis. <b>2021</b> , 9, e170-e180	8
481	A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes. <b>2021</b> , 4, e00164	1
480	The association of the level of self-care on adherence to treatment in patients diagnosed with type 2 diabetes. <b>2021</b> , 58, 437-445	3
479	Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non-interventional comparative study. <b>2021</b> , 75, e13802	
478	Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial. <b>2021</b> , 75, e13734	1
477	Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <b>2021</b> , 12, 537-545	0
476	One Anastomosis Gastric Bypass after Sleeve Gastrectomy Failure: Does a Single Procedure Fit for all?. <b>2021</b> , 31, 1722-1732	3
475	Targeting Insulin Resistance to Treat Cognitive Dysfunction. <b>2021</b> , 58, 2672-2691	6

- 474 Anti-diabetes Research in India: Contributions from Industrial Organizations. **2021**, 179-212
- 473 The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review. **2021**, 3
- 472 Drug Combinations. **2021**,
- 471 Molecular mechanisms of lipotoxicity-induced pancreatic  $\beta$  cell dysfunction. **2021**, 359, 357-402 6
- 470 Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting-the GOAL\_RO trial. **2021**, 9, 105 1
- 469 Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus. **2021**, 13, e13045 2
- 468 An Effective Model of Diabetes Care and Education: The ADCES7 Self-Care Behaviors 2021, 47, 30-53 27
- 467 Diabetes in French Guiana, adapting national standards of therapeutic education and care to the amazonian challenge. **2021**, 12, 98-107 4
- 466 *Garcinia linii* extracts exert the mediation of anti-diabetic molecular targets on anti-hyperglycemia. **2021**, 134, 111151 4
- 465 Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia. **2021**, 9, 2
- 464 Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study. **2020**, 11, 617409 0
- 463 Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies. **2021**, 12, 1386-1394 2
- 462 Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice. **2021**, 12, 133 5
- 461 2017 National Standards for Diabetes Self-Management Education and Support. **2021**, 47, 14-29 4
- 460 Drug-Drug Interactions at Organic Cation Transporter 1. **2021**, 12, 628705 5
- 459 Vã clînica de recuperaciã intensificada en cirugã cardiaca. Documento de consenso de la Sociedad Espa~ola de Anestesiologã, Reanimaciã y Terapùtica del Dolor (SEDAR), la Sociedad Espa~ola de Cirugã Cardiovascular y Endovascular (SECCE) y la Asociaciã Espa~ola de Perfusionistas (AEP). **2021**, 28, 1-40
- 458 Heart Rate Variability as a Potential Non-invasive Marker of Blood Glucose Level. **2021**, 47, 209-218
- 457 Testing an analogue game to promote peer support and person-centredness in education for people with diabetes: A realist evaluation. **2021**, 8, 2536-2550 1

456	Drug utilisation pattern over 3 years in the real-world treatment of type II diabetes. <b>2021</b> , 75, e14120	3
455	System Architecture for "Support Through Mobile Messaging and Digital Health Technology for Diabetes" (SuMMiT-D): Design and Performance in Pilot and Randomized Controlled Feasibility Studies. <b>2021</b> , 5, e18460	1
454	The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings. <b>2021</b> , 12, 633944	2
453	Mitochondrial Inhibition: a Treatment Strategy in Cancer?. <b>2021</b> , 23, 49	5
452	Diabetes mellitus in combination with COVID-19: modern views on therapy. <b>2021</b> , 8-20	
451	Guidelines for enhanced recovery after cardiac surgery. Consensus document of Spanish Societies of Anesthesia (SEDAR), Cardiovascular Surgery (SECCE) and Perfusionists (AEP). <b>2021</b> , 68, 183-231	1
450	Dual-Target Compounds against Type 2 : Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors. <b>2021</b> , 14,	3
449	Propolis ethanol extract abrogates hyperglycemia, lipotoxicity, and lowered hepatic poly (ADP-ribose) polymerase protein level in male albino rats. <b>2021</b> , 20, 683-696	0
448	Identifying sustainable lifestyle strategies for maintaining good glycemic control: a validation of qualitative findings. <b>2021</b> , 9,	0
447	Guidelines for enhanced recovery after cardiac surgery. Consensus document of Spanish Societies of Anaesthesia (SEDAR), Cardiovascular Surgery (SECCE) and Perfusionists (AEP). <b>2021</b> , 68, 183-231	
446	Eating behavior among persons with type 2 diabetes mellitus in North Ethiopia: a cross-sectional study. <b>2021</b> , 21, 99	1
445	Polar Solvent-Mediated Synthesis of Terminal Alkyne Derivatives of Thiazoles and Evaluation of Their Antidiabetic Activity. <b>2021</b> , 57, 801-808	0
444	Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. <b>2021</b> , 62, 592-600	1
443	Blood glucose lowering, glycaemic index, carbohydrate-hydrolysing enzyme inhibitory activities of potential functional food from plantain, soy-cake, rice-bran and oat-bran flour blends. <b>2021</b> , 15, 3761-3769	5
442	Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. <i>Diabetes Care</i> , <b>2021</b> , 44, 1462-1471	14.6 7
441	Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. <b>2021</b> , 21, 94	14
440	Evaluation of the Degree of Agreement of Four Methods for Diagnosing Diabetic Autonomic Neuropathy. <b>2021</b> , 12, 637099	0
439	Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study. <b>2021</b> , 45, 368-378	6

438	Serum Glucose Measurement after Five to Six Hours is Comparable to Eight Hours Fasting in Ramadan.. <b>2022</b> , 22, 123-128	
437	Sitagliptin-induced Pancreatitis: A case report and plausible mechanism. <b>2021</b> , 11, 1-3	
436	Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus. <b>2021</b> , 9,	
435	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. <b>2021</b> , 26, 415-428	
434	Comparison of Insulins Glargine and Degludec in Diabetic Rhesus Macaques () with CGM Devices. <b>2021</b> , 71, 247-255	0
433	The Influence of Baseline Hemoglobin A1c on Digital Health Coaching Outcomes in Adults With Type 2 Diabetes: Real-World Retrospective Cohort Study. <b>2021</b> , 6, e24981	1
432	Heart failure management; a perspective from diabetes care. <b>2021</b> , 176, 108849	1
431	Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. <b>2021</b> , 96, 1655-1669	3
430	Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus. <b>2021</b> , 11, 12400	1
429	Duodenal-jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity: A Multicenter Randomized Controlled Trial. <b>2021</b> , 275,	6
428	Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?. <b>2021</b> , 21, 263	5
427	Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. <b>2021</b> , 384, 2219-2228	71
426	Effects of dietary fiber on glycemic control and insulin sensitivity in patients with type 2 diabetes: A systematic review and meta-analysis. <b>2021</b> , 82, 104500	4
425	A cross-sectional study of the correlation between diabetic therapy and serum zinc concentrations.. <b>2022</b> , 13, 177-187	1
424	A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus. <b>2021</b> , 45, 606-612	0
423	DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain. <b>2021</b> , 10, 815-821	1
422	Water-Soluble Gold(III)-Metformin Complex Alters Mitochondrial Bioenergetics in Breast Cancer Cells. <b>2021</b> , 16, 3222-3230	4
421	Right ventricular systolic and diastolic function in heart failure with preserved ejection fraction. <b>2021</b> , 63, 295-303	

420	Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. <b>2021</b> , 11, e049130	2
419	Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. <b>2021</b> , 24, 887-903	3
418	The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature. <b>2021</b> , 11,	5
417	Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study. <b>2021</b> , 22,	1
416	Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Like Agonist, Exendin-4-Fc. <b>2021</b> , 27, 2517	
415	Persons With Diabetes and General/Family Practitioner Perspectives Related to Therapeutic Inertia in Type 2 Diabetes Mellitus Using Qualitative Focus Groups and the Theoretical Domains Framework: Results From the MOTION Study.. <b>2021</b> ,	0
414	The substantial burden of non-communicable diseases and HIV-comorbidity amongst adults: Screening results from an integrated HIV testing services clinic for adults in Soweto, South Africa. <b>2021</b> , 38, 101015	1
413	Identification of an allosteric hotspot for additive activation of PPAR $\alpha$ in antidiabetic effects. <b>2021</b> , 66, 1559-1570	9
412	Growth Factors, Reactive Oxygen Species, and Metformin-Promoters of the Wound Healing Process in Burns?. <b>2021</b> , 22,	1
411	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. <b>2021</b> , 1-14	0
410	The relationship between pre-procedural elevated arterial lactate and contrast-induced nephropathy following primary percutaneous coronary intervention. <b>2021</b> , 13, 5467-5476	0
409	Satisfaction, Preference and Injection Habits of Switching to 200 Units/ml Insulin Lispro Pen from 100 Units/ml: A Patient Survey in Germany. <b>2021</b> , 12, 2939-2953	
408	Management of type 2 diabetes without insulin: An update for the PCP. <b>2021</b> , 101290	
407	Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. <b>2021</b> , 31, 2745-2755	3
406	Diabetes Treatment and Control in U.S. Adults. <b>2021</b> , 385, e30	
405	An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist.. <b>2022</b> , 12, 560-574	0
404	Drug utilisation study of antidiabetic medication during 2012-2019 in Romania. <b>2021</b> , 75, e14770	0
403	Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification. <b>2021</b> , 59, 1031-1038	

402	Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. <b>2021</b> , 123, 154838	10
401	Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen <sup>®</sup> among US veterans with type 2 diabetes mellitus. <b>2021</b> , 35, 107995	
400	Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. <b>2021</b> , 180, 109035	3
399	Factors Associated with Glycated Hemoglobin Levels > 6.5% among Diabetic Patients Attending Kenyatta National Hospital, Kenya. <b>2021</b> , 11, 10-25	0
398	The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India. <b>2021</b> , 12, 679-695	0
397	Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial. <b>2021</b> , 26, e927984	4
396	Severe hyperglycemia in an insulin-deficient patient with type 2 diabetes responding well to oral antidiabetic therapy. <b>2021</b> ,	
395	Hypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study. <b>2021</b> , 7, 2	0
394	Pharmacological treatment of hyperglycemia in type 2 diabetes. <b>2021</b> , 131,	24
393	Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. <b>2013</b> , 382, 941-950	349
392	Kidney Disease in Diabetes. 58-86	1
391	Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles. <b>2015</b> , 3-43	3
390	Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?. <b>2020</b> , 2076, 1-30	5
389	Diabetes Mellitus and Chronic Kidney Disease (Stages 1&B). <b>2014</b> , 103-136	1
388	Diabetes upregulates the expression of HSP90 and downregulates HSP70 in the liver of diabetic rats. <b>2019</b> , 28, 473-478	4
387	Exercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks. <b>2020</b> , 57, 715-723	8
386	Patient-Provider communication with teach-back, patient-centered diabetes care, and diabetes care education. <b>2020</b> ,	5
385	Metformin and Systemic Metabolism. <b>2020</b> , 41, 868-881	33



384	ESVM Guideline on peripheral arterial disease. <b>2019</b> , 48, 1-79	46
383	5 Conservative treatment for PAD - Risk factor management. <b>2019</b> , 48, 1-12	6
382	SGLT inhibitors as antidiabetic agents: a comprehensive review.. <b>2020</b> , 10, 1733-1756	9
381	Epigenetic modification and therapeutic targets of diabetes mellitus. <b>2020</b> , 40,	13
380	Stages of change for physical activity and dietary habits in persons with type 2 diabetes included in a mobile health intervention: the Norwegian study in RENEWING HEALTH. <b>2016</b> , 4, e000193	23
379	A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. <b>2017</b> , 7, e018598	9
378	Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting. <b>2018</b> , 59, 251-256	2
377	Clinical use of sodium-glucose co-transporter-2 inhibitors in Chinese patients with type 2 diabetes mellitus. <b>2019</b> , 60, 309-313	2
376	Angiotensin II Promotes the Development of Carotid Atherosclerosis in Type 2 Diabetes Patients via Regulating the T Cells Activities: A Cohort Study. <b>2016</b> , 22, 4000-4008	8
375	Presence of White Matter Lesions Associated with Diabetes-Associated Cognitive Decline in Male Rat Models of Pre-Type 2 Diabetes. <b>2019</b> , 25, 9679-9689	3
374	Antidiabetic agents in patients with hepatic impairment. <b>2019</b> , 7, 380-388	3
373	Thyroid cancer risk is not increased in diabetic patients. <b>2012</b> , 7, e53096	45
372	The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study. <b>2013</b> , 8, e74355	36
371	Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. <b>2014</b> , 9, e103798	29
370	The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. <b>2014</b> , 9, e108844	79
369	Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. <b>2015</b> , 10, e0116851	23
368	The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. <b>2015</b> , 10, e0121553	13
367	Managing Type 2 Diabetes Mellitus through Periodical Hospital Visits in the Aftermath of the Great East Japan Earthquake Disaster: A Retrospective Case Series. <b>2015</b> , 10, e0125632	14

366	A Systematic Review of Interventions Addressing Adherence to Anti-Diabetic Medications in Patients with Type 2 Diabetes--Components of Interventions. <b>2015</b> , 10, e0128581	37
365	Trends in Emergency Department Visit Rates for Hypoglycemia and Hyperglycemic Crisis among Adults with Diabetes, United States, 2006-2011. <b>2015</b> , 10, e0134917	36
364	Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. <b>2016</b> , 11, e0147145	29
363	Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. <b>2016</b> , 11, e0153594	18
362	Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2Fc. <b>2016</b> , 11, e0156449	4
361	Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial. <b>2016</b> , 11, e0163350	21
360	Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. <b>2016</b> , 11, e0167190	6
359	Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer. <b>2018</b> , 13, e0192759	9
358	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. <b>2019</b> , 22, 1-121	14
357	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). <b>2013</b> , 16, 1-120	28
356	Hypoglycemia in type 2 diabetes patients treated with insulin: the advantages of continuous glucose monitoring. <b>2014</b> , 17, 75-80	6
355	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. <b>2017</b> , 20, 1-121	109
354	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. <b>2019</b> , 22, 1-121	139
353	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). <b>2015</b> , 18, 1-112	11
352	Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes. <b>2014</b> , 6, 127-32	7
351	The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin. <b>2016</b> , 23, 113-120	0
350	Quality of Life of Insulin-Naïve People with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs after the Addition of Insulin Glargine, in Every Day Clinical Practice in Greece. <b>2015</b> , 2,	1
349	Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance. <b>2016</b> , 5,	3

348	[Proposal for the modification of metformin use in patients with chronic kidney disease]. <b>2012</b> , 153, 1527-35	1
347	Diabetes: An Update on the Pandemic and Potential Solutions. <b>2017</b> , 209-234	9
346	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <b>2014</b> , 10, 23-30	11
345	Management of Type 2 Diabetes - Methods for Addition of Prandial to Basal Insulin. <b>2014</b> , 10, 124-130	2
344	What's next after metformin? focus on sulphonylurea: add-on or combination therapy. <b>2015</b> , 13, 606	8
343	Optimal therapy of type 2 diabetes: a controversial challenge. <b>2014</b> , 6, 187-206	32
342	Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. <b>2018</b> , 10, 386-401	22
341	Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: a meta-analysis. <b>2018</b> , 9, 12389-12399	1
340	A Scottish and Japanese experience of patient-centred diabetic care: descriptive study of interprofessional education on live webinar. <b>2018</b> , 80, 465-473	1
339	Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update. <b>2019</b> , 25, 2510-2525	20
338	New approaches to providing individualized diabetes care in the 21st century. <b>2015</b> , 11, 222-30	31
337	Mobile Phone-Based Telemedicine Practice in Older Chinese Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. <b>2019</b> , 7, e10664	33
336	Development and Efficacy of an Electronic, Culturally Adapted Lifestyle Counseling Tool for Improving Diabetes-Related Dietary Knowledge: Randomized Controlled Trial Among Ethnic Minority Adults With Type 2 Diabetes Mellitus. <b>2019</b> , 21, e13674	4
335	Telemonitoring and Health Counseling for Self-Management Support of Patients With Type 2 Diabetes: A Randomized Controlled Trial. <b>2017</b> , 2, e10	6
334	Perceptions of Persons With Type 2 Diabetes Treated in Swedish Primary Health Care: Qualitative Study on Using eHealth Services for Self-Management Support. <b>2018</b> , 3, e7	17
333	Understanding patient portal use: implications for medication management. <b>2013</b> , 15, e133	92
332	Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy. <b>2014</b> , 16, e235	14
331	Health Coaching Reduces HbA1c in Type 2 Diabetic Patients From a Lower-Socioeconomic Status Community: A Randomized Controlled Trial. <b>2015</b> , 17, e224	103

330	InsuOnline, an Electronic Game for Medical Education on Insulin Therapy: A Randomized Controlled Trial With Primary Care Physicians. <b>2017</b> , 19, e72	23
329	A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The ANODE Study). <b>2017</b> , 19, e360	36
328	A Low-Intensity Mobile Health Intervention With and Without Health Counseling for Persons With Type 2 Diabetes, Part 1: Baseline and Short-Term Results From a Randomized Controlled Trial in the Norwegian Part of RENEWING HEALTH. <b>2014</b> , 2, e52	59
327	InsuOnline, a Serious Game to Teach Insulin Therapy to Primary Care Physicians: Design of the Game and a Randomized Controlled Trial for Educational Validation. <b>2013</b> , 2, e5	41
326	A Virtual World Versus Face-to-Face Intervention Format to Promote Diabetes Self-Management Among African American Women: A Pilot Randomized Clinical Trial. <b>2014</b> , 3, e54	30
325	Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c. <b>2013</b> , 36, 568-73	8
324	A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT. <b>2020</b> , 7, 1-130	2
323	Endothelial Dysfunction in Diabetes Is Aggravated by Glycated Lipoproteins; Novel Molecular Therapies. <b>2020</b> , 9,	10
322	Optimal body mass index for minimizing the risk for osteoporosis and type 2 diabetes. <b>2020</b> , 35, 1432-1442	4
321	Management of Diabetic Peripheral Neuropathy. <b>2015</b> , 89, 277-281	4
320	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <b>2014</b> , 4, 324-32	22
319	Management of diabetic renal disease. <b>2015</b> , 3, 154	14
318	Long-term glycaemic control (HbA1c), not admission glucose, predicts hospital re-admission in diabetic patients. <b>2015</b> , 8, 189-99	4
317	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Developed by the American Diabetes Association and the European Association for the Study of Diabetes. <b>2012</b> , 13, 172	3
316	The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor. <b>2014</b> , 15, 158	4
315	Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy. <b>2015</b> , 6, 172-4	2
314	Influence of blood glucose level on the prognosis of patients with diabetes mellitus complicated with ischemic stroke. <b>2018</b> , 23, 10	5
313	Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. <b>2015</b> , 19, 577-96	59

312	Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature. <b>2016</b> , 20, 288-99	3
311	Bangladesh national guidelines on the management of tuberculosis and diabetes mellitus co-morbidity (summary). <b>2016</b> , 20, 853-857	4
310	Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus. <b>2019</b> , 23, 150-158	1
309	Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus. <b>2017</b> , 21, 898-902	7
308	Metformin-associated Encephalopathy in Hemodialysis. <b>2019</b> , 29, 194-196	3
307	Effect of an Integrated Naturopathy and Yoga Program on Long-Term Glycemic Control in Type 2 Diabetes Mellitus Patients: A Prospective Cohort Study. <b>2020</b> , 13, 42-49	2
306	Medication adherence and influencing factors in patients with type 2 diabetes attending a tertiary hospital in South-West Nigeria. <b>2019</b> , 16, 138	2
305	Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto) Soft Drinks in Rats: Application to Pharmacokinetics Studies. <b>2019</b> , 11, 49-59	1
304	Simple Insulin Dose Adjustment Using 3-3-1 Algorithm in Japanese Patients with Type 2 Diabetes: Start Kanazawa Study (Self-Titration Aggressive Algorithm with Glargine Trial). <b>2016</b> , 06, 197-203	1
303	Factors Affecting Medication Non Adherence in Type 2 Sudanese Diabetic Patients. <b>2016</b> , 07, 141-146	7
302	Structured SMBG in early management of T2DM: Contributions from the St Carlos study. <b>2014</b> , 5, 471-81	7
301	HLA alleles may serve as a tool to discriminate atypical type 2 diabetic patients. <b>2014</b> , 5, 711-6	2
300	Effects of glucose-lowering agents on cardiorespiratory fitness. <b>2018</b> , 9, 230-238	3
299	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. <b>2015</b> , 6,	1
298	Individualising Chronic Care Management by Analysing Patients' Needs - A Mixed Method Approach. <b>2017</b> , 17, 2	7
297	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. <b>2015</b> , 53, 115-28	28
296	Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. <b>2014</b> , 68, 313-6	3
295	Patient Partnerships Transforming Sleep Medicine Research and Clinical Care: Perspectives from the Sleep Apnea Patient-Centered Outcomes Network. <b>2016</b> , 12, 1053-8	15

294	Optimal Glycemic and Hemoglobin A1c Thresholds for Diagnosing Diabetes Based on Prevalence of Retinopathy in an Iranian Population. <b>2016</b> , 18, e31254	10
293	Metabolic impact of a successful lifestyle intervention in patients with new onset type 2 diabetes; a pilot study. <b>2013</b> , 2, 10	2
292	Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes. <b>2013</b> , 2013, 212255	8
291	Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin. <b>2015</b> , 4, 212288	5
290	Quality of Life and its Determinants in Patients with Diabetes Mellitus from Two Health Institutions of Sub-himalayan Region of India. <b>2021</b> , 25, 211-219	0
289	Glycemic control and its association with sociodemographics, comorbid conditions, and medication adherence among patients with type 2 diabetes in southwestern Nigeria. <b>2021</b> , 49, 3000605211044040	1
288	Energy expenditure due to gluconeogenesis in pathological conditions of insulin resistance. <b>2021</b> , 321, E795-E801	1
287	Prevention of Hyperglycemia.	
286	A nutraceutical combination of cinnamon, purple onion, and tea linked with key enzymes on treatment of type 2 diabetes. <b>2021</b> , 45, e13971	2
285	[Management of the older person with diabetes mellitus]. <b>2012</b> , 49, 561-8	
284	Characteristics of People with Newly Diagnosed Type 2 Diabetes Depending on Age at Onset. <b>2012</b> , 19, 381-387	
283	âPosition Paperâ Timely Insulinisation in Type 2 Diabetes Patients. <b>2012</b> , 19, 441-444	
282	[Management of life-style related diseases]. <b>2013</b> , 50, 40-2	
281	Antihyperglycemic Drug Therapy in Patients with Diabetes and Ckd: a Closer Look at Incretin-Based Therapies. <b>2013</b> , 19, 19-22	
280	Pharmacologic treatment strategies in children with type 2 diabetes mellitus. <b>2013</b> , 22, 1-8	3
279	Evidence-Based Glycemic Target for the Prevention of the Complications of Diabetes Mellitus Towards Individualized Therapy. <b>2013</b> , 44, 429-430	
278	The âCollateral benefitsâ of noninsulin therapies for Type 2 diabetes. <b>2013</b> , 3, 145-160	
277	EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus. <b>2013</b> , 16, 82-87	

- 276 Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin. **2013**, 2013, 212256 1
- 275 GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. **2014**, 385-394
- 274 DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus. **2013**, 59, 72-80
- 273 Diabetes.
- 272 Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. **2013**, 16, 97-102 3
- 271 Vascular Complications of Diabetes Mellitus. **2014**, 1-65
- 270 Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes. **2014**, 10, 117-123 0
- 269 Leitlinien, Betreuungsprogramme, Versorgungsforschung und Evaluation. **2014**, 33-55
- 268 Dipeptidyl Peptidase-4 Inhibitor. **2014**, 87, 1 1
- 267 Erkrankungen des Stoffwechsels \* \*Berarbeitet und aktualisiert von Dr. Walter Burghardt. **2014**, 271-380
- 266 The recent advances in therapy for diabetes mellitus. **2014**, 6, 21-32
- 265 Glycemia and CVD and Its Management. 116-139
- 264 Patterns and Stability over Time of Older Adults' Diabetes-related Beliefs. **2014**, 1, 111-121 1
- 263 Screening, diagnosis, and management of type II diabetes: A review of the 2014 American Diabetes Association guidelines. **2014**, 4, 107-113
- 262 Management of Diabetes Mellitus in Patients with Acquired Immunodeficiency Syndrome. **2014**, 21, 129-135
- 261 Microalbuminuria in Healthy Adolescents: A Comparative Study at High Altitude and at Sea Level. **2014**, 7, 82-85 1
- 260 Economic Impact of Therapeutic Choices: The Case of Incretins. **2014**, 1, GRHTA.5000181
- 259 [Is there any progress in the blood glucose lowering therapy of type 2 diabetes?]. **2014**, 155, 1215-20



- 258 Comparison of the efficacy of the herbs for upper medication on glucose tolerance induced by high fat/high sucrose feeding-induced mice. **2014**, 29, 1-8 1
- 257 The Physician and Evidence-Based Medicine. **2015**, 45-71
- 256 Conclusion: Time for Medical Reason. **2015**, 121-136
- 255 Drugs and the Endocrine System. **2015**, 131-140
- 254 Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. **2015**, 179-202
- 253 Early Phase Metabolic Research with Reference to Special Populations. **2015**, 225-242
- 252 Chapter 17. Diabetes Mellitus. **2015**,
- 251 Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. **2015**, 9, FC07-10 1
- 250 Introduction: Type-2 Diabetes. **2015**, 343-345
- 249 Transition to Insulin in Patients with Type-2 Diabetes. **2015**, 359-368
- 248 Hoofdstuk 5 Een individueel behandelplan voor de oudere patiënt met diabetes mellitus type 2. **2015**, 39-49
- 247 Personalized Diagnosis and Therapy. **2015**, 1-127
- 246 Chapter 12. T2DM and Premixed Insulin Conversion. **2015**,
- 245 [Changes of blood fatty acid in women with obesity and type 2 diabetes mellitus]. **2015**, 61, 760-4
- 244 Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments. **2015**, 06, 672-681
- 243 Evaluation and Management of the Newly Diagnosed Patient with Type-2 Diabetes. **2015**, 347-357
- 242 [Sulfonylureas in today's blood glucose lowering therapy. New data on advantages and potential barriers of an "old" antidiabetic group]. **2015**, 156, 511-5
- 241 Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study. **2015**, 18, 84-88

- 240 Age-Based Differences in the Genetic Determinants of Glycemic Control: A Case of FOXO3 Variations. **2015**, 10, e0126696 2
- 239 The value of patient-reported outcomes in patients with type 2 diabetes mellitus receiving insulin therapy: assessment of quality of life and hypoglycemia problems. **2015**, 18, 48-58 1
- 238 Personalized Diagnosis and Therapy. **2016**, 3167-3284 0
- 237 CHOICE OF THE ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CLINICAL PRACTICE. INITIAL RESULTS FROM A NON-INTERVENTIONAL MULTICENTER STUDY IN ROMANIA (REALITY). **2016**, 12, 455-460 1
- 236 Protective Effect of Nitric Oxide and Natural Antioxidants on Stability of Blood Vessel. **2016**, 05, 1-11
- 235 Late Onset Diabetes of Adults (LADA) Masked By Co-Existed Adrenal Failure in the Context of Autoimmune Polyglandular Syndrome 2. **2016**, 3,
- 234 Association between estimated blood glucose levels and glycated hemoglobin levels. **2016**, 31, 457-60
- 233 Combination Treatment of Oral Agents and Insulin in Type 2 Diabetes: A Narrative Review. **2016**, 1,
- 232 Diabetes type 2 diabetes in the elderly âolved and unsolved questions. **2016**, 19, 322-330 2
- 231 When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm. **2016**, 22, 12-14
- 230 When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm. **2016**, 22, 14-22
- 229 Guidelines for the Treatment of Type 2 Diabetes Mellitus. **2017**, 37-50
- 228 When and how to Use Ultralong-Acting Basal Insulin in T2Dm. **2016**, 22, 9-12
- 227 Clinical Use of SGLT-2 Inhibitors for the Management of Type 2 Diabetes in a Patient Centered Medical Home. **2016**, 3,
- 226 The relationship between social capital components and control of type 2 diabetes: A path analysis model. **2017**, 31, 21 2
- 225 Lifestyle Changes in Diet and Physical Activities after Group Education for Type 2 DiabetesâThe Active Ingredient in the Education. A Qualitative Study. **2017**, 07, 1181-1195 1
- 224 Knowledge, Attitudes and Practices Survey in Management of Type 2 Diabetes by General Practitioners in Dakar. **2017**, 07, 294-301
- 223 How much do persons with diabetes in a rural area of South India know about diabetes management? A step toward person-centered care. **2017**, 6, 605-609 0

222 Concentrated Rapid-Acting Insulin Preparations. **2017**, 23, 18-23

221 Diabetes. **2017**, 187-209

1

220 The parallel comparative study of metabolism of fatty acids in erythrocytes and other tissues under experimental diabetes mellitus. **2017**, 23, 27-30

219 Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm. **2017**, 63, 87-92

218 Perceptions of Persons With Type 2 Diabetes Treated in Swedish Primary Health Care: Qualitative Study on Using eHealth Services for Self-Management Support (Preprint).

1

217 When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus. **2017**, 20, 363-373

216 How Safe is It to Place Titanium Dental Implants in Patients with Autoimmune Disorders?. **2018**, 8, 1-1

215 Effects of exercise on blood glucose levels in type 2 diabetic patients âLiterature review.

214 Effect of Insulin Therapy on Endothelial Dysfunction in Type 2 Diabetic Subjects without any Complications. **2018**, 22, 132-137

213 Grieving the Loss of Self: Challenges in Type 2 Diabetes Mellitus Self-Management. **2018**, 11, 25-34

0

212 The impact of lifestyle change on the parameters of glycemic control in type 2 diabetes. **2018**, 24, 23-32

211 The Involvement of the Patient and his Perspective Evaluation of the Quality of Healthcare. **2018**, 121-144

210 Effect of Insulin Therapy on Endothelial Dysfunction in Type II Diabetic Subjects without Any Complications. **2018**, 22, 94-99

209 Glycemic Targets and Prevention of Chronic Complications. **2018**, 421-450

208 Overtreatment in Implant Dentistry. **2018**, 8, 2-2

207 Type 1 diabetes therapeutic education in a non-governmental association T1 Diams: an overview. **2018**, 6,

206 EFFICACY AND SAFETY OF ADDITION OF EMPAGLIFLOZIN IN DIABETIC PATIENTS UNCONTROLLED WITH GLIMEPIRIDE + METFORMIN + TENELIGLIPTIN. **2018**, 4, 1226-1230

205 Hypoglycemia among Insulin-treated Patients with Diabetes: Egypt Cohort of IO HAT Study. **2018**, 8, 34-47

204 When should bolus insulin be added to basal insulin in type 2 diabetes?. **2018**, 21, 32-33

203 Diabetes and Cardiovascular Disease. **2019**, 709-730

202 Early Phase Metabolic Research with Reference to Special Populations. **2019**, 517-538

201 Assessment of Safety and Effectiveness of Glargine<sup>&reg;</sup> (Wockhardts<sup>®</sup> Insulin Glargine) in a Prospective, Multi-Centric Post Marketing Observational Study in Nepalese Having Type 2 Diabetes Mellitus. **2019**, 09, 21-33

200 Clinical Practice Guidelines, Evidence-Based Medicine, and Diabetes. **2019**, 333-355

199 Serum chemerin as a predictor of left ventricle hypertrophy in patients with coronary artery disease. **2019**, 16, 25

198 Peripheral Arterial Disease and Diabetes Mellitus. **2019**, 747-763

1

197 Does Diabetes Influence Oral Health in Children?. **2019**, 26, 65-71

196 The Impact of Structured Diabetes Education on Glycemic Control in Patients with Type 2 Diabetes at Initiation of Basal Insulin – The Basal-EDUC-RO Study: A Randomized Prospective Study. **2019**, 26, 185-198

0

195 Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. **2019**, 22, 159-164

1

194 Managing type 2 diabetes mellitus: Role of family physicians in successful treatment goal achievement. **2019**, 16, em146

193 Early combination therapy for type 2 diabetes. Time for new decisions. **2019**, 115-121

192 Insulin resistance: Unsolved issues of harm and use. **2020**, 34, 39-48

191 Diabetes mellitus and osteoarthritis. **2020**, 285-315

190 Cystic fibrosis-related diabetes: The unmet need. **2020**, 11, 213-217

0

189 Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. **2020**,

2

188 Die diabetische Angiopathie. **2020**, 18, 200-207

187 Evaluation of in vitro antioxidant activity of okra mucilage and its antidiabetic and antihyperlipidemic effect in alloxan-induced diabetic mice.. **2021**, 9, 6854-6865

2

- 186 DNA Methylation and Type 2 Diabetes: Novel Biomarkers for Risk Assessment?. **2021**, 22, 2
- 185 The Metformin Paradox. **2020**, 16, 143-147 2
- 184 Overview of Type 2 Diabetes Drugs on the Market. **2020**, 08, 1-14
- 183 Guidelines for enhanced recovery after cardiac surgery. Consensus document of Spanish Societies of Anesthesia (SEDAR), Cardiovascular Surgery (SECCE) and Perfusionists (AEP). **2020**, 5-77
- 182 Standard Pharmacological Treatment of Diabetes Based on the Guidelines. **2021**, 179-187
- 181 Predictors of Adherence Toward Specific Domains of Diabetic Self-Care Among Type-2 Diabetes Patients. **2020**, 13, 1179551420981909 4
- 180 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82
- 179 System Architecture for "Support Through Mobile Messaging and Digital Health Technology for Diabetes" (SuMMiT-D): Design and Performance in Pilot and Randomized Controlled Feasibility Studies (Preprint).
- 178 Surgery or medical treatment for low baseline BMI patients with type 2 diabetes mellitus?. **2020**, 12-14
- 177 Feeding behavior pattern and glycosylated hemoglobin in people with type 2 diabetes at the beginning and end of an educational intervention. **2020**, 67, 155-163 1
- 176 Variants in STAU2 associate with metformin response in a type 2 diabetes cohort: a pharmacogenomics study using real-world electronic health record data.
- 175 Trends in cardiovascular risk factors and treatment goals in patients with diabetes in Singapore-analysis of the SingHealth Diabetes Registry. **2021**, 16, e0259157 0
- 174 Serum chemerin correlated to the SYNTAX score in obese Egyptian patients with coronary artery disease. **2020**, 62, 257-266
- 173 Does peer-navigated linkage to care work? A cross-sectional study of active linkage to care within an integrated non-communicable disease-HIV testing centre for adults in Soweto, South Africa. **2020**, 15, e0241014 1
- 172 EPIGENETICS AND AGING. **2020**, 1-3
- 171 Testing an analogue game to promote peer support and person-centredness in education for people with type 2 diabetes: a realist evaluation.
- 170 The Influence of Baseline Hemoglobin A1c on Digital Health Coaching Outcomes in Adults With Type 2 Diabetes: Real-World Retrospective Cohort Study (Preprint).
- 169 Management of diabetic patient profiles using ontologies. **2020**, 65, 218 1

168	Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus. <b>2012</b> , 37, 699-708	7
167	Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies. <b>2012</b> , 37, 687-96	9
166	Diabetes and cardiovascular disease: what have we learned in 2012?. <b>2013</b> , 40, 290-2	
165	Type 2 diabetes and hemoglobin A1c targets. <b>2013</b> , 59, 1193	
164	Canagliflozin (invokana), a novel oral agent for type-2 diabetes. <b>2013</b> , 38, 656-66	8
163	Alogliptin (nesina) for adults with type-2 diabetes. <b>2014</b> , 39, 186-202	9
162	Treating to target: ready, fire, aim. <b>2014</b> , 60, 541	2
161	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. <b>2014</b> , 18, 617-23	6
160	Complications of diabetes: progress, but significant challenges ahead. <b>2014</b> , 2, 120	8
159	Overview of insulin and non-insulin delivery devices in the treatment of diabetes. <b>2014</b> , 39, 866-76	7
158	Patient profiling in diabetes and role of canagliflozin. <b>2014</b> , 7, 367-77	1
157	New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. <b>2014</b> , 7, 452-63	43
156	Cardiovascular safety profile of currently available diabetic drugs. <b>2014</b> , 14, 616-32	27
155	Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus. <b>2015</b> , 40, 62-7	4
154	Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus. <b>2014</b> , 18, 306-9	10
153	The methodology of glucose monitoring in type 2 diabetes mellitus. <b>2013</b> , 86, 93-6	1
152	Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis. <b>2015</b> , 2015, 26-30	2
151	Social support and self-care activities among the elderly patients with diabetes in Kelantan. <b>2015</b> , 10, 34-43	6

150	An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus. <b>2015</b> , 25, 1349-52	4
149	Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. <b>2015</b> , 8, 131-4	6
148	Observations on factors that influence thyroid nodules in diabetic and non-diabetic patients in the Zhejiang province of China. <b>2015</b> , 8, 19332-8	4
147	Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. <b>2015</b> , 8, 14141-50	15
146	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <b>2015</b> , 19, 195-9	7
145	Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics. <b>2015</b> , 210, 914-8	2
144	Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus. <b>2018</b> , 47, 575-583	4
143	Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus. <b>2019</b> , 18, 2180-2190	
142	Paradox of Patient-Centered Care and the Implications for Patient Involvement in Continuing Professional Development. <b>2021</b> , 41, 238-246	1
141	Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. <b>2021</b> , 178, 18-25	0
140	Structure and properties of insulin. <b>2022</b> , 29-70	
139	Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review. <b>2021</b> , 13, 131	
138	Bilateral Ureteral Obstruction Causing Acute Kidney Injury and Resultant Metformin Toxicity.. <b>2021</b> , 13, e19635	
137	Diabète de type 2 de la personne âgée. Vers des recommandations actualisées? L'apport de la cohorte GERODIAB. <b>2021</b> ,	
136	The role of sulfonylureas in the treatment of type 2 diabetes. <b>2021</b> , 1-17	1
135	In Silico Prediction of Potential Drug Combinations for Type 2 Diabetes Mellitus by an Integrated Network and Transcriptome Analysis. <b>2021</b> ,	
134	Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring.. <b>2021</b> , 12, 754820	0
133	Hallmarks of Testicular Aging: The Challenge of Anti-Inflammatory and Antioxidant Therapies Using Natural and/or Pharmacological Compounds to Improve the Physiopathological Status of the Aged Male Gonad. <b>2021</b> , 10,	1



- 132 Scopoletin stimulates the secretion of insulin via a KATP channel-dependent pathway in INS-1 pancreatic cells.. **2022**, 0
- 131 Senioren mit Diabetes: Lebensqualität vor strenger Blutzuckereinstellung.
- 130 Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion.. **2021**, 10, 4398-4409
- 129 Identifying and delineating the type 2 diabetes population in the Netherlands using an all-payer claims database: characteristics, healthcare utilisation and expenditures. **2021**, 11, e049487 0
- 128 2022 National Standards for Diabetes Self-Management Education and Support.. **2022**, 26350106211072203 6
- 127 Safety of Cinnamon: An Umbrella Review of Meta-Analyses and Systematic Reviews of Randomized Clinical Trials.. **2021**, 12, 790901 1
- 126 Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.. **2021**, 12, 794363
- 125 2022 National Standards for Diabetes Self-Management Education and Support.. *Diabetes Care*, **2022**, 45, 484-494 14.6 3
- 124 Low-carbohydrate versus balanced-carbohydrate diets for reducing weight and cardiovascular risk.. **2022**, 1, CD013334 3
- 123 Liraglutide Overdose-Induced Acute Pancreatitis.. **2022**, 14, e21616 0
- 122 Uncontrolled Blood Pressure and Associated Factors Among Persons With Diabetes: A Community Based Study From Kerala, India.. **2021**, 9, 778235 1
- 121 The experiences of people with type 2 diabetes in communicating with general practitioners in China - a primary care focus group study.. **2022**, 23, 24 0
- 120 Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment.. **2021**, 9, 782964 0
- 119 Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.. **2022**, 13, 85-96 0
- 118 Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.. **2022**, 15, 281-295 7
- 117 Impact of Pharmacist-Led Diabetes Self-Care Education on Patients With Type 2 Diabetes in Pakistan: A Randomized Controlled Trial.. **2022**, 13, 754999 0
- 116 Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives.. **2022**, 41, 53 0
- 115 Increased prevalence of cardiovascular risk factors in newly diagnosed type 2 diabetes patients - a retrospective study.. **2021**, 17, 331-336

114	Remission of tuberculosis following control of glycemc excursions in a patient with type 2 diabetes mellitus: A case report. <b>2022</b> , 13, 133	
113	GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes. <b>2022</b> , 335-343	
112	Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.. <b>2022</b> , 13, 389	0
111	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.. <b>2022</b> ,	0
110	The effect of empagliflozin on p wave peak time and other p wave parameters in patients with diabetes mellitus.. <b>2022</b> ,	
109	Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes.. <b>2022</b> , 13, 619	0
108	Effectiveness of restricted diet with a plate in patients with type 2 diabetes: A randomized controlled trial.. <b>2022</b> ,	
107	Association of Insulin Resistance and Elevated Androgen Levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature.. <b>2022</b> , 2022, 9240569	4
106	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.. <b>2022</b> , 32, 529-536	1
105	Metformin Intervention-A Panacea for Cancer Treatment?. <b>2022</b> , 14,	2
104	The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study.. <b>2022</b> , 1	
103	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.. <b>2021</b> , 108110	1
102	2022 National Standards for Diabetes Self-Management Education and Support.	1
101	Shared decision making in primary care: Process evaluation of the intervention in the OPTIMAL study, a cluster randomised trial.. <b>2022</b> ,	0
100	Potential Over-Treatment and Over-Testing among Older Adults with Type-2 Diabetes across Canada: An Observational Retrospective Cohort Study. <b>2022</b> ,	
99	Bibliometric and Visualized Analysis of 2011-2020 Publications on Physical Activity Therapy for Diabetes.. <b>2022</b> , 9, 807411	0
98	Analysis of Use and Outcomes of the Balance Digital Disease Management Tool for Patients with Type 2 Diabetes. <b>2021</b> , 2021, 1372-1375	
97	Pi-Dan-Jian-Qing Decoction Ameliorates Type 2 Diabetes Mellitus Through Regulating the Gut Microbiota and Serum Metabolism.. <b>2021</b> , 11, 748872	1

96 Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.. **2021**,

95 Acute high intensity interval exercise is similarly effective as moderate intensity continuous exercise on plasma glucose control in type 2 diabetic men aged 30 to 50 years: a randomized controlled trial.. **2021**,

94 Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016-2018. **2021**, 6, 219

93 Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007-2018.. **2022**,

92 Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications.. **2022**, 14, 13-20

91 Increased Patient Empowerment Is Associated with Improvement in Anxiety and Depression Symptoms in Type 2 Diabetes Mellitus: Findings from the INDICA Study.. **2022**, 19,

90 data\_sheet\_1.docx. **2018**,

89 Data\_Sheet\_1.docx. **2018**,

88 DataSheet1.DOCX. **2018**,

87 Image\_1.tif. **2018**,

86 Image\_2.tif. **2018**,

85 Image\_3.tif. **2018**,

84 Table\_1.DOCX. **2018**,

83 Table\_2.DOCX. **2018**,

82 Table\_3.DOCX. **2018**,

81 Table\_4.DOCX. **2018**,

80 Table\_5.DOCX. **2018**,

79 Table\_6.DOCX. **2018**,

0

1

0

- 78 Exploring the Perspective of Diabetes, Diabetes Self-Management, and Quality of Life Among Older Adults With Type 2 Diabetes: A Qualitative Study Before and During the COVID-19 Pandemic.. **2022**, 26350106221094527
- 77 Antihyperglycemic and antidyslipidemic effects of *Artemisia arborescens* aqueous extract in streptozotocin-induced diabetic rat.. **2022**,
- 76 Social inequality and diabetes mellitus - developments over time among the adult population in Germany.. **2019**, 4, 11-28 1
- 75 Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. **2014**, 18, 617 7
- 74 Serum Untargeted Metabolomics Analysis of the Mechanisms of Evodiamine on Type 2 Diabetes Mellitus Model Rats. 0
- 73 The Reproducibility and Usefulness of Estimated Average Glucose for Hyperglycemia Management during Health Checkups: A Retrospective Cross-Sectional Study. **2022**, 10, 824
- 72 Factors Associated with Weight Loss in People with Overweight or Obesity Living with Type 2 Diabetes Mellitus: Insights from the Global DISCOVER Study.. **2022**,
- 71 Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation.. **2022**, 16, 1201-1211
- 70 Multi target interactions of essential oil nanoemulsion of *Cinnamomum travancoricum* against diabetes mellitus via in vitro, in vivo and in silico approaches. **2022**, 118, 190-204 0
- 69 Precision Nutrition for Type 2 Diabetes. **2022**, 233-249
- 68 Randomized Clinical Trial of How Long-Term Glutathione Supplementation Offers Protection from Oxidative Damage and Improves HbA1c in Elderly Type 2 Diabetic Patients. **2022**, 11, 1026 1
- 67 Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia. **2022**, 17, e0268639 0
- 66 Fear of hypoglycemia—An underestimated problem. 1
- 65 The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) —Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes. Volume 15, 1627-1638
- 64 Ultra-Fast Measurement of Metformin in the Clinical Setting Using Probe Electrospray Ionization Mass spectrometry (PESI-MS).
- 63 Effects of Yoga on Blood Glucose and Lipid Profile of Type 2 Diabetes Patients Without Complications: A Systematic Review and Meta-Analysis. 4, 0
- 62 Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century. **2022**, 15, 866 1
- 61 Manejo anestésico en la cirugía de reparación valvular mitral. **2022**,

- 60 A narrative review: The pharmaceutical evolution of phenolic syringaldehyde. **2022**, 153, 113339 2
- 59 Metformin's effects on varicocele, erectile dysfunction, infertility and prostate-related diseases: A retrospective cohort study. 13, 0
- 58 Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology. **2022**, 199-229
- 57 Diabetes mellitus: what the neurologists need to know. pn-2022-003395
- 56 N-Octyl Caffeamide, a Caffeic Acid Amide Derivative, Prevents Progression of Diabetes and Hepatic Steatosis in High-Fat Diet Induced Obese Mice. **2022**, 23, 8948
- 55 Metformin and Dementia Risk: A Systematic Review with Respect to Time Related Biases. **2022**, 6, 443-459 0
- 54 CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma. 1-15 0
- 53 Levels and Correlates of Numeracy Skills in Lebanese Adults with Diabetes: A Cross-Sectional Study. **2022**, 19, 10557
- 52 Acute effect of Melon Manis Terengganu peel powder on glycemic response, perceived satiety, and food intake: a randomized, placebo-controlled crossover trial in adults at risk of type 2 diabetes. **2022**, 8,
- 51 The association of glycemic control and fall risk in diabetic elderly: a cross-sectional study in Hong Kong. **2022**, 23,
- 50 Gambaran Peresepan Metformin pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit Nasional Diponegoro Semarang. **2021**, 1, 37-43 0
- 49 Potential anti-diabetic components of *Apocynum venetum* L. flowers: Optimization, chemical characterization and quality evaluation. **2023**, 115, 104930 0
- 48 Targeting pancreatic  $\beta$  cells for diabetes treatment. **2022**, 4, 1097-1108 0
- 47 Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. **2022**, 11, 5435 0
- 46 Phase separation and thermodynamics of the mixture of metformin hydrochloride + triton X-100 in ammonium salts media: impacts of composition of media. 2
- 45 Probiotics with anti-type 2 diabetes mellitus properties: targets of polysaccharides from traditional Chinese medicine. **2022**, 20, 641-655 0
- 44 Digital algorithm-guided insulin therapy in home healthcare for elderly persons with type 2 diabetes: A proof-of-concept study. 3, 0
- 43 Long-term pharmacokinetic and pharmacological evaluations of a novel indole-benzazepinone derivative on obese Type 2 diabetes mellitus. 0

42	A Fuzzy System Classification Approach for QSAR Modeling of $\alpha$ -Amylase and $\alpha$ -Glucosidase Inhibitors. <b>2022</b> , 18,	0
41	Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.	0
40	A Microtube-Based Wearable Closed-Loop Minisystem for Diabetes Management. <b>2022</b> , 2022, 1-14	0
39	Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus. 9,	1
38	A mixed blessing for liver transplantation patients âRapamycin. <b>2022</b> ,	0
37	Recent Trends in Diabetes-Associated Hospitalizations in the United States. <b>2022</b> , 11, 6636	0
36	Prediabetes is more than a pre-disease: additional evidences supporting the importance of its early diagnosis and appropriate treatment.	0
35	Comparative efficacy and complications of long-acting and intermediate-acting insulin regimens for adults with type 1 diabetes: an individual patient data network meta-analysis. <b>2022</b> , 12, e058034	0
34	Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China. 13,	0
33	Lactic Acidosis Related to Pharmacotherapy and Human Diseases. <b>2022</b> , 15, 1496	2
32	Attrition and social vulnerability during 2-year-long structured care in type 2 diabetes, the ERMIES randomized controlled trial. <b>2022</b> , 22,	0
31	Étude Transversale sur les Effets Indésirables de la Chlorhydrate de Méformine chez 130 Patients Diabétiques Type 2 Admis au Centre Médical et à la Maison du Diabète de Sidi Bel-Abbès. <b>2022</b> ,	0
30	Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.	0
29	Clinical efficacy and safety of warm acupuncture in the treatment of type 2 diabetic kidney disease: A protocol of a randomized controlled trial. <b>2022</b> , 101, e32034	0
28	Association between METS-IR and Prediabetes or Type 2 Diabetes Mellitus among Elderly Subjects in China: A Large-Scale Population-Based Study. <b>2023</b> , 20, 1053	0
27	The predictive ability of C peptide in distinguishing type1 diabetes from type 2 diabetes: A Systematic Review and Meta-Analysis. <b>2023</b> ,	0
26	Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.	0
25	Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. <b>2023</b> , 11, e002919	0

- 24 Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker. ○
- 23 Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists. ○
- 22 Continuity of Medication Use by US Adults With Diabetes, 2005-2019. **2023**, 6, e2253562 ○
- 21 Metabolic Control, Diabetic Complications and Drug Therapy in a Cohort of Patients with Type 1 and Type 2 Diabetes in Secondary and Tertiary Care between 2004 and 2019. **2023**, 20, 2631 ○
- 20 Support Provided by Caregivers for Community-Dwelling Diabetic Hispanic Adults with Intellectual Disabilities and Comorbid Conditions. **2023**, 24, 3848 ○
- 19 Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen. ○
- 18 GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice. **2023**, 40, 1418-1429 ○
- 17 Efficacy and Safety of Therapeutic Proteins. **2023**, 275-296 ○
- 16 Hydrophobicity Regulation of Energy Acceptors Confined in Mesoporous Silica Enabled Reversible Activation of Optogenetics for Closed-Loop Glycemic Control. **2023**, 145, 5941-5951 ○
- 15 Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?. **2023**, 28, ○
- 14 A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors. **2023**, 12, 487-499 ○
- 13 HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study. ○
- 12 Pune GSH supplementation study: Analyzing longitudinal changes in type 2 diabetic patients using linear mixed-effects models. 14, ○
- 11 Problem-based shared decision-making in diabetes care: a secondary analysis of video-recorded encounters. [bmjebm-2022-112067](#) ○
- 10 Current Strategies of New Drugs for Diabetes Management. **2023**, 22-47 ○
- 9 Pharmacogenetics of Metformin in Type 2 Diabetes: Perspectives for Latin America. ○
- 8 Diabetes and Heart Failure. **2023**, 177-204 ○
- 7 Person-Centered Endocrinology (Including Diabetes and Obesity). **2023**, 487-500 ○



- 6 Electrically assisted cycling for individuals with type 2 diabetes mellitus: a pilot randomized controlled trial. **2023**, 9,
- 5 The effect of moderate-intensity endurance plus resistance training combined with MCCR diet on glycemic status in prediabetes.
- 4 Trends in dietary patterns over the last decade and their association with long-term mortality in general US populations with undiagnosed and diagnosed diabetes. **2023**, 13,
- 3 Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography Tandem Mass Spectrometry Analysis in Rats. **2023**, 10, 282
- 2 EMERGENCY DEPARTMENT MANAGEMENT OF UNCOMPLICATED HYPERGLYCEMIA IN PATIENTS WITHOUT HISTORY OF DIABETES. **2023**,
- 1 HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial. **2023**, 24,